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Abstract 
Part I 
Stevioside is a natural product from the Stevia rebaudiana Bertoni plant native to South 
America. It is one of the major steviol glycosides, with rebaudioside A as the other main 
natural product, isolated from the Stevia plant and comprises 5 – 22% by weight from the 
dried plant leaves. These natural products are commercially sold as natural sweeteners with 
reports of being 200 to 300 times sweeter than table sugar. Steviol glycosides are made up 
of a tetracyclic diterpene, also called ent-kaurene, core structure attached to varying sugar 
chains at the A ring carboxyl group or C-ring hydroxyl group; Stevioside contains three 
glucose molecules while rebaudioside A contains four glucose molecules. The stevioside 
diterpene serves as novel template for analog development and exploration because there 
are numerous directions to diversify the different rings, mainly the A, C and D rings, within 
the molecule. Stevioside undergoes enzymatic or basic hydrolysis to form the steviol acid, 
which rearranges to the isosteviol acid under acidic conditions via a Wagner-Meerwein 
methyl shift of the bridging carbon. These two diterpenes were further explored via a 
diversity-oriented synthetic approach to yield other diterpene scaffolds from which 
compound libraries were synthesized in order to explore novel chemical space. Testing of 
the libraries demonstrate initial activity in several biological assays, thus proving that the 
ent-kaurene core scaffold is a viable starting point to elicit biological activity and for 
therapeutic development. 
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Part II 
Through the efforts by the National Institutes of Health, research is being conducted to 
develop non-hormonal reversible male contraceptive agents. Current forms of male 
contraception include a temporary barrier by means of condoms or permanent surgical 
sterilization. Their unpopularity and the unmet need for something more tolerable have led 
to the development of non-hormonal male contraceptive agents targeting the retinoic acid 
receptor alpha (RARa) nuclear receptor. Previous research has shown that RARa disrupts 
spermatogenesis during mitosis and the administration of RAR agonists to Vitamin A 
deficient mice, which is similar to RARa gene knockout mice, reversed infertility effects. 
Given these promising results, we designed and synthesized retinoids for the development 
of RARa antagonists. Four compounds were produced and assayed for activity in RARa 
as well as selectivity against RAR beta (RARb) and RAR gamma (RARg).  
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1 
PART I- STEVIOSIDE LIBRARY DEVELOPMENT 
Chapter 1. Design and Synthesis of Diterpene Scaffolds from Stevioside 
A. Background of Stevioside, Steviol, and Isosteviol 
 For centuries, the indigenous people of South America have been using the ka’a 
he’ê plant, meaning “sweet herb,” for its sweetening power and potential medicinal 
aspects.1, 2 After introduction to European settlers and continued use by both natives and 
non-natives, the plant has become scientifically known 
as Stevia rebaudiana Bertoni and commonly called 
“stevia” (Figure I-1).3 The plant was named by Italian-
Swiss botanist Moises Santiago de Bertoni, when he 
first gained a sample in 1887.4 He at first named it 
Eupatorium rebaudianum after Paraguayan chemist 
Ovidio Rebaudi,5 but then later corrected the genus as 
Stevia, after the Spanish botanist Pedro Jaime Esteve, 
who first researched the plants in a territory of Paraguay.6 While the Stevia genus contains 
over 230 species, S. rebaudiana has been the only plant observed to contain sweetening 
agents.7 Eight natural products isolated from the S. rebaudiana Bertoni leaf tissues were 
identified with sweetening properties: dulcoside A (I-1), rebaudiosides A-E (I-2:I-6), 
Figure I-1. Stevia rebaudiana 
Bertoni plant. 
    
 
2 
steviolbioside (I-7), and stevioside (I-8) (Figure I-2).8 The four main sweeteners are 
rebaudioside A (I-2), rebaudioside C (I-4), dulcoside A (I-1), and stevioside (I-8).9  
Figure I-2. Stevia sweetening agents. 
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These compounds are classified as ent-kaurene glycosides or steviol glycosides, because 
they all contain that same kaurenoid precursor. The ent-kaurene core is formed by the 
methyleryththritol 4-phosphate (MEP) pathway (Scheme I-1).10  
Scheme I-1. Biosynthesis of steviol via the MEP pathway. 
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Figure I-3. Biosynthesis of steviol glycoside.10 
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5 
diphosphate synthase (HDS) and then reduced by 1-hydroxy-2-methyl-2(E)-butenyl 4-
diphosphate reductase (HDR) to provide the MEP pathway products: dimethylallyl 
pyrophosphate (I-17, DMAPP) and its isomer isopentyl pyrophosphate (I-18, IPP).13 
DMAPP I-17 and IPP I-18 advance to diterpene synthesis starting with the conversion to 
geranylgeranyl pyrophosphate (I-19, GGPP) by GGPP synthase (GGPPS) and three 
successive condensation steps.14 Next, copalyl diphosphate (I-20, CDP) is made from CDP 
synthase (CDPS) and then, kaurene synthase produces (–)-kaurene (I-21, or ent-kaurene) 
via an ionization dependent cyclization step.10 Interestingly, GGDP, CDP, and kaurene 
synthases also play crucial roles in the gibberellic acid biosynthetic pathway and low 
concentrations of gibberellic acid are found in Stevia plant tissues.15 However, further 
research is ongoing to determine the special organization of these enzymes and how they 
divert the synthesis of steviol glycosides from gibberellic acid (I-24, GA).16 
Next in the steviol glycoside biosynthesis, the kaurene I-21 is oxidized to kaurenoic 
acid (I-22) by the p450 mono-oxygenase kaurene oxidase (KO). The KO enzyme is also 
found in the GA biosynthetic pathway and is highly expressed in the same tissues as CDP 
and kaurene synthases, but the oxidation step has been shown to occur in the endoplasmic 
reticulum not chloroplasts (Figure I-3).16 Acid I-22 is then hydroxylated by kaurenoic acid 
13-hydroxylase (KAH) at C-13 to give the steviol diterpene I-23 (Scheme I-1).17 The 
hydroxylation step by KAH is completely separate and different from the GA biosynthetic 
pathway, marking the divergence of steviol glycoside formation from the gibberellic acid 
pathway.18 Additionally, acid treatment of I-23 will give its isomeric diterpene isosteviol 
I-25 via a Wagner-Meerwein rearrangement (Scheme I-2).19 This alternative structure of 
steviol I-23 will be further explored within this chapter.  
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Scheme I-2. Hydrolysis of stevioside (I-8). 
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Scheme I-3. Biosynthesis of stevioside (I-8) and rebaudioside A (I-2). 
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O
HO O
OO
OHO
HO
OH
OH
HO
HO
OH
4
13
19
1'
2'
O
O O
O
OO
O
HO
HO
HO
OH
HO
OH
OH
HO
HO
OH
stevioside
I-8
OH
4
13
19
2'
UGT
UGT
O
O O
O
OO
O
HO
O
HO
OH
HO
OH
OH
HO
HO
OH
rebaudioside A
I-2
OH
4
13
19
2'
UGT
O
steviolbioside
I-7
HO
OH
HO
OH
steviol
I-23
OH O
HO O
OHO
HO
OH
OH
4
13
19
1'
2'
UGT
steviolmonoside
I-26
3'
OHO
A B
C D
    
 
8 
2. Biological evaluation of stevioside and its metabolites 
These diterpene natural products were isolated from the leaves in 1931 and found 
to be at least 300 times sweeter than sucrose, or table sugar.23 Specifically, stevioside (I-
8), which contains one glucose molecule at the C-4 carboxyl end of the A-ring and another 
two glucose molecules at the C-13 hydroxyl end of the C-ring, has been shown to be 150-
250 times sweeter than sucrose.24 Rebaudioside A (I-2), which contains four glucose 
molecules: one at the C-4 carboxyl end and three at the C-13 hydroxyl end, is 200-300 
times more sweet.24 Due to its sweetness from the steviol glycosides, the stevia plant has 
become commercially sold as a food additive and non-caloric natural sweetener, after being 
used as such for centuries by the indigenous Guarani natives in South America.25 
Moreover, the steviol glycosides and their aglycone structures from the stevia plant have 
been extensively reviewed for their pharmacological effects,25-31 including glucoregulation 
for diabetes mellitus treatment,32 anti-hypertensive activity for blood pressure regulation,33 
anti-tumor effects for cancer therapy,34 anti-microbial effects,35 anti-diarrheal or anti-
rotavirus capabilities for treatment of gastrointestinal problems,36 renal function regulation 
for kidney disease treatment,37 antiviral activity,38 antifungal properties,39 anti-HIV 
research,40 hepatoprotective effects,41 immunomodulatory, and anti-inflammatory 
effects.42 Most of these aforementioned studies were performed on mice or rats with 
ongoing research being conducted for the full effect of stevioside or its metabolites in the 
human body.43, 44  
A study of the metabolism of rebaudioside A (I-2) and stevioside (I-8) from extracts 
of S. rebaudiana plants containing either 85% w/w I-8 or 90% w/w I-2 was performed on 
eleven healthy human subjects and found no levels of either I-2 or I-8 in the fecal 
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analysis.45 A separate human metabolism study of ten healthy human subjects given 250mg 
stevioside (I-8) capsules for 3 times daily for a period of 3 days did not detect any amounts 
of stevioside in the blood, urine, or fecal collections examined.46 Both of these two human 
studies did find steviol in the stool collections and determined that it was not further 
degraded. Instead, the human microflora had completely hydrolyzed the steviol glycosides 
down to the aglycone steviol (I-23) metabolite. Moreover, Geuns et al. showed that the 
Caco-2 cell line absorbed steviol but not stevioside.47 Blood samples taken from the healthy 
subjects did not identify stevioside (I-8), the aglycone steviol (I-23), or any other possible 
steviol metabolites in the blood. Urine analysis from the study by Geuns et al. revealed the 
presence of steviol glucuronide as the major metabolized product.46 These two studies 
suggest that stevioside and rebaudioside A are completely metabolized in the colon to 
steviol, which is then absorbed and glucuronidated in the liver for eventual urine excretion. 
Given the increased interest in stevioside (I-8) and its metabolites for biological 
activity evaluation, we determined that this natural product was an excellent source and 
starting place for our compound library development.  
 
 
B. Rationale for Developing ent-Kaurene Scaffolds  
1. Pilot Scale Libraries Initiative  
Under the Pilot Scale Libraries Initiative, our goal was to synthesize and submit 
compounds to become part of the NIH Molecular Libraries Small Molecule Repository 
(MLSMR) and to be evaluated in the NIH-funded Molecular Libraries Screening Center 
Network (MLPCN) centers.48 The MLPCN is a consortium of centers around the United 
States that perform high throughput screening assays with the library of over 300,000 small 
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molecules from the MLSMR and the information from these activities are deposited on to 
the PubChem public database.49  
Stevioside (I-8), a widely used natural sweetener, was chosen for library 
development for several reasons. First, natural products isolated from plant, marine, and 
microbial sources are excellent leads for library generation. They are a source of varied 
molecular structure and continue to be an excellent resource for probing and discovering 
new therapeutic agents. Therefore, probing biological systems with natural products or 
natural product-like compounds remains fertile ground to uncover novel lead structures of 
biomedical significance. Second, carbon skeletons of the complexity of the steviol 
glycoside natural product cannot be readily accessed via total synthesis. This library project 
had a unique opportunity to explore the potential of stevioside (I-8), which is already 
produced commercially worldwide through extraction of Stevia rebaudiana.50 The Pilot 
Scale Libraries project is part of the NIH Molecular Libraries Initiative. The purpose of 
this work is to synthesize molecules that explore sparsely populated chemical space and 
then submit them to the MLSMR. The MLSMR is part of the MLPCN and once they are 
submitted, any screening information will be made available on PubChem, an online 
database that stores all publicly available structural and biological data, (Scheme I-4).49 
 
 
Scheme I-4. Outline for the PSL. 
  
COMPOUNDSPSL MLSMR MLCPN PUBCHEM
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Unlike many other natural products, stevioside (I-8) is readily available in kilogram 
quantities and can be easily hydrolyzed to provide two scaffolds: steviol (I-23) and 
isosteviol (I-25) ideally suited for the development of natural product-derived 
combinatorial libraries. Library synthesis for these structures is facilitated by the extensive 
work already published for steviol glycoside chemistry, and chemical transformations that 
lead to different types of scaffolds are well known.51-53 Since stevioside (I-8), steviol (I-
23), isosteviol (I-25), and related natural products such as gibberellic acid derivatives 
possess a variety of biological activities, we hypothesized that stevioside-derived libraries 
could provide promising opportunities to generate hits in screening campaigns.28, 54-56  
 
2. Natural Products and Steviol-Related Compounds 
Natural products can serve as excellent scaffolds for chemical library development 
due to their inherent structural diversity and complexity, as compared to synthetic 
products.57 In addition, natural products have been shown to occupy areas of chemical 
space that are generally not well covered by synthetic compounds.58, 59 Furthermore, natural 
products, their analogs, and natural product-inspired bioactive compounds have been 
sources of new drugs over many decades. In a report by Newman et al., over 40% of the 
1562 approved drugs from 1981 to 2014 are either natural products, mimic natural 
products, are derived from natural products, or are synthesized from a natural product 
(Figure I-4).60 Therefore, natural products provide a solid platform for the discovery of 
biologically active small molecules.61 It has been suggested that because natural products 
are molded by protein domains, their shape is more likely to be complementary to other 
protein domains.62 
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Figure I-4. All new approved drugs from 1981 until 2014.60 
“B”: Biological, usually a large (>50 residues) peptide or protein either isolated from an 
organism/cell line or produced by biotechnological means in a surrogate host; “N”: Natural 
product, unmodified in structure, though might be semi- or totally synthetic; “NB”: Natural 
product “botanical drug” (in general these have been recently approved); “ND”: Derived 
from a natural product and is usually a semisynthetic modification; “S”: Totally synthetic 
drug, often found by random screening/modification of an existing agent; “S*”: Made by 
total synthesis, but the pharmacophore is/was from a natural product; “V”: Vaccine; “NM”: 
Natural product mimic 
 
 
Additionally, natural products also occupy a large area of chemical space. Chemical 
space, or multi-dimensional descriptor space, is like a map of the area a molecule occupies. 
Since it is so vast, chemical space is a region defined by a particular choice of descriptors 
and limits placed on them. Dobson et al. compare the molecular diversity of compounds 
from combinatorial chemistry, natural products, and drugs (Figure I-5).63 From the 
parameters shown, there is still a large amount of “space” or white areas that are not 
speckled with data.  
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Figure I-5. Chemical space analysis of compounds 
from a) combinatorial chemistry b) natural products, 
and c) drugs.63, 64 
 
 
 
 
 
Two major issues associated with the development of high-value information-rich 
small molecule libraries are achieving skeletal diversity65-67 and mining areas of 
biologically relevant chemical space.64 Because nature can impart chemical diversity in 
many different areas of chemical space, cheminformatics research for drug discovery aims 
to chart out these areas and explore their potential.68 Additionally, Larsson et al. introduced 
ChemGPSNP,69 a tool for exploring chemical diversity that identifies volumes of chemical 
space related to particular biological activities and tracks changes in chemical properties  
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that have been used for natural product drug development.70, 71 Other more recent 
cheminformatics tools have been developed to assess chemical space and diversity.72 With 
these tools in mind, developing small molecule libraries that are novel and valuable is 
possible. Stevioside (I-8), as mentioned earlier, is easily and readily available and its 
biosynthetic intermediates could also be used for divergent template development. 
Potentially, the steviol glycoside scaffold could provide access to templates 
representative of the large and diverse family of diterpenes derived from the 
methylerythritol 4-phosphate pathway10 and subsequent metabolic processes. 
Representative diterepenes from this family include platensimycin (I-27), and triptolide (I-
28), labdane (I-29) with antibiotic,73 anticancer,74 and neuroprotective properties,75 
respectively (Figure I-6). 
 
 
Figure I-6. Structures of steviol-related natural products. 
 
 
These compounds have attracted much attention from the synthetic community and 
therefore a large amount of literature has been produced over the last eight decades 
pertaining to the synthesis76-81 and structural modification of stevioside82-84 and 
structurally-related diterpenes.85-87 Moreover, studies have revealed that steviol (I-23) and 
isosteviol (I-25) have exhibited pharmacological activities;28 thus, we will unlock their 
potential by making these molecules as the initial scaffolds for our library. 
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C. Design of Diterpene Scaffolds with Diversity-Oriented Synthesis 
1. Background on DOS and its utilities 
 In order to create functional diverse small-molecule libraries that occupy novel 
areas of chemical space, a synthetic approach was introduced by Schreiber et al. called 
diversity-oriented synthesis.88 It is an efficient approach to design and develop multiple 
small molecules that populate structurally diverse areas of chemical space. “Diversity-
oriented synthesis involves the deliberate, simultaneous, and efficient synthesis of more 
than one target compound in a diversity-driven approach to answer a complex problem.”89 
This method provides rapid access to known and previously ‘un-tapped’ regions of bioactive 
chemical space to yield complex compound libraries for biological screening.90 In contrast 
to target-oriented synthesis (TOS), which focuses on the synthesis of structural analogs in 
a dense region of chemical space, DOS explores a broad area of chemical space that 
features compounds with different skeletal and stereochemical moieties.91 Furthermore, 
while Fragment-based Drug Design (FBDD) focuses on the synthesis of a small library of 
compounds or fragments with high structural diversity, DOS is able to achieve a library 
with both high structural diversity and molecular complexity through a series of parallel 
reactions.92 Through DOS, it is possible to create libraries of compounds from a single 
building block (scaffold) or collections of compounds from structurally similar scaffolds. 
To generate compounds that are structurally diverse, complex, and have natural product-
like properties, we chose to work with stevioside (I-8) to provide numerous, different 
scaffolds from its core skeleton, the ent-kaurene.   
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2. Introduction of Scaffolds 
Scheme I-5 illustrates several approaches that can be taken. Path I involves an 
allylic oxidation of the C-17 methylene of steviol to furnish diol I-30, which can be further 
oxidized to the C-15 ketone analog I-31. For path II, the Wagner-Meerwein rearrangement, 
as discussed above, is achieved with hydrochloric acid to yield isosteviol (I-25). From 
isosteviol, several different scaffolds can be generated after one or two synthetic steps. 
Through route III, a Baeyer-Villiger oxidation of isosteviol (I-25) produces lactone I-32. 
Formation of an oxime and subsequent Beckmann rearrangement (path IV) yields lactam 
I-33, and photo-Beckman rearrangement leads to the corresponding amide regioisomer I-
34 (path V).  As shown for path VI, the Beckman fragmentation product, nitrile I-35, can 
also be obtained with a slight change to reaction conditions. Optimized protocols for 
isosteviol oxime formation, Beckman rearrangement and Beckmann fragmentation have 
all been reported by us.51 In addition to forming novel scaffolds, the functional groups in 
the molecules can be easily modified for library synthesis.53 Reductive amination of 
isosteviol (I-25) via route VII yields amine I-36.93, 94 Other obvious modifications involve 
the carboxylic acid moiety of the A-ring, which can be reduced to the corresponding 
aldehyde, alcohol, or methyl group. The carboxylic acid can also be converted to an acid 
chloride or activated ester for amide bond formation, which will be discussed later in this 
section. Additionally, formation of the acid chloride from the C-4 carboxylic acid and 
subsequent acyl azide can lead to a Curtius rearrangement toward the formation of a 4-
amine analog.95 The double bond of steviol can be transformed to a hydroxymethyl group 
or an epoxide, and ozonolysis of the double bond provides the corresponding ketone.53  
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Scheme I-5. DOS approach to the ent-kaurene scaffold of steviol (I-23) by D-ring 
modifications. 
 
 
We focused on steviol (I-23) and D-ring modified compounds I-25, I-33, I-35, and 
I-36 as the scaffolds for library development. We also describe the synthesis of several 
pilot scale libraries, their evaluation in multiple high throughput screens and an in silico 
analysis of the chemical and drug-like properties of the compounds prepared in this study.  
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3. Synthesis of DOS Scaffolds  
Enzymatic hydrolysis of stevioside under well-known reaction conditions provided 
steviol (I-23) in good yield. Basic hydrolysis also provided steviol (I-23) in low yield while 
acid hydrolysis gave isosteviol (I-25) in good yield (Scheme I-6).21, 96  
Scheme I-6. Hydrolysis of stevioside. 
 
From the steviol scaffold, an allylic oxidation with selenium (IV) dioxide afforded 
the diol I-30 in good yield (Scheme I-7).97 This Riley oxidation step is an excellent way to 
introduce a hydroxyl moiety into the allylic position of the methylene group.98 Then, a 
PDC oxidation of the secondary hydroxyl afforded ketone I-31.99 
 
 
 
Scheme I-7. Steviol DOS products. 
 
When treated with hydrochloric acid, steviol generated the isomerized product, 
isosteviol (I-25), in quantitative yield (Scheme I-8). Isosteviol has a variety of DOS routes 
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to produce other interesting scaffolds for library development. With mCPBA, isosteviol (I-
25) undergoes a Baeyer-Villiger oxidation to give lactone I-32 (Scheme 1-8).100 
 
  
Scheme I-8. Synthesis of isosteviol DOS products. 
 
Isosteviol can also be converted to oxime I-37 with hydroxyl amine under basic conditions 
in excellent yield. The oxime intermediate can also be reduced with sodium borohydride 
and molybdenum trioxide to give amine I-36.101 Additionally, treatment of oxime I-37 with 
thionyl chloride affords both the Beckmann rearrangement lactam product I-33 as well as 
the Beckmann fragmentation nitrile product I-35. The freshness of the thionyl chloride can 
affect the yields of the Beckman reaction products with a significantly decreased lactam I-
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33 yield if fresh reagent is not used. The chemistry of the Beckmann reaction and its 
reaction products are described in the next section.51, 102  
 
Chapter 2. Exploring the Beckmann Rearrangement Reaction  
A. Background of the Beckmann Reaction 
Since its discovery in 1886 by Ernst Beckmann,103 the eponymous rearrangement 
reaction has been a useful tool in organic synthesis to incorporate a nitrogen atom into a 
molecule. This is typically achieved by a modification of a ketone or aldehyde via oxime 
formation. The Beckmann rearrangement reaction is an important method to convert 
oximes in open chain and cyclic systems to the corresponding amides and lactams. 
Additionally, a Beckmann fragmentation can instead occur during the rearrangement 
process to form a nitrile group from the initial oxime. The Beckmann reactions have been 
extensively reviewed because of their versatility and wide synthetic scope.104-109 Given 
their utility and significance in synthetic organic chemistry, our group employed this 
reaction to uncover new steviol and isosteviol scaffolds. This chapter contains sections of 
a review that we previously published in the book Molecular Rearrangements in Organic 
Synthesis.102, 110 
 
1. Lactam Formation from the Beckmann Rearrangement 
The Beckmann rearrangement is the most recognized of the Beckmann reactions 
and generally describes the conversion of a ketone or aldehyde I-38 to an oxime I-39 
(Scheme I-9). Oxime I-39, under acidic and dehydrating conditions, rearranges to an amide 
I-40. This conversion occurs with the carbon bond anti to the oxime hydroxyl group 
    
 
21 
migrating to the nitrogen. Moreover, the Beckmann rearrangement of aldoximes (where R1 
or R2 = H) produces primary amides via hydrogen migration in a non-stereospecific manner 
Acyclic ketoximes produce the corresponding secondary amide groups, while cyclic 
ketoximes yield the lactam moieties (Scheme I-9).  
 
     
Scheme I-9. General Beckmann rearrangement reaction. 
  
Conventionally, the Beckmann reaction requires a strong acid to initiate the 
rearrangement reaction; however, there have been reports of milder, greener, and non-
acidic conditions for this transformation including: Lewis acids, solid catalysts,105, 111 ionic 
liquids,112 and organocatalysts.113 Activation of the oxime intermediate I-39 begins by 
transforming the N-hydroxyl group of the oxime into a better leaving group by reaction 
with an acid or formation of an ester or an ether. As shown in Scheme I-10, the oxime 
hydroxyl of I-39 is converted into a better leaving group with an electrophile, subsequently 
forming the oxonium intermediate I-41. Next in the Beckmann rearrangement, the nitrilium 
ion I-42 is formed. This is achieved when the leaving group departs and the substituent 
situated anti to the nitrogen-oxygen (N-O) bond of I-41 migrates to the nitrogen atom.106 
R1 R2
O
R1 or R2 = H, alkyl, or aryl
R1 ≠ R2 when R1 = H
R1 R2
N OH
NH R2
O
anti 
to -OH
syn 
to -OH R1
I-38 I-39 I-40
    
 
22 
This process maximizes the antiperiplanar electron delocalization of the carbon-carbon (C-
C) s orbital to the antibonding s* orbital of the N-O bond.114 
 
  
Scheme I-10. Mechanism for Beckmann rearrangement reaction. 
   
 
Subsequently, the nitrilium ion I-42 reacts with a nucleophile, such as water, to form 
intermediate I-43. This intermediate is deprotonated to furnish imidic acid I-44, which then 
tautomerizes to yield amide I-45 (Scheme I-10). In fact, the oxime I-39 can exist in two 
different and distinct isomers: the E or anti isomer and the Z or syn isomer (Scheme I-11). 
The (E)-isomer I-46 rearranges to give the N-isopropylamide I-47 upon treatment with 
aluminum oxide, while the (Z)-oxime isomer I-46 yields the N-methylamide I-48 under 
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the same normal Beckmann reaction conditions.115 In some cases, the interconversion of 
the two distinct isomers takes place. This type of non-stereospecific conversions explains 
 
 
  
Scheme I-11. E- vs Z- oxime isomer. 
 
 
 
the different products observed, particularly under acidic conditions and in protic 
solvents.116 When both alkyl groups are able to migrate, the more bulky group forms the 
amide in greater proportion.105 
Kenyon et al. investigated the stereochemical course of the Beckmann reaction by 
studying the optically active (R,E)-3-ethylheptan-2-one oxime I-49 and its conversion to 
the corresponding amide I-50 (Scheme I-12).117 They treated the dextrorotatory oxime I-
49 with phosphorus pentachloride to afford the dextrorotatory amide product I-50.118 Then, 
they compared the optical activity of the amide product I-50 with its corresponding dl-
amide and determined that the asymmetry of the migrating group was preserved. 
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Scheme I-12. Examples of retention of stereochemistry  
during the Beckmann Rearrangement. 
 
 
Likewise, experiments by Hill et al. showed the same retention of stereochemistry 
of the Beckmann rearrangement on a system with a trisubstituted-stereogenic carbon 
(Scheme I-12).119 They treated cis-decalin oxime I-51 with p-toluenesulfonic acid chloride 
in pyridine to produce cis-amide I-52 in very good yield. These examples confirm that the 
Beckmann rearrangement reaction proceeds in an intramolecular fashion with retention of 
configuration of the migrating group.120  
Subsequently, Ericksson and colleagues used DFT calculations to show that in the 
case of certain organo-mediated Beckmann rearrangements, a self-propagating mechanism 
is energetically-favored over other mechanisms (Scheme I-13).121 In their proposal, the 
chloride reagent I-54 only initiates the reaction with oxime I-53 rather than actually 
catalyzing the reaction.122 In the initialization step oxime I-53 reactions with chloride I-54 
to yield oxime complex I-55, which then forms nitrilium ion I-56. Next, an addition of 
another oxime I-53 to nitrilium ion I-56 forms a dimer-like structure I-57. Intermediate I-
57 then undergoes the phenyl migration to produce the rearrangement product I-58 while 
simultaneously regenerating the phenyl-nitrilium ion I-56.  
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Scheme I-13. Proposed self-initiation mechanism for  
Beckmann rearrangement reaction. 
 
 
 
2. Nitrile Formation from the Beckmann Fragmentation 
First discovered by Wallach in 1889, the Beckmann reaction can also form a nitrile 
product instead of the amide by a Beckmann fragmentation reaction. Sometimes called the 
abnormal or second-order Beckmann rearrangement, or Beckmann fission, this reaction 
begins like the Beckmann rearrangement reaction with oximes I-39 derived from linear or 
cyclic ketones I-38 (Scheme I-14).  The fragmentation occurs when the C-C a bond breaks 
after shifting to the nitrogen atom, this results in the formation of a nitrile product I-59 and 
carbocation intermediate I-60 (Scheme I-14). In a cyclic system, the fragmentation 
sequence causes the cyclic oxime ring I-39 to open and generate the non-cyclic nitrile 
product I-61.  
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Scheme I-14. Beckmann fragmentation reaction. 
 
In general, the fragmentation reaction can take place when the hydroxyl group of 
an oxime is anti to a group that can stabilize a positive charge, such as a quaternary carbon 
or a heteroatom. The process begins with the addition of an electrophile to activate oxime 
I-39 (Scheme I-15). From here, the oxonium ion I-41 is formed and then nitrilium ion I-
42. Next, I-42 converts into nitrile I-59 and carbocation I-60. Whether Beckmann 
rearrangement or fragmentation takes place is wholly dependent on the exact reaction 
conditions employed, such as using light radiation for promoting the photo-Beckmann 
rearrangement.  
 
  
Scheme I-15. Mechanism of Beckmann fragmentation reaction. 
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3. Photo-Beckmann Rearrangement 
In 1963, De Mayo et al. observed a different product from the direct irradiation of 
aldoxime I-39.123 The aldoxime derived from ketone I-38 forms an oxaziridine 
intermediate I-61 before conversion to amide I-62 (Scheme I-16). This photochemical 
reaction proceeds through an intramolecular oxygen migration and is commonly 
considered a photo-Beckmann rearrangement reaction.124 Ogata and coworkers later 
determined the exact mechanism for this photochemical reaction through studies with 18O-
labeled oximes.125 Also, the photochemical Beckmann rearrangement is not accompanied 
by the corresponding alpha-fission to produce nitrile products, like in the Beckmann 
fragmentation reaction. Instead, the photo-Beckmann reaction is a method to produce the 
regioisomeric amide product I-62 (Scheme I-16). 
 
  
Scheme I-16. Photo-Beckmann reaction. 
 
 
Traditional acid-catalyzed Beckmann reactions typically show the migration of the 
carbon bond anti to the hydroxyl group of the oxime. Whereas in the photo-Beckmann 
reaction, stereoelectronic control dictates that the group anti to the lone pair of the 
oxaziridine is the one that migrates to the nitrogen atom.  Only empirical evidence of this 
transformation exists; it suggests that the photo-Beckmann rearrangement reaction 
involves the photochemical E,Z-isomerization of oxime I-39 (Scheme I-16).126 The work 
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of Suginome et al. for the photo-Beckmann reaction shows the transformations of the 
excited singlet E- and Z-oximes I-39 into oxaziridine intermediate I-61 before  the 
molecule is reorganized to the resulting amide I-62 in a fully concerted manner.  
Lattes and coworkers studied oxaziridine I-63 in which both bonds adjacent to the 
oxaziridine ring are chemically equivalent which rules out a possible steric influence of 
neighboring groups (Scheme I-17).127 X-ray analysis and NMR spectroscopy of I-63 and 
its reaction product after irradiation of the oxaziridine, determined the formation of lactam 
I-64. Their work also concluded that the position of the nitrogen lone pair is anti to bond 
“a.” Thus, oxaziridine I-63 generated amide I-64 by breaking bond “a” and not bond “b” 
and lactam I-65 did not form.  
 
  
Scheme I-17. Mechanism of oxaziridine in photo-Beckmann rearrangement. 
 
 
The interesting outcomes of the possible Beckmann reactions encouraged us to look into 
this existing research further when developing scaffolds around steviol and isosteviol. The 
next section covers our published work with oximes reactions of these aglycones.51 
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B. Oxime Reactions of Steviol and Isosteviol 
The following examples show the versatility of the Beckmann reaction in the 
formation of novel structures by exploring the ent-kaurene skeleton of stevioside (I-8). Our 
group initially applied a diversity-oriented approach to synthesize multiple templates from 
steviol (I-23) and isosteviol (I-25), but continued to explore various reaction routes from 
two of those scaffolds: the steviol and isosteviol oximes, I-67 and I-37, respectively 
(Scheme I-18).51 To synthesize the steviol oxime, the acid and the hydroxyl moieties were 
protected to ease the handling of the compounds and the reaction products. First, 
esterification with dimethyl sulfate followed by acetylation of the C-13 hydroxyl gave 
intermediate ester I-66 in good yields for both reactions. Next, ozonolysis of the methylene 
produced a ketone that was then treated with hydroxylamine to generate the steviol oxime 
I-67. Isosteviol oxime I-37 was produced by esterification of the C-4 acid followed by 
oxime formation of the C-16 ketone. From these oximes, multiple scaffolds were prepared 
from Beckmann rearrangement, Beckmann fragmentation, and photo-Beckmann reactions.  
 
  
 
 
Scheme I-18. Synthesis of steviol oxime I-67 and isosteviol oxime I-37. 
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From isosteviol oxime I-37, we initially observed the Beckmann rearrangement and 
fragmentation products (Scheme I-8). When I-37 was treated with thionyl chloride, an 
almost 1:2 mixture of the lactam and nitrile products, respectively, was observed. We then 
tried to change reaction conditions to selectively engender either the Beckmann 
rearrangement product or the Beckmann fragmentation product in a series of trials (and 
errors). First, oxime I-37 was treated with mesyl chloride to produce the mesylated-oxime 
intermediate I-68 (Scheme I-23). Then, under acidic conditions made with hydrochloric 
acid, lactam I-33, the Beckmann rearrangement product, was obtained as the sole product, 
thus shutting out the Beckmann fragmentation pathway.51 This idea was developed from 
studying the work of White et al. during their morphine synthesis. They formed a 
brosylated oxime intermediate in acetic acid to provide the desired lactam, whereas the 
 
 
 
Scheme I-19. Beckmann rearrangement of oxime I-37. 
 
 
reaction of the corresponding oxime under acidic conditions did not yield any lactam 
product.128 Despite being relatively hindered, this amide lends itself well to alkylation and 
was useful in the development of small-molecule libraries of lactam derivatives, vida 
supra.   
I-37
MsCl, Et3N,
CH2Cl2
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Previously, Coates et al. reported a Beckmann fragmentation reaction using TsCl 
in DMF, but this delivered a 2:1 mixture of the alkenes that required a difficult 
separation.129 With this problem in mind, we investigated the suitability of this 
fragmentation pathway for further library production (Scheme I-20). In our hands, a 
selective Beckmann fragmentation was achieved by reaction of isosteviol oxime I-37 with 
acetic anhydride in acetonitrile, followed by treatment with pTsOH in acetonitrile at 90 °C.  
This reaction with p-toluenesulfonic acid cleanly delivered the Δ12:Δ13 olefinic nitriles I-
35 and I-69 in an 8:1 ratio, respectively, in 84% yield.  Through a single crystallization 
 
  
 Scheme I-20. Beckmann Fragmentation of isosteviol oxime I-37. 
 
 
with dichloromethane and ethyl acetate, this mixture could be enriched to 20:1 in favor of 
the ∆12-nitrile product I-35. The more robust 2-step procedure perhaps proceeds via a 
tetrahedral intermediate in a similar fashion to that described by White et al., in which the 
less sterically crowded anti-stereoisomer favors the migration of the bridgehead carbon in 
the lactam formation.130 The Beckmann fragmentation reaction is well documented for 
systems with a quaternary carbon.131  
Likewise, we repeated the Beckmann fragmentation reaction with the steviol oxime 
intermediate I-67 (Scheme I-21). Upon reaction with acetic anhydride and p-
toluenesulfonic acid in acetonitrile at 90 °C, the steviol oxime I-67 exclusively formed 
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nitrile I-70, as expected, in 67% yield. However, when the solvent is changed, the reaction 
product was completely unexpected. With vigorous heating in toluene, we observed a 
bicyclo[2.2.2]octane product I-71. We determined that the oxime I-67 undergoes a Thorpe-
Ziegler-type cyclization process to afford the octane diketone I-71.51 These experiments 
suggest that the reaction outcomes are partly determined by the character of the oxime 
leaving groups.  Good leaving groups such as sulfonates promote Beckmann rearrangement 
pathway, whereas poorer leaving groups such as the acetates promote the Beckmann 
fragmentation route.   
  
Scheme I-21. Beckmann fragmentation of steviol oxime I-67. 
  
Additionally, when the isosteviol oxime I-37 was subjected to the same reaction 
conditions as the steviol oxime I-67 Beckmann fragmentation sequence in an effort to favor 
the D12-nitrile I-35, this unexpectedly led to the formation of lactone I-32 and another 
bicyclo[2.2.2]octane I-72 in an almost 1:1 ratio of products in 73% yield (Scheme I-22). 
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Scheme I-22. Cyclic products from the isosteviol Beckmann fragmentation product I-35. 
 
The lactone I-32 product has been previously observed, vide supra, while the cyclic ketone 
I-72 product is novel to this work. We conclude that the formation of I-72 was the result 
of a cyano-Prins-type cyclization to generate the ketone product.51 We have proposed the 
following scheme to show mechanistically how the formations of the cyclic products are 
possible (Scheme I-23). 
 
 
  
Scheme I-23. Proposed mechanisms for the formation of cyclic products. 
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In our exploration of the Beckmann reaction products of the steviol and isosteviol 
scaffolds, we also explored the photo-Beckmann rearrangement reaction (Scheme I-24).132  
This work was initially done to verify the isosteviol lactam I-32 product. We first converted 
isosteviol I-25 to its ester I-73. From there, the isosteviol ester I-73 was heated in the 
presence of benzylamine under dehydrating conditions to afford imine I-74.133 Then, to 
generate the oxaziridine ring for irradiation, the imine I-74 was epoxidized with m-
chloroperoxybenzoic acid to provide oxaziridine I-75. 
 
    
 
Scheme I-24. Photo-Beckmann of isosteviol ester I-73. 
 
 
Notably, the oxidation occurred exclusively at the exo face of the CD-rings. The structure 
of the oxaziridine was not independently confirmed until we were able to compare the 
photo-Beckmann lactam product I-76 with its regioisomeric lactam I-77 from the 
photolysis step (Scheme I-24). Equipped with a photochemical immersion well reactor and 
a 254 nm mercury lamp,134 we were able to generate a flow reaction and regioselectively 
deliver the expected photo-Beckmann lactam I-76 in 56% yield and the minor regioisomer 
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I-77 in 7% yield. The minor product I-77 can also be obtained by synthesizing alkylated 
lactam libraries of amide I-33, (vida infra, Scheme I-26). For the Beckmann 
rearrangement, the bond that migrates is the one that is anti to the lone pair on nitrogen,135 
however, the outcome of the photo-Beckmann is also stereoelectronically defined. That is 
to say, the stereoelectronic effect of the oxaziridine ring is able to promote the migration 
of the N-O bond antiperiplanar to the nitrogen lone pair. Formation of minor regioisomer 
I-77 is a result from the exo-oxaziridine derived from the other imine isomer, (Z)-I-74 (not 
shown). As stated earlier, the isolation of the lactam I-76 helped confirm the assignment 
of the E-imine I-74. 
 
 
Chapter 3. Design and Synthesis of Small Molecule Libraries from the Stevioside 
Diterpene Scaffolds 
A. Synthesis of Mono-functional Small Molecule Libraries 
Steviol and isosteviol serve as scaffolds for library development with reactions 
aimed at transforming the carboxylic acid moiety of the A-ring in both compounds to 
amides. Additionally, formation of the oxime intermediate I-37 from the C-16 ketone of 
isosteviol was crucial in providing lactam I-33, nitrile I-35, and amine I-36 (Scheme I-8). 
Each of these transformations yielded reaction products that can be further used for library 
synthesis through amide formation. Another route enlisted explores the D-ring of the ent-
kaurene core skeleton. D-ring modifications from alkylation of the hydroxyl or amino 
moieties can further create diverse compounds to explore chemical space.  
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1. Initial Amide Validation Array 
With the steviol aglycones in hand, we set out to prepare a small molecule library using 
these scaffolds. Validation arrays were set up for the steviol (I-23) and isosteviol (I-25) 
molecules for amide bond formation utilizing both solution and solid phase chemistry to 
provide amides I-79 and I-80 (Scheme I-25). These reactions were carried out to compare 
product yields, ease of work-up, and purity of products. For the solution phase chemistry, 
steviol (I-23) and isosteviol (I-25) was converted to the corresponding acid chloride by 
reaction with oxalyl chloride and then reacted with amines I-78a, b, d, and j (Figure I-7) 
to furnish amides I-79a, b, d, and j and I-80a, b, d, and j. For the second array, we used 
polymer-bound 1-hydroxybenzotriazole (HOBt), a reagent that reacts with the acid moiety 
to form a reactive ester intermediate. Isosteviol was loaded on to the polymer by using the 
coupling reagent EDCI in the presence of DMAP.  The polymer bound activated ester was 
purified by several washes and then reacted with amines I-78a, b, d, and j to form the 
corresponding amides I-79a, b, d, and j and I-80a, b, d, and j.  Use of the amine as the 
limiting reagent in this reaction assures high purity of the resulting amide reaction products.  
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Scheme I-25. Validation array for steviol (I-23) and isosteviol (I-25) by solution phase 
(A) and solid phase synthesis (B). 
 
 
With the solution-phase method we encountered unanticipated problems with solubility 
during the purification process and NMR analysis showed only 25 to 50 percent conversion 
of most of the compounds. Eventually, this method was abandoned for an easier solid phase 
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chemistry approach to obtain multiple compounds in parallel with much easier work up 
and purification conditions. After careful analysis and comparison of both the solution and 
solid phase approaches, we decided to carry out a polymer-supported parallel synthesis for 
the synthesis of our libraries. The resin-bound synthesis approach allowed for a simple 
filtration to obtain the final products in high purity.  
 
  
Figure I-7. Amines I-78a-z for library synthesis. 
 
 
 
 
 
2. Amide Libraries 
Using parallel solid phase synthesis, we then prepared small libraries from steviol 
(I-23), isosteviol (I-25), lactam I-33, nitrile I-35 and amine I-36 with amines I-78 (Scheme 
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I-26). A selection of diverse primary amines was used in the library production (Figure I-
7). This work produced almost 60 compounds of diverse amide libraries for evaluation. 
 
  
Scheme I-26. Amide Libraries I-79, I-80, I-82, I-84, and I-86. 
 
3. Ether and Amine Libraries 
After modifying the carboxylic acid moiety on the A ring, modifications of the C 
and D rings were explored through alkylation of the hydroxyl group of steviol, reduction 
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of the ketone of isosteviol, and alkylation of the D-ring lactam (Scheme I-27). A small set 
of alkyl halides were used for the synthesis of alkylated products (Figure I-8).  
 
 
 
Figure I-8. Alkyl halide compounds for library synthesis. 
 
 
We first converted the acid functionalities of scaffolds I-23, I-25, I-33, I-35, and I-36 to 
the corresponding methyl esters.  Reacting the hydroxyl group of the steviol methyl ester 
with alkylating agents I-87a-i provided ethers I-88a-i (Scheme I-27).  The C-16 ketone 
group of the isosteviol methyl ester was reduced with sodium borohydride to yield the 
corresponding secondary alcohol, which then was alkylated with I-87a-f to provide ethers 
I-89a-f.136 N-Alkylated lactams I-90a-j were obtained by reaction of lactam I-33 with I-
87a-j, while N-alkylated amines I-91a-e were generated from reacting amine I-36 with I-
87a-e.  The alkylation reactions for steviol, isosteviol, and lactam I-33 were carried out 
with sodium hydride, because a strong base was necessary to facilitate the removal of the 
hydroxyl proton for ether formation and amide proton for lactam alkylation. This route 
created a 30-membered library of O- and N-alkylated reaction products. 
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Scheme I-27. Synthesis of ether and amine libraries. 
 
 
B. Synthesis of Bifunctional Small Molecular Libraries 
1. Rationale for Bifunctional Libraries 
In the drug development and chemical biology disciplines, achieving binding 
between a target and a small molecule that is generating a biological effect is the starting 
point that drives further structure-activity exploration. In order to enhance biological 
activity, often more than one functional group is added to the molecule to form a bi- or 
multi-functional molecule. A bifunctional molecule can interact either with one protein or 
with two protein molecules simultaneously. In some instances, a molecule that consists of 
two protein-binding groups can be connected via a linker.137 While most linker regions 
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consist of cleavable groups138 or drug molecules,139 there have been molecules with a 
natural product in the linker region.140 In the synthesis of our bifunctional libraries, the ent-
kaurene will essentially serve as the linker with functional groups flanking either end of 
the scaffold. In addition, drug-like combinatorial libraries can be generated from 
combinations of “natural product-like” scaffolds and “drug-like” functional groups.141 As 
noted by Corson et al., having two functional groups that can potentially bind is better than one, 
especially in terms of increasing activity.137 Here, we attempted to expand the potential of 
biological activity of our compounds by generating bifunctional molecules. 
 
2. Synthesis of Bifunctional Libraries 
Bifunctional libraries can be prepared using alkylated products I-87 through I-90 
and synthesizing their respective amides. Scheme I-28 shows a representative example of 
one such library: the reaction of N-methyl amide analog I-90a from previous library 
synthesis, vide supra, with amines I-78a-d. First, we hydrolyzed the ester to expose the 
carboxylic acid for amide production. Then, standard amide formation with polymer-
supported chemistry, vide supra, generated bifunctional N-methyl lactam amides I-92a-d. 
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Scheme I-28. Synthesis of a bifunctional library from amide I-50a. 
 
 
C. Evaluation of Steviol- and Isosteviol-Derived Libraries 
1. Biological Activity of Steviol and Isosteviol Library of Analogs  
Compounds were then submitted to the NIH Molecular Libraries Small Molecule 
Repository for biological evaluation.48  Through PubChem mining, we were able to 
visualize the activity of our compounds. Table I-1 below provides a listing of compounds 
that were evaluated in over 50 assays by the Molecular Libraries Screening Center Network 
so far. Several library members, including previously submitted compounds I-37, I-66, I-
67, and I-93 (Figure I-9) that displayed single digit or double digit micromolar inhibition 
of target proteins are displayed.  
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Figure I-9. Other steviol and isosteviol derivatives submitted to the MSLMR. 
 
 
Table I-1 shows current PubChem data on submitted compounds that have been tested by 
the MLSMR.142, 143 The compounds were tested in a variety of assays to determine their 
bioactivity and identified as a chemical probe, active, inactive, inconclusive, or unspecified 
in the experiments. The table below only displays compounds that were found to be 
“active” in primary screens or “active” with concentration data in confirmatory assays. 
Compounds that were found inactive, inconclusive, or unspecified from the bioactivity 
results, which make up a majority of the available screening data, are not listed. Typically, 
initial or primary screens were performed first to determine whether or not a compound is 
active, followed by confirmatory screens to determine the concentration of the compound 
in the activity screen. 
 
Table I-1. Activity of Steviol and Isosteviol Analogs 
Compound PubChem ID 
Assay 
ID BioAssay 
Activity (if given) 
Assay 
Type 
Result or 
Value 
(µM) 
I-23 
 
9905087 602438 
uHTS identification of 
modulators of interaction 
between CendR and NRP-1 
using Fluorescence 
Polarization assay 
Primary 
screen active 
I-25 
 
42601320 652104 qHTS of TDP-43 inhibitors Confirmatory screen 
IC50A 
19.953 
OAc
OMeO
I-66
O
OAc
OMeO
N
OAc
OMeO
N
OMeO
OHOH
I-93I-67I-37
OHO
OH
OHO
O
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I-33 
 
42601318 720706 
HTS for bacterial rRNA 
inhibitors measured in 
microorganism-based 
system 
Primary 
screen active 
I-79b 
 
42601330 
540271 
In vivo-based yeast HTS to 
detect compounds rescuing 
yeast growth/survival of 
Plasmodium Falciparum 
HSP40-mediated toxicity 
measured in whole organism 
system 
Confirmatory 
screen 
AbsACC 
1.427 
686978 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
18.356 
652041 
Cell-based secondary assay 
to test the inhibitory activity 
of small molecule on 
Plasmodium falciparum 
(HB3 strain) survival in red 
blood cells measured in cell-
based system 
Confirmatory 
screen 
AbsAC 
21.72 
652047 
Cell-based secondary assay 
to test the inhibitory activity 
of small molecule on 
Plasmodium falciparum 
(3D7 strain) survival in red 
blood cells measured in cell-
based system 
Confirmatory 
screen 
AbsAC 
30.22 
2825 
uHTS Luminescent assay for 
identification of inhibitors of 
NALP3 in yeast 
Primary 
screen active 
435006 
Single concentration 
confirmation of uHTS for the 
identification of inhibitors of 
NALP3 in yeast using a 
luminescent assay 
Primary 
screen active 
504582 
In vivo-based yeast HTS to 
detect compounds rescuing 
yeast growth/survival of 
Plasmodium Falciparum 
HSP40-mediated toxicity 
measured in whole organism 
system 
Primary 
screen active 
I-79d 42601335 624417 qHTS of GLP-1 Receptor Inverse Agonists 
Confirmatory  
screen 
EC50 
10 
OMeO
NH
O
OHN
O
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624466 
Fluorescence-based cell-
based primary HTS assay to 
identify antagonists of 
human TAAR1 
Primary 
screen active 
2825 
uHTS Luminescent assay for 
identification of inhibitors of 
NALP3 in yeast 
Primary 
screen active 
504582 
In vivo-based yeast HTS to 
detect compounds rescuing 
yeast growth/survival of 
Plasmodium Falciparum 
HSP40-mediated toxicity 
measured in whole organism 
system 
Primary 
screen active 
I-79j 
 
42601331 
488784 
Single concentration 
confirmation of inhibitors of 
NALP3 in yeast using 
Caspase-1-ASC counter 
screen 
Primary 
screen active 
2685 
qHTS Assay for Lipid 
Storage Modulators in 
Drosophila S3 Cells 
Confirmatory 
screen 
EC50 
0.651 
2825 
uHTS Luminescent assay for 
identification of inhibitors of 
NALP3 in yeast 
Primary 
screen active 
463195 
uHTS identification of small 
molecule inhibitors of tim10 
yeast via a luminescent assay 
Primary 
screen active 
435006 
Single concentration 
confirmation of uHTS for the 
identification of inhibitors of 
NALP3 in yeast using a 
luminescent assay 
Primary 
screen active 
488794 
Single concentration 
confirmation of uHTS for the 
identification of inhibitors of 
NALP3 in yeast using a 
luminescent assay-retest 
Primary 
screen active 
I-79k 
 
 
42601329 
2825 
uHTS Luminescent assay for 
identification of inhibitors of 
NALP3 in yeast 
Primary 
screen active 
488784 
Single concentration 
confirmation of inhibitors of 
NALP3 in yeast using 
Caspase-1-ASC counter 
screen 
Primary 
screen active 
OHN
O
OMe
OHN
O
O
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488794 
Single concentration 
confirmation of uHTS for the 
identification of inhibitors of 
NALP3 in yeast using a 
luminescent assay-retest 
Primary 
screen active 
I-79m 
 
42601326 2825 
uHTS Luminescent assay for 
identification of inhibitors of 
NALP3 in yeast 
Primary 
screen active 
I-79n 
 
42601334 686978 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
23.109 
I-79s 
 
42601327 
686978 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
23.109 
686979 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
18.356 
602438 
uHTS identification of 
modulators of interactions 
between CendR and NRP-1 
using Fluorescence 
Polarization assay 
Primary 
screen active 
I-79t 
 
42601332 
602123 
Fluorescence polarization-
based primary biochemical 
HTS assay to identify 
inhibitors of E. coli DNA-
binding ATP-dependent 
protease La (eLon) 
Primary 
screen active 
624169 
Luminescence-based cell-
based primary HTS assay to 
identify agonists of the 
mouse HTR2A 
Primary 
screen active 
I-79u 
 
42601333 
652048 qHTS of D3 Dopamine Receptor Agonist 
Primary 
screen active 
652051 qHTS of D3 Dopamine Receptor Potentiators 
Primary 
screen active 
I-79v 
 
42601336 504582 
In vivo-based yeast HTS to 
detect compounds rescuing 
yeast growth/survival of 
Plasmodium Falciparum 
HSP40-mediated toxicity 
measured in whole organism 
system 
Primary 
screen active 
O
ON
H
OHN
O
O
OHN
O
ON
O
ON
O
O
OHN
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I-79w 
 
42601328 602438 
uHTS identification of 
modulators of interactions 
between CendR and NRP-1 
using Fluorescence 
Polarization assay 
Primary 
screen active 
I-90a 
 
42601319 - Inconclusive data in 7 assays and inactive in 417 assays 
Primary 
screen inactive 
I-77/I-90b 
 
53299290 - N/A N/A N/A 
I-90c 
 
42601337 
624132 
Shn3: Dual-Go Shn3RL 
cells measured in cell-based 
system 
Confirmatory 
screen 
AC50D 
10.58 
624133 
Schnurri-3 Inhibitors: 
specific inducers of adult 
bone formation measured in 
cell-based system 
Confirmatory 
screen 
AC50 
8.16 
504832 
Primary qHTS for delayed 
death inhibitors of the 
malarial parasite plastid, 48 
hr incubation 
Confirmatory 
screen 
IC50 
1.651 
504834 
Primary qHTS for delayed 
death inhibitors of the 
malarial parasite plastid, 96 
h incubation 
Confirmatory 
screen 
IC50 
1.472 
504444 Nrf2 qHTS screen for inhibitors 
Confirmatory 
screen 
IC50 
14.581 
651820 qHTS assay for inhibitors of Hepatitis C Virus 
Confirmatory 
screen 
IC50 
12.589 
686978 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
6.513 
686979 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
11.582 
743417 
Schnurri-3 Inhibitors: 
specific inducers of adult 
bone formation measured in 
cell-based system 
Confirmatory 
screen 
AC50 
8.16 
I-91b 
 
42601325 686978 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
20.596 
O
OHN
Cl
MeO O
N
O
MeO O
N
O
Ph
MeO O
N
O
OMe
OHO
NH
Ph
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I-66 
 
42601321 
588850 
uHTS identification of cystic 
fibrosis induced NFkB 
inhibitors in a fluorescence 
assay 
Primary 
screen active 
686979 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
18.356 
602438 
uHTS identification of 
modulators of interactions 
between CendR and NRP-1 
using Fluorescence 
Polarization assay 
Primary 
screen active 
I-93 
 
42601322 
686979 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
20.596 
624466 
Fluorescence-based cell-
based primary HTS assay to 
identify antagonists of 
human TAAR1 
Primary 
screen active 
I-67 
 
42601323 
686978 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
16.360 
686979 
qHTS for inhibitors of 
human TDP1: qHTS in cells 
in absence of CPT 
Confirmatory 
screen 
EC50 
16.360 
I-37 
 
42601324 
686978 
qHTS of inhibitors of human 
TDP1: qHTS in cells in 
absence of CPT 
Confirmatory 
screen 
EC50B 
20.596 
463212 
uHTS identification of small 
molecule inhibitors of 
tim23-1 yeast via a 
luminescent assay 
Primary 
screen active 
463218 
Single concentration 
confirmation of small 
molecule inhibitors of 
tim23-1 yeast via a 
luminescent assay 
Primary 
screen active 
AIC50= concentration of an inhibitor required for 50% inhibition of maximum control response; 
BEC50= concentration of an agonist required to produce 50% maximum (effective) response; 
CAbsAC= Absolute active concentration with compounds below 10 µM to be considered active 
hits; DAC50= concentration required to elicit a 50% response in an in vitro assay 
 
Our small molecule libraries showed activity in numerous assays with a variety of 
protein targets, including neuropilin-1 (NRP-1), tyrosyl-DNA phosphodiesterase 1 
OMeO
OAc
O
OAc
OMeO
N
OAc
OMeO
OH
OMeO
NOH
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(TDP1), NACHT, Leucine-rich repeat, Pyrin domain-containing-3 (NALP3), hepatitis C 
virus (HCV), glucagon-like peptide-1 (GLP1), or lipid storage modulators. NRP-1 is a 
protein receptor for vascular endothelial growth factor; it plays a role in angiogenesis and 
is being studied for its role in tumor growth progression for anticancer research.144, 145 The 
TDP1 enzyme is also investigated for its anticancer development through its mechanism 
of DNA repair and treatment for spinocerebellar ataxia, which is caused by a TDP1 
mutation.146 Furthermore, many of our compounds showed activity in an assay for NALP3, 
a protein that is involved in the inflammatory process of the human innate immune 
system.147 Primary screens for inhibitors of the NALP3 protein can provide potential 
starting points for anti-inflammatory therapeutic development.148 Lactam I-50c showed 
low micromolar activity in a confirmatory inhibitor assay for HCV (Table I-1).  Current 
treatments for HCV infections are costly and poorly accessible, and there is an unmet need 
to develop a detection method  to diagnose those who are infected.149 Recently, Lin et al. 
created a 33 ureido- and amide-substituted steviol analogs, similar to amide products I-
40a-k of steviol (I-23), to study their inhibitory effects against the Hepatitis B Virus 
(HBV), which similar to HCV infections can lead to liver cirrhosis and cancer.95 Their 
work demonstrates the importance of using natural products and their analogs as sources 
for therapeutic research as well as implies the potential for isosteviol analogs to be further 
investigated in HBV drug development. Finally, both GLP1 and lipid storage modulators 
have been instrumental in diabetes and anti-obesity research.150, 151 Our compounds showed 
at least 10 micromolar activity in confirmatory assays for these proteins (Table I-1). 
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2. Computational Comparison with Commercial Libraries 
Additionally, we sought to determine the potential utility of the compounds by 
measuring parameters beyond the Lipinski’s “rule of five.”152 Walters and coworkers 
previously analyzed over 415,000 molecules reported in the Journal of Medicinal 
Chemistry from 1959 to 2009.153 In their investigation, they identified eight important 
properties for all the drugs or drug-like molecules to be molecular weight (MW), cLogP, 
total polar surface area (TPSA), rotatable bonds, hydrogen bond donors (HBD), hydrogen 
bond acceptors (HBA), complexity, and fraction of sp3 carbons (Fsp3). From this 
information, Hergenrother and coworkers established the importance for compounds to 
have higher Fsp3 values, from 0 to 1, and lower cLogP values, lower than 5 units, in order 
to be developed into drugs.154 The Fsp3 value pertains to the number of sp3-hybridized 
carbon atoms in a compound divided by the sum of carbon atoms and this value can indicate 
lower melting points as well as enhanced aqueous solubility.155 They calculated four main 
parameters: Fsp3, cLogP, number of stereocenters, and Tanimoto similarity coefficients of 
their compounds compared to a 150,000-member ChemBridge collection. In our case, we 
compared our library to the ChemBridge CombiSet and the Maybridge Diversity Set of 
compounds, which contain 30,000 and about 54,000 compounds, respectively. We 
expected this would offer insight in to the diversity of our libraries relative to two 
commercially-available libraries. 
Similarly, our group employed the Pipeline Pilot software to calculate ALogP 
values,156 the number of stereocenters, and the Fsp3 ratio.157 While our compounds have 
an average cLogP of 4.69, the compounds investigated by Hergenrother et al. had an 
average cLogP of 2.90 (Chart I-1).154  
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Chart I-1. Comparison of cLogP values. 
 
The ChemBridge and MayBridge library sets that we chose for comparison have an average 
cLogP value of 3.11 and 3.04, respectively. With such a lipophilic core scaffold, we 
endeavored to create less lipophilic compounds by adding various substituents and 
hydrophilic groups that would lower cLogP values. Our Fsp3 calculations yielded an 
average of 0.79, while the ChemBridge and MayBridge libraries have average Fsp3 values 
of 0.45 and 0.22, respectively (Chart I-2).  
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Chart I-2. Comparison of Fsp3 values. 
 
 
The number of stereocenters in a compound can correlate to its structural 
complexity; on average, the structures in our compound library contained six stereocenters, 
while the ChemBridge and Maybridge libraries both have zero averages. Interestingly, 
Hergenrother’s library of compounds had an average of 5.17 stereocenters (Chart I-3).154 
The majority of the compounds in the commercial libraries contain aromatic rings and aryl 
group substitutions to account for their lack of stereocenters.  
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Chart I-3. Comparison of the number stereocenters per molecule. 
 
Our compounds as well as those in the compound library of Hergenrother’s group 
appear to be more structurally complex with a greater number of stereocenters because they 
are natural product analogs. ChemBridge and Maybridge compound libraries contain 
compounds with no or few stereocenters. This is perhaps because less complex molecules 
are relatively easier to synthesize.158  
Furthermore, similarity coefficients were generated (Tanimoto, ECFP_4) to 
determine the structural similarity between the compounds in our libraries. These values 
are graphed in a matrix format in Chart 1 to allow visualization of the pairwise similarity 
of the compounds. That is an intersection of a column and a row contains the calculated 
similarity between the compounds in the row and column. Low scores (blue) indicate a 
relatively high level of difference between the structures, while high scores (red) indicate 
very similar (0.700< ratio <1.00) or the identical structure (coefficient = 1.00) when a 
compound is compared to itself. Low (blue) pairwise similarity is desired in a diverse 
library. The calculated average similarity between compounds in the library was 0.44. 
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Over half, or 63%, of the complete steviol and isosteviol analog library compounds had 
similarities below 0.44, represented in Chart 1 as indicated by the blue cells in Chart 1. 
 
 
Chart I-4. A representative chart of the pairwise similarity for the steviol and isosteviol 
library compounds described herein. Red indicates similarity coefficient of 1.0 (identical) 
and Blue indicates pairwise structural comparison with similarities less than the average 
pairwise similarity for the entire library. a 
aA full chart is available in the Appendix A. 
 
 
D. Concluding Remarks 
In conclusion, we have designed and synthesized a number of diverse and novel 
scaffolds from the stevioside aglycones: steviol I-23 and isosteviol I-25. This research was 
aimed at eliciting potential biological activity from the modified ent-kaurene core given 
the precedence of natural products exhibiting pharmacological properties that can be used 
for drug discovery. We have shown different approaches in library development from many 
different templates as well as explored the synthesis of multiple structures derived from the 
Beckmann reaction pathways. The submitted compounds from our libraries that have been 
Cmpd 24 25 11{1} 10{1} 13{1} 11{5} 10{5} 13{5} 19{2} 17{2} 15{2} 20{3} 20{5} 21{3} 21{5} 22{3} 22{5} 23{1} 26 27 8 5 7 2 1
24 1.000 0.792 0.456 0.406 0.389 0.403 0.346 0.333 0.677 0.329 0.262 0.444 0.463 0.472 0.507 0.438 0.456 0.384 0.737 0.567 0.525 0.576 0.420 0.443 0.525
25 0.792 1.000 0.380 0.455 0.394 0.338 0.405 0.354 0.561 0.333 0.265 0.451 0.470 0.500 0.538 0.444 0.463 0.389 0.750 0.576 0.534 0.614 0.426 0.526 0.435
11{1} 0.456 0.380 1.000 0.695 0.661 0.657 0.440 0.423 0.427 0.425 0.346 0.321 0.329 0.346 0.368 0.333 0.342 0.651 0.378 0.406 0.348 0.391 0.295 0.444 0.691
10{1} 0.406 0.455 0.695 1.000 0.712 0.453 0.631 0.453 0.382 0.437 0.354 0.329 0.338 0.372 0.397 0.342 0.351 0.700 0.370 0.462 0.358 0.424 0.303 0.648 0.444
13{1} 0.389 0.394 0.661 0.712 1.000 0.436 0.453 0.647 0.367 0.419 0.341 0.317 0.325 0.358 0.382 0.329 0.338 0.667 0.355 0.380 0.343 0.644 0.291 0.438 0.424
11{5} 0.403 0.338 0.657 0.453 0.436 1.000 0.721 0.690 0.450 0.487 0.405 0.318 0.294 0.341 0.329 0.345 0.306 0.430 0.337 0.359 0.308 0.346 0.279 0.389 0.594
10{5} 0.346 0.405 0.440 0.631 0.453 0.721 1.000 0.746 0.395 0.507 0.420 0.329 0.305 0.369 0.358 0.357 0.317 0.447 0.333 0.411 0.320 0.378 0.289 0.565 0.375
13{5} 0.333 0.354 0.423 0.453 0.647 0.690 0.746 1.000 0.381 0.487 0.405 0.318 0.294 0.356 0.345 0.345 0.306 0.430 0.321 0.342 0.308 0.567 0.279 0.389 0.360
19{2} 0.677 0.561 0.427 0.382 0.367 0.450 0.395 0.381 1.000 0.434 0.357 0.514 0.432 0.500 0.473 0.468 0.427 0.363 0.529 0.500 0.463 0.507 0.413 0.391 0.463
17{2} 0.329 0.333 0.425 0.437 0.419 0.487 0.507 0.487 0.434 1.000 0.521 0.453 0.411 0.354 0.325 0.507 0.425 0.413 0.316 0.338 0.583 0.342 0.288 0.368 0.357
15{2} 0.262 0.265 0.346 0.354 0.341 0.405 0.420 0.405 0.357 0.521 1.000 0.281 0.241 0.289 0.261 0.322 0.253 0.337 0.253 0.268 0.250 0.272 0.662 0.289 0.282
20{3} 0.444 0.451 0.321 0.329 0.317 0.318 0.329 0.318 0.514 0.453 0.281 1.000 0.656 0.583 0.434 0.712 0.529 0.313 0.427 0.457 0.581 0.464 0.395 0.352 0.342
20{5} 0.463 0.470 0.329 0.338 0.325 0.294 0.305 0.294 0.432 0.411 0.241 0.656 1.000 0.421 0.537 0.529 0.683 0.321 0.443 0.477 0.643 0.484 0.389 0.364 0.353
21{3} 0.472 0.500 0.346 0.372 0.358 0.341 0.369 0.356 0.500 0.354 0.289 0.583 0.421 1.000 0.682 0.575 0.416 0.461 0.453 0.486 0.449 0.515 0.403 0.400 0.370
21{5} 0.507 0.538 0.368 0.397 0.382 0.329 0.358 0.345 0.473 0.325 0.261 0.434 0.537 0.682 1.000 0.429 0.529 0.493 0.486 0.523 0.484 0.556 0.411 0.431 0.397
22{3} 0.438 0.444 0.333 0.342 0.329 0.345 0.357 0.345 0.468 0.507 0.322 0.712 0.529 0.575 0.429 1.000 0.662 0.325 0.421 0.451 0.571 0.457 0.390 0.347 0.338
22{5} 0.456 0.463 0.342 0.351 0.338 0.306 0.317 0.306 0.427 0.425 0.253 0.529 0.683 0.416 0.529 0.662 1.000 0.333 0.437 0.470 0.632 0.477 0.384 0.358 0.348
23{1} 0.384 0.389 0.651 0.700 0.667 0.430 0.447 0.430 0.363 0.413 0.337 0.313 0.321 0.461 0.493 0.325 0.333 1.000 0.351 0.375 0.338 0.400 0.288 0.431 0.418
26 0.737 0.750 0.378 0.370 0.355 0.337 0.333 0.321 0.529 0.316 0.253 0.427 0.443 0.453 0.486 0.421 0.437 0.351 1.000 0.732 0.500 0.548 0.403 0.444 0.431
27 0.567 0.576 0.406 0.462 0.380 0.359 0.411 0.342 0.500 0.338 0.268 0.457 0.477 0.486 0.523 0.451 0.470 0.375 0.732 1.000 0.544 0.596 0.433 0.564 0.467
8 0.525 0.534 0.348 0.358 0.343 0.308 0.320 0.308 0.463 0.583 0.250 0.581 0.643 0.449 0.484 0.571 0.632 0.338 0.500 0.544 1.000 0.554 0.415 0.414 0.400
5 0.576 0.614 0.391 0.424 0.644 0.346 0.378 0.567 0.507 0.342 0.272 0.464 0.484 0.515 0.556 0.457 0.477 0.400 0.548 0.596 0.554 1.000 0.439 0.491 0.450
7 0.420 0.426 0.295 0.303 0.291 0.279 0.289 0.279 0.413 0.288 0.662 0.395 0.389 0.403 0.411 0.390 0.384 0.288 0.403 0.433 0.415 0.439 1.000 0.324 0.314
2 0.443 0.526 0.444 0.648 0.438 0.389 0.565 0.389 0.391 0.368 0.289 0.352 0.364 0.400 0.431 0.347 0.358 0.431 0.444 0.564 0.414 0.491 0.324 1.000 0.640
1 0.525 0.435 0.691 0.444 0.424 0.594 0.375 0.360 0.463 0.357 0.282 0.342 0.353 0.370 0.397 0.338 0.348 0.418 0.431 0.467 0.400 0.450 0.314 0.640 1.000
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tested, demonstrate initial activity in a variety of different assays, thus proving the ent-
kaurene core scaffold is a viable starting point to elicit biological activity and for 
therapeutic development.  
 
Chapter 4. Experimental Data 
A. General Methods 
Unless otherwise stated, reactions were carried out open to air with reagent grade solvents 
without purification. Tetrahydrofuran (THF), toluene, diethyl ether (Et2O), and 
dichloromethane (CH2Cl2 or DCM) were purified by passage through a bed of activated 
alumina. Purification of reaction products was carried out by flash column chromatography 
using silica gel 60 (230-400 mesh). Analytical thin layer chromatography (TLC) was 
performed on 0.25 mm silica gel 60-F plates. Visualization was accomplished with UV 
light and cerium molybdate stain followed by heating. Infrared spectra (IR) were reported 
on NaCl or KBr plates using a FT-IR spectrometer. High-resolution mass spectral data 
were acquired utilizing the electrospray ionization technique. Optical rotations were 
measured using a polarimeter. 1H NMR spectra were recorded at ambient temperature at 
400 MHz and are reported in ppm using a solvent as an internal standard (CDCl3 at 7.26 
ppm or CD3OD at 3.31 ppm). Proton-decoupled 13C NMR spectra were recorded at 100 
MHz and are reported in ppm using a solvent as an internal standard (CDCl3 at 77.16 ppm). 
The data are reported as follows: chemical shift on the d scale, multiplicity (b = broad, s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz), and 
integration. Melting points were determined with Electrothermal Digital Mel-Temp 3.0 
melting point apparatus. High-resolution mass spectra were recorded with electron-spray 
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ionization (ESI) or electron ionization (EI) with a Bruker BioTOF II ESI/TOF-MS 
instrument, while low-resolution mass spectra were recorded with a CombiFlash Rf+ 
PurIon instrument. 
 
 
B. DOS Scaffolds 
 
Steviol (I-23). 
 
Enzymatic route: To a 2 L round-bottomed flask containing stevioside (I-23) (100 g, 124 
mM) in citrate-phosphate buffer (1 L, pH 4) was added hesperidinase enzyme from 
Aspergillus niger (330 g, 100 units).159 The reaction was allowed to stir at 50 °C for a week, 
at which time TLC analysis indicated that the starting material was consumed. The 
precipitate was collected by filtration in a Buchner flask to yield 30 g of crude steviol (1) 
as a colorless powder. The crude compound was then dissolved in ethanol (50 mL) and 
allowed to crystallize overnight to give steviol (I-23, 21 g, 52%).  
Non-enzymatic route: To a solution of stevioside (10.0 g, 12.4 mmol) in 200 mL of 
deionized water was added NaIO4 (7.98 g, 37.3 mmol). The mixture was stirred overnight 
at 0 °C (Cryocool apparatus). Then, KOH (6.95 g, 124 mmol) was added slowly to the 
resulting solution, which was subsequently refluxed for another 2 h. The resulting solution 
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was cooled, acidified with acetic acid to a pH of 3–4, and extracted with EtOAc. The 
combined extracts were washed with distilled water and brine, dried over MgSO4, and 
concentrated in vacuo to give the crude product, which was then purified by flash 
chromatography with 25% EtOAc:Hex to give 790 mg of steviol (I-23) in 20% yield. mp 
203-208 °C (Lit 206-207 ºC);160 1H NMR (400 MHz, CDCl3): δ 4.83 (d, J = 66.2 Hz, 2H), 
2.17 – 1.97 (m, 4H), 1.93 – 1.76 (m, 3H), 1.76 – 1.63 (m, 3H), 1.59 – 1.44 (m, 3H), 1.37 
(td, J = 13.3, 3.9 Hz, 2H), 1.26 – 1.21 (m, 1H), 1.17 (s, 3H), 1.04 – 0.91 (m, 3H), 0.89 (s, 
3H), 0.76 (td, J = 13.1, 3.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 183.2, 155.7, 103.0, 
80.3, 56.8, 53.8, 47.4, 46.9, 43.6, 41.7, 41.2, 40.5, 39.5, 39.3, 37.7, 28.8, 21.8, 20.4, 19.0, 
15.4. HRMS (ESI) (m/z): [M+Na]+ calcd for C20H30O3Na 341.2087, found 341.2080; 
[a]23  D  –63.8º (c 1.00, CHCl3).    
 
 
 
Isosteviol (I-25). 
 
To a 3L 3-necked round-bottomed flask, mounted on a heating mantle, was added 
stevioside (I-8) (201 g, 250.0 mmol) and MeOH (1 L) at ambient temperature. Upon 
dissolution of the stevioside, concentrated HCl (75 mL) was added carefully. A reflux 
condenser was fitted to the flask and the temperature slowly increased until reflux. After 2 
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h the heating mantle was turned off and the reaction allowed to cool to room temperature 
overnight. The methanolic solution was then poured with care into a 5 L Erlenmeyer flask 
(fitted with a mechanical stirrer) of stirring water (3 L). After stirring for 30 minutes, the 
precipitate was collected by filtration in a 200 mm diameter Buchner flask. The flask was 
left under vacuum overnight to dry the precipitate to yield 75 g of crude isosteviol as an 
off-white powder. The crude compound was then dissolved in ethanol (400 mL) and 
allowed to crystallized overnight to give isosteviol (I-6) as colorless crystals (65 g, 82 %): 
Rf = 0.6 (Hex:EtOAc 2:1); mp 230-232 °C (Lit 230-231 ºC);161 1H NMR (400 MHz, 
CDCl3): d 11.66 (br s, 1 H), 2.63 (dd, J = 18.7, 3.7 Hz, 1H), 2.14 (d, J = 13.3 Hz, 1H), 1.87 
(dd, J = 13.9, 1.9 Hz, 1H), 1.81 (d, J = 18.7 Hz, 2H), 1.73 (d, J = 12.9 Hz, 2H), 1.65 (ddd, 
J = 26.4, 14.2, 5.0 Hz, 3H), 1.55 (dd, J = 11.6, 2.5 Hz, 1H), 1.34-1.51 (m, 4H), 1.24 (s, 
3H), 1.18 (ddd, J = 14.0, 12.1, 4.7 Hz, 3H), 0.98-1.06 (m, 1H), 0.97 (s, 3H), 0.90 (td, J = 
13.2, 13.1, 4.1 Hz, 1H), 0.76 (s, 3H); 13C NMR (100 MHz, CDCl3): d 222.8, 183.9, 57.0, 
54.7, 54.3, 48.7, 48.4, 43.7, 41.4, 39.7, 39.5, 38.2, 37.6, 37.3, 28.9, 21.6, 20.3, 19.8, 18.8, 
13.3; IR (film) 2957, 1736, 1693, 1455, 1108 cm–1; HRMS (ESI) (m/z): [M+Na]+ calcd for 
C20H30O3Na 341.2087, found 341.2080; [a]23  D  –89.1º (c 1.00, CHCl3).    
 
 
(4R,4aS,6aR,9S,11aR,11bS)-Methyl 4,9,11b-Trimethyl-8-oxotetradecahydro-6a,9-
methanocyclohepta[a]naphthalene-4-carboxylate (I-73). 
 (4R,4aS,6aR,9S,11aR,11bS,E)-Methyl 8-(Hydroxyimino)-4,9,11b-trimethyl-
tetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-37). 
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To a flame-dried 500 mL round-bottomed flask was added isosteviol (I-25, 20 g, 63 mmol) 
and dry THF (120 mL). Upon dissolution, LiOH•H2O (2.9 g, 68 mmol) was added and the 
reaction stirred for 1 h at room temperature under an atmosphere of nitrogen. Me2SO4 (6.5 
mL, 69 mmol) was slowly added, then a reflux condenser was fitted to the flask and the 
temperature was raised to 80 °C for 18 h. The colorless precipitate was then recovered 
through filtration. The cake was washed repeatedly with Et2O and then concentrated in 
vacuo to furnish methyl ester I-73 (18.3 g, 88%). The reaction was quenched with 10% 
NaOH and then washed with brine and dried over MgSO4. Filtration and removal of the 
solvent under reduced pressure afforded an additional 2.2 g (11%) of ester I-73: Rf = 0.3 
(Hex:EtOAc 9:1); mp 200-202 ºC (Lit 202-203 ºC)1; 1H NMR (400 MHz, CDCl3): d 3.63 
(s, 3H), 2.62 (dd, J = 18.6, 3.8 Hz, 1H), 2.18 (d, J = 13.3 Hz, 1H), 1.89 (dd, J = 13.6, 2.9 
Hz, 1H), 1.74-1.85 (m, 2H), 1.57-1.74 (m, 5H), 1.52 (ddd, J = 17.8, 12.5, 3.3 Hz, 2H), 
1.33-1.45 (m, 3H), 1.19-1.30 (m, 2H), 1.19 (s, 3H), 1.10-1.16 (m, 1H), 0.99-1.06 (m, 1H), 
0.97 (s, 3H), 0.92 (dd, J = 13.2, 4.2 Hz, 1H), 0.68 (s, 3H); 13C NMR (100 MHz, CDCl3): d 
222.4, 177.8, 57.0, 54.7, 54.3, 51.2, 48.7, 48.5, 48.4, 43.8, 41.5, 39.8, 39.4, 37.9, 37.3, 28.8, 
21.7, 20.3, 19.9, 18.9, 13.2; IR (film) 2952, 1744, 1720, 1452, 1240, 1175, 1153 cm-1; 
HRMS (ESI) (m/z): [M+Na]+ calcd for C21H32O3Na 355.2244; found 355.2234; [a]23  D          
–82.2 (c 1.00, CHCl3); reported [a]25  D –69.0º (c 1.02, CHCl3).  
To a 1 L round-bottomed flask was added I-73 (18 g, 55 mmol), EtOH (250 mL), CH2Cl2 
(150 mL), NH2OH•HCl (10.6 g, 165 mmol) and KOAc (16.2 g, 165 mmol). The mixture 
was heated to 50 °C for 1 h after which time TLC analysis indicated the starting material 
was consumed. The mixture was then filtered and the solvent was removed under reduced 
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pressure. The colorless residue was taken up in CH2Cl2 (200 mL). The organic layer wash 
then washed with 10% HCl (100 mL), 1M NaOH (100 mL), and brine (100 mL). The 
aqueous layers were then re-extracted with CH2Cl2 (200 mL) and the combined organic 
layers dried over MgSO4 and filtered. The solvent was then removed under reduced 
pressure and the residue chromatographed on silica gel (Hex:EtOAc 9:1 à 4:1) to yield 
oxime I-37 (18 g, 93%): Rf = 0.2 (Hex:EtOAc 4:1); mp 154-156 ºC (Lit 153-155 ºC);3 1H 
NMR (400 MHz, CDCl3): d 7.42 (br s, 1H), 3.63 (s, 3H), 2.96 (dd, J = 18.6, 3.2 Hz, 1H), 
2.17 (d, J = 13.5 Hz, 1H), 1.97 (d, J = 18.6 Hz, 1H), 1.54-1.89 (m, 8H), 1.38-1.47 (m, 4H), 
1.19-1.31 (m, 2H), 1.18 (s, 3H), 1.10 (d, J = 3.3 Hz, 3H), 1.07 (t, J = 3.3, 3.3 Hz, 1H) 1.00 
(td, J = 13.5, 13.4, 4.2 Hz, 1H), 0.88 (td, J = 13.2, 13.1, 4.2 Hz, 1H), 0.74 (s, 3H); 13C NMR 
(100 MHz, CDCl3): d 178.0, 170.4, 57.1, 56.3, 54.9, 51.2, 43.8, 43.8, 40.9, 40.3, 39.9, 39.5, 
38.05, 38.00, 36.8, 28.7, 22.1, 21.7, 20.4, 18.9, 13.1; IR (film) 3292, 2948, 1724, 1453, 
1235, 1153, 930, 737 cm-1; HRMS (ESI) (m/z): [M+Na]+ calcd for C21H33NO3Na 
370.2353; found 370.2338; [a]23  D  –57.1º (c 1.00, CHCl3).  
 
 
Methyl (4R,4aS,6aR,9S,11aR,11bS)-8-Amino-4,9,11b-trimethyltetradecahydro-6a,9-
methanocyclohepta [a]naphthalene-4-carboxylate (I-36). 
 
To a solution of oxime ester I-37 (348 mg, 1.00 mmol, 1.0 equiv) in MeOH, cooled to 0 
°C (ice bath), was added sodium borohydride (189 mg, 5.00 mmol, 5.0 equiv) then 
molybdenum (VI) oxide (216 mg, 1.50 mmol, 1.5 equiv). The reaction was stirred at 
OMeO
NH2
I-36
NaBH4,
MoO3
20%
OMeO
NOH
I-37
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room temperature overnight. The next day the reaction was filtered, and then the solvent 
was evaporated.  The resulting residue was treated with aqueous KOH (20%) and 
extracted with CH2Cl2. The combined organic layers were washed with brine, dried with 
MgSO4, and then concentrated in vacuo. Column chromatography with 5% MeOH/ 
CH2Cl2 provided amine I-36 in 20% yield. mp 255-258 ºC; 1H NMR (400 MHz, CDCl3): 
3.60 (s, 3H), 3.12 (dd, J = 10.8, 6.6 Hz, 1H), 2.95 – 2.78 (m, 1H), 2.13 (d, J = 13.3 Hz, 
1H), 1.87 – 1.50 (m, 10H), 1.40 – 1.28 (m, 4H), 1.24 (s, 1H), 1.14 (s, 3H), 1.11 – 1.02 
(m, 2H), 1.00 (s, 3H), 0.99 – 0.95 (m, 1H), 0.87 – 0.79 (m, 2H), 0.72 (s, 3H). 13C NMR 
(125 MHz, CDCl3): 178.2, 59.8, 57.1, 56.2, 55.7, 51.3, 49.8, 43.9, 42.6, 41.3, 41.3, 39.9, 
39.2, 38.2, 33.2, 28.9, 24.7, 21.8, 20.3, 18.9, 13.0. HRMS (ESI) (m/z): [M+H]+ calcd for 
C21H36NO2 334.2746, found 334.2747; [a]23  D  –95.3º (c 0.468, EtOH).    
 
 
 
(3S,6aR,8aR,9R,12aR,12bR)-Methyl 3,12a-Dimethyl-5-oxotetradecahydro-1H-3,6a-
methanonaphtho[2,1-d]azocine-9-carboxylate (I-33) and 1R,4aR,4bR,8aR,10aR)-
Methyl 8a-(Cyanomethyl)-4a,7-dimethyl-1,2,3,4,4a,4b,5,8,8a,9,10,10a-
dodecahydrophenanthrene-1-carboxylate (I-35). 
 
 
To a 500 mL flame-dried round-bottomed flask of oxime I-37 (10.0 g, 28.8 mmol) in 
chloroform (200 mL), was added thionyl chloride (6.25 mL, 86.3 mmol). The flask was 
flushed with nitrogen and heated to 60 °C for 10 h until TLC analysis had indicated the 
consumption of starting material. After reaction cooled to room temperature, the organic 
I-33, 30% I-35, 65%OMeO
NH
O
OMeO
CN
OMeO
NOH
I-37
SOCl2
+
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layer was then washed with 1 M NaOH (10 mL) and brine and the aqueous layers were re-
extracted with EtOAc (2x20 mL). The combined organic layers were then dried over 
MgSO4, filtered and the solvent removed under reduced pressure. The residue was 
chromatographed on silica gel (Hex:EtOAc 9:1à CH2Cl2:MeOH 9:1) to give nitrile I-35 
(6.23g, 65%) as white needle-like crystals and lactam I-33 (2.70 g, 27%) as an off-white 
solid.  
I-33: Rf = 0.2 (10% MeOH: CH2Cl2); mp 163-165 °C; IR (film) 3193, 1723, 1657 cm-1; 1H 
NMR (400 MHz, CDCl3): d 5.59 (br s, 1H), 3.62 (s, 3H), 2.91 (dd, J = 18.4, 2.2 Hz, 1H), 
2.17 (d, J = 13.40 Hz, 1H), 1.90 (d, J =18.4 Hz, 1H), 1.72-1.89 (m, 4H), 1.58-1.71 (m, 3H), 
1.55 (d, J = 13.0 Hz, 1H), 1.36-1.50 (m, 3H), 1.28-1.33 (m, 1H), 1.20-1.25 (m, 1H), 1.17 
(s, 3H), 1.16 (s, 3H), 1.07 (dd, J = 11.4, 3.2 Hz, 1H), 1.00 (td, J = 13.5, 13.4, 4.4 Hz, 1H), 
0.85 (ddd, J = 17.8, 12.9, 3.8 Hz, 2H), 0.77 (s, 3H); 13C NMR (100 MHz, CDCl3): d 177.7, 
173.6, 57.4, 56.8, 51.8, 51.2, 49.4, 44.2, 43.8, 40.4, 39.9, 39.7, 38.0, 37.8, 35.2, 28.9, 28.5, 
19.6, 18.9, 18.8, 13.6; HRMS (ESI) (m/z): [M+Na]+ calcd for C21H33NO3Na requires 
370.2353; found 370.2345; [a]23  D  –15.3º (c 0.300, CHCl3).    
I-35: Rf = 0.5 (Hex:EtOAc 4:1); mp 186-187 ºC; IR (film) 2949, 2242, 1720, 1451, 1150 
cm-1; 1H NMR (400 MHz, CDCl3): d 5.36 (d, J = 1.7 Hz, 1H), 3.65 (s, 3H), 2.57, 2.42 
(dABq, J = 16.6, 1.9 Hz, 2H), 2.01-2.19 (m, 4H), 1.93-1.68 (m, 6H), 1.65 (s, 3H), 1.44 
(ddd, J = 12.8, 4.8, 2.0 Hz, 1H), 1.30 (dd, J = 11.8, 5.4 Hz, 1H), 1.19 (s, 3H), 1.12 (dd, J = 
12.2, 2.3 Hz, 2H), 0.96-1.04 (m, 1H), 0.88 (td, J = 13.2, 13.1, 4.2 Hz, 1H), 0.65 (s, 3H); 
13C NMR (100 MHz CDCl3): d 177.7, 131.2, 119.8, 119.0, 57.1, 51.7, 51.3, 45.7, 43.7, 
39.8, 39.0, 37.8, 37.3, 35.2, 28.6, 23.3, 22.2, 20.0, 19.8, 18.9, 13.3; HRMS (ESI) (m/z): 
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[M+Na]+ calcd for C21H31NO2Na requires 352.2247; found 352.2241; [a]23  D  –86.2º (c 
1.00, CHCl3). 
 
C. Oxime Reaction Compounds 
 
  
(4R,4aS,6aR,9S,11aR,11bS,E)-Methyl 4,9,11b-Trimethyl-8-
(((methylsulfonyl)oxy)imino)tetradecahydro-6a,9-
methanocyclohepta[a]naphthalene-4-carboxylate (I-68). 
 
To a flame dried 100 mL round-bottomed flask was added oxime (1.00 g, 2.88 mmol) and 
dichloromethane (40 mL). The flask was cooled to 0 °C (ice bath) then flushed with 
nitrogen. Triethylamine (5.00 mL) and MsCl (0.450 mL, 5.76 mmol) was added. After 30 
min TLC analysis indicated that the starting material was consumed and sat. NaHCO3 (10 
mL) was added and the mixture stirred for 10 min. The organic layer was then washed with 
brine and the aqueous layers re-extracted with CH2Cl2 (20 mL). The combined organic 
layers were then dried over MgSO4, filtered and the solvent removed under reduced 
pressure to give mesylate ester II-68 (1.22 g, 99% crude), which was then carried on 
without further purification. Then, to another 100 mL flame-dried round-bottomed flask 
solution of mesylate ester (1.22 g, 2.86 mmol) in MeOH (25 mL) and toluene (5 mL), was 
added concentrated HCl (416 mg, 11.4 mmol). The mixture was then heated to 60 °C and 
stirred overnight. The reaction was allowed to cool to room temperature then partitioned 
I-37
MsCl, Et3N,
CH2Cl2
0 ºC
NH
O
HCl, MeOH,
PhMe
87% 2 steps
I-68 I-33
MeO O MeO O MeO O
NOH N
OMs
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with saturated aqueous bicarbonate and toluene. The organic phase was dried over MgSO4, 
filtered, and the solvent removed under reduced pressure to yield lactam I-33 (870 mg, 
87%).  
 
  
(1R,4aS,4bR,8aR,10aS)-Methyl 8a-(Cyanomethyl)-1,4a,7-trimethyl-
1,2,3,4,4a,4b,5,8,8a,9,10,10a-dodecahydrophenanthrene-1-carboxylate (I-35) and 
(1R,4aS,4bS,8aS,10aS)-Methyl 8a-(Cyanomethyl)-1,4a,7-trimethyl-
1,2,3,4,4a,4b,5,6,8a,9,10,10a-dodecahydrophenanthrene-1-carboxylate (I-69). 
 
 To a 10 mL flame-dried round-bottomed flask was added oxime I-37 (10 mg, .029 mmol) 
and MeCN (5 mL). The flask was then flushed with nitrogen and Ac2O (6.0 µL, 0.064 
mmol) added. After 10 min TLC indicated all the starting material was consumed and 
pTsOH (5.5 mg, 0.032 mmol) was added. The reaction was stirred for 10 min after which 
time TLC analysis indicated that the reaction was complete. The MeCN was removed 
under reduced pressure and residue taken up in Et2O (10 mL) and washed with 10% NaOH, 
and brine. The aqueous layers were then re-extracted with Et2O (2x10 mL) and the 
combined organic layers were dried over MgSO4, filtered, and the solvent was removed 
under reduced pressure. The residue was chromatographed on silica gel (Hex:EtOAc 
9:1à4:1) to yield the nitriles I-35 and I-69 (7.9 mg, 84%) as a 8:1 mixture with nitrile I-
35 as the major alkene (7 mg, 75%). Recrystallization with EtOAc:DCM enriched the 
mixture to 20:1.   
N
I-35
Δ12, 75%
N
I-69
Δ13, 9%
+
N
OH
I-37
Ac2O, MeCN,
then pTsOH, 
90 °C
84%
12
13
14
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14
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(3S,6aR,8aS,9R,12aS,12bR)-Methyl 3,9,12a-Trimethyl-5-oxotetradecahydro-3,6a-
methanonaphtho[2,1-d]oxocine-9-carboxylate (I-32) and (3S,4aS,4bS,8R,8aS,10aS)-
Methyl 2,4b,8-Trimethyl-12-oxo-4,4a,4b,5,6,7,8,8a,9,10-decahydro-3H-3,10a-
ethanophenanthrene-8-carboxylate (I-72). 
 
To a 50 mL flame-dried round-bottomed flask was added nitrile ester I-35 (100 mg, 0.30 
mmol) in toluene (10 mL).  Then pTsOH (57 mg, 0.30 mmol) was added. The reaction was 
heated to 90 °C for 24 h. After the flask was cooled to ambient temperature, the reaction 
mixture was passed through a silica plug (Hex:EtOAc 9:1). The solvent was then removed 
under reduced pressure and the residue chromatographed on silica gel (Hex:EtOAc 9:1) to 
yield both the ketone I-32 (36 mg, 36%) and lactone I-72 (39 mg, 37%). 
I-32: Rf = 0.1 (Hex:EtOAc 4:1); mp 194-202 °C; IR (film) 2935, 2848, 1732, 1693, 1216 
cm-1; 1H NMR (400 MHz, CDCl3): d 3.63 (s, 3H), 3.07 (dd, J = 18.6, 2.7 Hz, 1H), 2.16 (s, 
1H), 2.02 (d, J = 18.6 Hz, 1H), 1.94-2.00 (m, 1H), 1.67-1.89 (m, 5H), 1.53-1.59 (m, 2H), 
1.44 (d, J = 8.2 Hz, 1H), 1.36-1.40 (m, 1H), 1.34 (s, 3H), 1.24 (ddd, J = 14.3, 9.5, 4.2 Hz, 
3H), 1.17 (s, 3H), 1.07 (dd, J = 11.8, 2.7 Hz, 1H), 1.00 (d, J = 4.4 Hz, 1H), 0.94 (dd, J = 
12.7, 3.1 Hz, 1H), 0.85 (d, J = 4.4 Hz, 1H), 0.75 (s, 3H); 13C NMR (100 MHz, CDCl3): d 
117.6, 172.6, 80.3, 57.2, 55.8, 51.3, 47.7, 43.7, 43.6, 39.0, 38.7, 38.4, 37.9, 37.8, 34.9, 28.6, 
28.3, 19.5, 18.8, 18.6, 13.4; HRMS (ESI) (m/z): [M+H]+ calcd for C21H33O4 requires 
349.2379; found 349.2366 ; [a]23  D –86.0º (c 1.03, CHCl3). 
I-35
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pTsOH, PhMe
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I-72: Rf = 0.4 (Hex:EtOAc 4:1); mp 163-165 °C; IR (film) 2947, 2848, 1721, 1466, 1444, 
1235, 1164 cm-1; 1H NMR (400 MHz, CDCl3): d 5.78 (t, J = 1.46 Hz, 1H), 3.63 (s, 3H), 
2.87 (dt, J = 3.5, 1.8, 1.8 Hz, 1H), 2.54 (d, J = 18.7 Hz, 1H), 2.17 (d, J = 14.0 Hz, 1H), 
1.99 (dt, J = 13.3, 3.2, 3.2 Hz, 1H), 1.86-1.90 (m, 1H), 1.78-1.85 (m, 1H), 1.77 (d, J = 1.5 
Hz, 3H), 1.70-1.75 (m, 2H), 1.51-1.57 (m, 4H), 1.37-1.44 (m, 1H), 1.25 (ddd, J = 11.4, 6.6, 
1.7 Hz, 1H), 1.20 (s, 3H), 1.15 (dd, J = 12.0, 2.4 Hz, 1H), 1.02 (td, J= 13.5, 13.5, 4.2 Hz, 
1H), 0.92 (td, J = 13.5, 13.4, 4.3 Hz, 1H), 0.71 (s, 3H); 13C NMR (100 MHz, CDCl3): d 
213.9, 177.6, 138.4, 135.5, 56.6, 54.4, 51.8, 51.2, 43.6, 42.8, 40.9, 40.3, 38.1, 37.9, 36.8, 
28.6, 24.8, 20.2, 19.8, 18.5, 12.5; HRMS (ESI) (m/z): [M+H]+ calcd for C21H31O3 requires 
331.2273; found 331.2274; [a]23  D  –93.5º  (c 0.26, CHCl3).    
 
 
 
 
  
(3'S,4R,4aS,6aR,9S,11aR,11bS)-Methyl 2'-Benzyl-4,9,11b-trimethyldodecahydro-
1H-spiro[6a,9-methanocyclohepta[a]naphthalene-8,3'-[1,2]oxaziridine]-4-
carboxylate (I-75). 
 
To a 100 mL round-bottomed flask was added benzylimine (I-74) (1.0 g, 2.35 mmol) in 
CH2Cl2 (50 mL).  After cooling to 0 °C mCPBA (520 mg, 2.80 mmol) and NaHCO3 (240 
mg, 2.80 mmol) were added. The mixture was allowed to stir for 10 min, at which time 
TLC analysis indicated that the starting material was consumed. The reaction was 
N
(E)-I-74
mCPBA, 
NaHCO3 
85% 2 steps
N
I-75
O
MeO O MeO O
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quenched with an aqueous solution of NaS2O3 (15 mL) then washed with 1M NaOH (100 
mL) and brine (100 mL). The aqueous layers were then re-extracted with CH2Cl2 (50 mL) 
and the combined organic layers dried over MgSO4 and filtered. The solvent was then 
removed under reduced pressure and the residue chromatographed on silica gel 
(Hex:EtOAc 9:1) to yield benzyl oxaziridine I-75 (822 mg, 80%): Rf = 0.6 (Hex:EtOAc 
2:1); mp 192-198 °C; IR (film) 2949, 2906, 1741, 1719 cm-1; 1H NMR (400 MHz, CDCl3): 
d 7.36 (s, 1H), 7.27-7.35 (m, 2H), 7.18-7.26 (m, 2H), 3.87, 3.75 (ABq, JAB = 13.8 Hz, 2H), 
3.59 (s, 3H), 2.54 (dd, J = 15.3, 2.6 Hz, 1H), 2.11 (d, J = 13.3 Hz, 1H), 1.80 (dd, J = 14.9, 
3.5 Hz, 1H), 1.50-1.74 (m, 7H), 1.30-1.43 (m, 3H), 1.16 (ddd, J = 8.4, 5.4, 2.3 Hz, 1H), 
1.12 (s, 3H), 1.08 (d, J = 2.4 Hz, 1H), 0.92 (dddd, J = 35.9, 18.4, 12.7, 7.8 Hz, 4H), 0.73-
0.81 (m, 1H), 0.64 (s, 3H), 0.57 (s, 3H); 13C NMR (100 MHz, CDCl3): d 177.5, 136.3, 
128.06, 128.05, 127.1, 94.0, 60.9, 56.6, 54.7, 54.2, 50.8, 43.3, 41.0, 40.9, 40.7, 39.4, 37.5, 
37.4, 36.1, 35.4, 28.4, 21.3, 19.5, 19.3, 18.5, 12.9; HRMS (ESI) (m/z): [M+H]+ calcd for 
C28H40NO3 requires 438.3008; found 438.3003; [a]23  D –97.6º (c 1.00, CHCl3).    
 
 
(3S,6aS,8aS,9R,12aS,12bS)-Methyl 5-Benzyl-3,9,12a-trimethyl-4-oxotetradecahydro-
1H-3,6a-methanonaphtho[2,1-c]azocine-9-carboxylate (I-76) and 
(3S,6aR,8aS,9R,12aS,12bR)-Methyl 4-Benzyl-3,9,12a-trimethyl-5-
oxotetradecahydro-1H-3,6a-methanonaphtho[2,1-d]azocine-9-carboxylate (I-77/I-
90b). 
 
N
N
O
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To a 25-mL round-bottomed flask was added benzyl oxaziridine I-75 (110 mg, 0.25 mmol) 
in toluene (5 mL) and was allowed to stir under an Hg lamp (254 nm) for 1.5 h, at which 
time TLC analysis indicated the starting material was consumed. The reaction was then 
chromatographed on silica gel (Hex:EtOAc 4:1) to yield benzyl lactam I-76 (69 mg, 56%) 
and benzyl lactam I-77/I-90b (8 mg, 7%) as a yellowish solid.  
I-76: Rf = 0.21 (Hex:EtOAc 4:1); mp 145-151 °C; IR (film) 2947, 2848, 2235, 1723, 1638, 
1453, 1233, 1154 cm-1; 1H NMR (400 MHz, CDCl3): d 7.29 (d, J = 4.35 Hz, 4H), 7.21-
7.26 (m, 1H), 5.00, 4.04 (ABq, JAB = 14.0 Hz, 2H), 3.63 (dd, J = 12.7, 2.1 Hz, 1H), 3.60 
(s, 3H), 2.87 (d, J = 12.7 Hz, 1H), 2.11 (d, J =13.4 Hz, 1H), 1.99 (dd, J = 11.6, 2.4 Hz, 
1H), 1.59-1.82 (m, 5H), 1.45-1.59 (m, 3H), 1.34-1.43 (m, 1H), 1.23 (ddd, J = 7.7, 9.4, 3.5 
Hz, 2H), 1.18 (s, 3H), 1.16 (d, J = 3.6 Hz, 1H), 1.13 (s, 3H), 0.93-1.10 (m, 2H), 0.89 (dd, 
J = 12.4, 3.2 Hz, 1H), 0.78 (td, J = 13.4, 13.3, 4.3 Hz, 1H), 0.26 (s, 3H);  13C NMR (100 
MHz, CDCl3): d 177.6, 174.9, 137.6, 128.8, 128.7, 128.4, 127.9, 127.2, 126.9, 57.5, 57.0, 
55.5, 51.1. 50.0, 48.9, 43.7, 43.3, 39.7, 39.3, 39.0, 37.7, 34.2, 28.6, 25.3, 20.1, 20.0, 18.8, 
12.7; HRMS (ESI) (m/z): [M+H]+ calcd for C28H40NO3  requires 438.3008; found 
438.3011; [a]23  D –250.0º (c 1.00, CHCl3);  
I-77/I-90b: Rf = 0.5 (Hex:EtOAc 4:1); mp 209-211 °C; IR (film) 2946, 2848, 1722, 1633, 
145, 1399, 1151 cm-1; 1H NMR (400 MHz, CDCl3): d 7.27-7.29 (m, 1H), 7.17-7.22 (m, 
3H), 5.00, 4.19 (ABq, J = 15.8 Hz, 2H), 3.64 (s, 3H), 3.08, 2.19 (dABq, JAB= 18.4, 2.7 Hz, 
2 H), 2.15-2.19 (m, 1 H), 1.85-1.95 (m, 1H), 1.74-1.83 (m, 4H), 1.70 (dd, J = 13.0, 2.7 Hz, 
1H), 1.55-1.58 (m, 3H), 1.42-1.46 (m, 1H), 1.30 (dd, J = 13.0, 2.8 Hz, 1H), 1.20-1.25 (m, 
2H), 1.17 (s, 3H), 1.12 (s, 3H), 0.96-1.09 (m, 3H), 0.80-0.91 (m, 2H), 0.79 (s, 3H); 13C 
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NMR (100 MHz, CDCl3): d 177.7, 172.4, 139.8, 128.3, 126.8, 126.5, 57.4, 56.9, 56.5, 51.6, 
51.2, 44.6, 44.3, 43.7, 41.1, 39.9, 38.0, 37.8, 37.0, 34.1, 28.5, 28.0, 19.7, 18.8, 18.6, 13.6; 
HRMS (ESI) (m/z): [M+H]+ calcd for C28H40NO3 requires 438.3008; found 438.3001; 
[a]23  D –53.5º (c 1.00, CHCl3). 
 
   
(4R,4aS,6aR,9S,11aR,11bS)-Methyl 9-Acetoxy-4,11b-dimethyl-8-
methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-
66). 
 
To a solution of steviol (I-23, 10 g, 32 mmol) in THF (50 mL) in a 500-mL round-bottomed 
flask at room temperature was added LiOH•H2O (1.5g, 34 mmol) The reaction stirred at 
room temperature for 1 h under nitrogen, then Me2SO4 (3.3 mL, 35 mmol) was slowly 
added, and the reaction vessel was fitted with a reflux condenser. The reaction was refluxed 
for 18 h at 80 C. Once the reaction cooled to room temperature, the off-white precipitate 
was collected via filtration to furnish methyl ester I-94 (7.6 g, 73%). mp 117-118 °C (Lit 
113-115 ºC);160 1H NMR (400 MHz, CDCl3): δ 4.92 (d, J = 64.0 Hz, 2H), 3.66 (s, 3H), 2.28 
– 2.04 (m, 4H), 1.93 – 1.73 (m, 7H), 1.62 – 1.40 (m, 5H), 1.33 – 1.26 (m, 1H), 1.19 (s, 3H), 
1.10 – 0.93 (m, 3H), 0.85 (s, 3H), 0.82 – 0.75 (m, 1H).; 13C NMR (100 MHz, CDCl3): δ 
178.0, 156.0, 102.9, 80.3, 56.9, 53.8, 51.2, 47.4, 46.9, 43.8, 41.6, 41.3, 40.7, 39.4, 39.2, 
38.0, 28.7, 21.9, 20.4, 19.1, 15.3. HRMS (ESI) (m/z): [M+Na]+ calcd for C21H32O3Na 
355.2249, found 355.2080; [a]23  D  –191.3º (c 1.00, CHCl3).    
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Then, the steviol methyl ester I-94 (5.0 g, 15.0 mmol) was taken up in dry CH2Cl2 (200 
mL) and under an atmosphere of nitrogen cooled to 0 °C. Et3N (28 mL, 200 mmol) and 
Ac2O (19 mL, 200 mmol) where added. After 30 min DMAP (200 mg) was added and the 
ice bath removed and the reaction was allowed to stir for 18 h. The reaction was cooled to 
0 °C and H2O (10 mL) added and the reaction was stirred for 30 minutes. The organic layer 
was then washed with water (100 mL), 10% HCl (100 mL), 1M NaOH (100 mL) and brine 
(100 mL). The aqueous layers were then re-extracted with ether (100 mL) and the 
combined organic layers dried over MgSO4, filtered, and the solvent removed under 
reduced pressure to give an oil which was then chromatographed on silica gel (9:1 
Hex:EtOAc) to provide the acetoxy methyl ester I-66 as an oil (4.79 g, 85%): Rf = 0.7 
(Hex:EtOAc 4:1); IR (KBr) 2948, 1726, 1447, 1366, 1236, 1149, 1047 cm-1;  1H NMR (400 
MHz, CDCl3): d 4.90 (dd, J = 2.7, 2.0 Hz, 1H), 4.86 (d, J = 0.6 Hz, 1H), 3.63 (s, 3H), 2.57 
(dd, J = 10.9, 2.6 Hz, 1H), 2.25 (ddd, J = 13.2, 4.9, 2.4 Hz, 2H), 2.14-2.20 (m, 1H), 1.98-
2.05 (m, 1H), 2.02 (s, 3H), 1.85 (dd, J = 9.9, 7.6 Hz, 3H), 1.70-1.78 (m, 3H), 1.63 (dd, J = 
7.5, 6.0 Hz, 1H), 1.56 (t, J = 3.26, 3.26, 1H), 1.44 (ddd, J = 15. 0, 11.3, 7.6 Hz, 3H), 1.16 
(s, 3H), 1.1 (ddd, J = 22.3, 12.6, 5.6 Hz, 3H), 0.86 (s, 3H), 0.80 (d, J = 4.2 Hz, 1H); 13C 
NMR (100 MHz, CDCl3): d 177.9, 169.9, 152.1, 103.4, 87.6, 556.9, 53.7, 51.2, 46.9, 43.8, 
42.6, 42.1, 41.1, 40.7, 39.2 (x2), 38.1, 36.7, 28.7, 21.8, 20.0, 19.1, 15.1; HRMS (ESI) (m/z): 
[M+Na]+ calcd for C23H34O4Na requires 397.2347; found 355.2356 [(M+Na)-Ac]+; [a]23  D   
–55.8º (c 1.00, CHCl3). 
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(4R,4aS,6aR,9S,11aR,11bS,E)-Methyl 9-Acetoxy-8-(hydroxyimino)-4,11b-
dimethyltetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-
67). 
 
To a 50 mL flame-dried round-bottomed flask of acetoxy methyl ester I-66 (904 mg, 2.4 
mmol) in CH2Cl2 (30 mL) that was cooled to -78 °C, ozone was bubbled through the 
solution until the distinctive blue color was maintained for 30 min. The ozone line was then 
removed and nitrogen was bubbled through the solution until it was clear. Dimethylsulfide 
(703 mL, 9.6 mmol) was then added and the reaction was allowed to warm to ambient 
temperature and stir for 18 h. The CH2Cl2 was then removed under reduced pressure and 
residue dissolved in Et2O (50 mL). The organic layer was washed with H2O (10 mL) and 
brine (10 mL). The aqueous layers were then re-extract with Et2O (x2, 50 mL) and the 
combined organic layers where then dried over MgSO4, filtered, and the solvent removed 
under reduced pressure. The resulting keto-acetoxy methyl ester was chromatographed on 
silica gel (25:1à7:1) Hex:EtOAc.  From there, a 50 mL round-bottomed flask of the keto-
acetoxy methyl ester (437 mg, 1.2 mmol) in dry THF (25 mL) and EtOH (2 mL), was added 
NH2OH•H2O (240 mg, 3.5 mmol) and KOAc (354 g, 3.5 mmol). The mixture was heated 
to 50 °C for 1 h after which time TLC analysis indicated that the starting material was 
consumed. The mixture was then filtered and the solvent removed under reduced pressure. 
The colorless residue was taken up in CH2Cl2 (50 mL) and the organic layer was then 
washed with 10% HCl (10 mL), 1M NaOH (10 mL), and brine (10 mL). The aqueous layers 
were then re-extracted with CH2Cl2 (20 mL) and the combined organic layers dried over 
OAc
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MgSO4 and filtered. The solvent was then removed under reduced pressure and the residue 
chromatographed on silica gel (Hex:EtOAc 9:1 à 4:1) to give the 13-acetoxy oxime I-67 
(422 mg, 60% over 2 steps) as a colorless solid: Rf = 0.44 (Hex:EtOAc 4:1); mp 178-180 
°C; IR (film) 3293, 2946, 1723, 1462, 1446, 1237 1149 cm-1; 1H NMR (400 MHz, CDCl3): 
d 8.17 (s, 1H), 3.63 (s, 3H), 2.53 (dd, J = 11.1, 2.0 Hz, 1H), 2.28 (d, J = 2.2 Hz, 1H), 2.17-
2.22 (m, 2H), 2.03 (s, 3H), 1.98 (dd, J = 11.1, 2.3 Hz, 1H), 1.84 (ddd, J = 13.3, 10.7, 6.9 
Hz, 5H), 1.66-1.77 (m, 2H), 1.55-1.65 (m, 2H), 1.47 (dd, J = 39.3, 15.9 Hz, 2H), 1.17 (s, 
3H), 1.03 (ddd, J = 20.2, 9.9, 3.2 Hz, 3H), 0.86 (s, 3H), 0.77-0.83 (m, 1H); 13C NMR (100 
MHz, CDCl3): d 177.8, 169.7, 163.3, 84.9, 56.6, 53.2, 51.3, 43.7, 42.3, 41.8, 41.7, 40.7, 
40.6, 39.2, 37.9, 35.6, 28.6, 21.9, 21.4, 19.5, 18.9, 15.3; HRMS (ESI) (m/z): [M+H]+ calcd 
for C22H34NO5  requires 392.2437; found 392.2439; [a]23  D –47.7º (c 0.98, CHCl3).    
 
 
(1R,4aS,4bR,8aR,10aS)-Methyl 8a-(Cyanomethyl)-1,4a-dimethyl-7-
oxotetradecahydrophenanthrene-1-carboxylate (I-70). 
 
To a 100 mL flame-dried round-bottomed flask containing 13-acetoxy oxime I-67 (13 g, 
39 mmol) and dry acetonitrile (100 mL) flushed with nitrogen, Ac2O (7.4 mL, 86 mmol) 
was added. After 10 min TLC indicated that all the starting material was consumed and 
then pTsOH (8 g, 43 mmol) was added. The reaction was heated to reflux for 2 h and then 
cooled with an ice bath. NaOH (17 g, 390 mmol) dissolved in H2O (300 mL) was then 
added and stirred for 5 min. The layers where then partitioned and the aqueous layer was 
OAc
CO2Me
N
CO2Me
O
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re-extracted with EtOAc (2x100 mL). The combined organic layers where dried over 
MgSO4, filtered, and then the solvent was removed under reduced pressure. The residue 
was chromatographed on silica gel (400 mL) with 3 L of 9:1 Hex:EtOAc to furnish ketone 
nitrile I-70 (8.66 g, 67%):  Rf = 0.6 (Hex:EtOAc 2:1); mp 136-138 °C; IR (film) 2951, 
1759, 1724, 1464, 1447, 1368, 1238, 1150 cm-1; 1H NMR (400 MHz, CDCl3): d 3.66 (s, 
3H), 2.96 (d, J = 15.5 Hz, 1H), 2.47 (ddd, J = 16.8, 12.9, 8.3 Hz, 1H), 2.29-2.39 (m, 2H), 
2.13-2.28 (m, 3H), 1.78-2.01 (m, 6H), 1.61-1.76 (m, 3H), 1.53 (d, J = 14.4 Hz, 1H), 1.47 
(d, J = 7.0 Hz, 1H), 1.23 (s, 3H), 1.06 (dd, J = 7.4, 4.5 Hz, 2H), 0.98 (s, 3H); 13C NMR 
(100 MHz, CDCl3): d 211.0, 177.6, 117.1, 56.0, 51.4, 48.2, 43.7, 41.2, 39.4, 39.3, 38.3, 
37.5, 31.2, 28.6, 20.8, 19.8, 19.1, 16.4; HRMS (ESI) (m/z): [M+H]+ calcd for C20H30NO3 
requires 332.2226; found 332.2231; [a]23  D –75.5º (c 1.24, CHCl3).    
 
 
(3S,4aR,4bS,8R,8aS,10aS)-Methyl 4b,8-Dimethyl-2,12-dioxododecahydro-1H-3,10a-
ethanophenanthrene-8-carboxylate (I-71).80 
 
To a 0.5-2.0 mL microwave vial of 13-acetoxy oxime I-67 (50 mg, 0.100 mmol) and 
toluene (1 mL) was added Ac2O (25 µL, 0.25 mmol). After 10 min, pTsOH (23 mg, 0.100 
mmol, 1 equiv) was added. The vial was capped and the reaction was heated to 140 °C and 
stirred for 30 min in the microwave. The reaction mixture was then taken up in EtOAc (35 
mL) and washed with 10% NaOH, and brine. The aqueous layers were then re-extracted 
with EtOAc (2x50 mL) and the combined organic layers were dried over MgSO4, filtered, 
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and the solvent removed under reduced pressure. The residue was chromatographed on 
silica gel (Hex:EtOAc 9:1) to give diketone I-71 (13 mg, 15 %): Rf = 0.35 (Hex:EtOAc 
2:1); mp 238-239 °C; IR (film) 2953, 1743, 1715 cm-1;  1H NMR (400 MHz, CDCl3): 
d 3.65 (s, 3H), 3.18 (t, J = 3.0 Hz, 1H), 2.90 (dd, J = 19.7, 3.5 Hz, 1H), 2.26-2.07 (m, 4H), 
1.96-1.77 (m, 6H), 1.59-1.35 (m, 4H), 1.21 (s, 3H), 1.15 (dd, J = 11.9, 2.8 Hz, 1H), 1.08-
1.00 (m, 1H), 0.93 (d, J = 4.3 Hz, 1H), 0.70 (s, 3H); 13C NMR (100 MHz, CDCl3): d 207.0, 
206.9, 177.4, 64.6, 56.4, 55.5, 51.5, 50.5, 46.3, 43.8, 39.6, 38.2, 38.1, 37.9, 37.6, 28.8, 25.5, 
19.9, 18.6, 12.4; HRMS (ESI) (m/z): [M+Na]+ calcd for C20H28O4Na requires 355.1880; 
found 355.1891; [a]23  D –65.8º (c 0.25, CHCl3).  
 
 
D. Mono- and Bi-functional Library Compounds 
 
Standard procedure for the solution phase amide bond formation (Scheme I-25). To an 
oven-dried reaction flask under nitrogen at 0 °C (ice bath), was added DMF (37 µL, 0.47 
mmol, 1.5 equiv) in DCM (1.0 mL) followed by oxalyl chloride (41 µL, 0.47 mmol, 1.5 
equiv). The ice bath was removed and the mixture was allowed to stir at room temperature 
for 1 h. Then the reaction flask was cooled to 0 °C (ice bath) and isosteviol (I-25, 100 mg, 
0.31 mmol) and Et3N (130 µL, 0.47 mmol, 3 equiv) in DCM (1.0 mL) were added.  After 
stirring for 5 min, allylamine (I-78a, 1 mL) was added and the mixture was stirred for 2 h. 
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Then the mixture was loaded onto a 20-mL silica gel plug in a 70-mL column and eluted 
with dry THF. The solvent was removed under vacuum, the residue was dissolved in 
CH2Cl2 (10 mL), and methylisocyanate polystyrene resin was added. The mixture was 
shaken for 20 h and was then loaded onto a 20-mL silica gel plug in a 70-mL column and 
eluted with ethyl acetate (40 mL). The solvent was removed and the residues was purified 
using column chromatography with 10% EtOAc:Hex as the eluent to provide the allyl 
amide product I-79a in 47% yield. 
 
 
Standard procedure for solid phase amide bond formation (Schemes I-25, I-26, and I-28).  
To a flame-dry reaction vial of isosteviol (I-25, 100.0 mg, 0.318 mmol, 1.0 equiv) in 
CH2Cl2/DMF (4:1) was added PS-hydroxybenzotriazole (PS-HOBt, 1.00 mmol/g, 0.67 
equiv), 4-dimethylaminopyridine (15.5 mg, 0.127 mmol, 0.40 equiv), and then 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (148 mg, 0.954 mmol, 3.0 equiv). The reaction 
mixture was shaken slowly for 24 h and then filtered. The resin was washed with MeOH 
(5 mL) and CH2Cl2 (5 mL) thrice to remove excess acid. Then, the resin was added to a 
solution of allylamine (I-78a, 15.5 µL, 0.220 mmol, 0.70 equiv) and diisopropylethylamine 
(55.4 µL, 0.318 mmol, 1.0 equiv) in CH2Cl2 and shaken slowly for another 24 h. The 
mixture was filtered again was washed with MeOH (5 mL) and CH2Cl2 (5 mL) thrice 
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before the solvent was removed under vacuum. Column chromatography with 20% 
EtOAc:Hex as the eluent gave amide product I-79a in 43 mg (38% yield).  
 
 
(4R,4aS,6aR,9S,11aR,11bS)-N-Allyl-4,9,11b-trimethyl-8-oxotetradecahydro-6a,9-
methanocyclohepta[a]naphthalene-4-carboxamide (I-79a). 
 
1H NMR (400 MHz, CDCl3): d 5.83 – 5.70 (m, 1H), 5.62 (br s, 1H), 5.09 (dd, J = 23.1, 
13.7 Hz, 2H), 3.79 (t, J = 5.1 Hz, 2H), 2.58 (dd, J = 18.6, 3.6 Hz, 1H), 2.01 – 1.85 (m, 3H), 
1.77 – 1.25 (m, 9H), 1.19 – 1.15 (m, 2H), 1.13 (s, 3H), 1.10 – 1.05 (m, 2H), 0.91 (s, 3H), 
0.89 – 0.82 (m, 2H), 0.71 (s, 3H), 0.67 – 0.63 (m, 1H). 13C NMR (125 MHz, CDCl3): d  
222.6, 176.4, 134.4, 116.6, 57.5, 57.2, 54.7, 54.2, 48.7, 48.4, 43.7, 41.9, 41.7, 40.2, 39.5, 
38.1, 37.3, 30.2, 22.2, 20.3, 19.9, 19.2, 13.6;  
 
 
(4R,4aS,6aR,9S,11aR,11bS)-N-Benzyl-4,9,11b-trimethyl-8-oxotetradecahydro-6a,9-
methanocyclohepta[a]naphthalene-4-carboxamide (I-79b). 
 
1H NMR (400 MHz, CDCl3): d 7.36 – 7.25 (m, 5H), 5.86 (t, J = 4.9 Hz, 1H), 4.40 (d, J = 
5.4 Hz, 2H), 2.62 (dd, J = 18.6, 3.6 Hz, 1H), 2.06 – 1.90 (m, 2H), 1.83 – 1.63 (m, 6H), 1.59 
– 1.32 (m, 7H), 1.27 – 1.22 (m, 1H), 1.21 (s, 3H), 1.18 – 1.12 (m, 2H), 0.96 (s, 3H), 0.95 
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– 0.79 (m, 1H), 0.74 (s, 3H). 13C NMR (125 MHz, CDCl3): d  222.4, 176.4, 138.5, 128.9, 
128.7, 128.0, 127.5, 127.5, 57.6, 54.7, 54.3, 48.7, 48.4, 43.7, 41.7, 40.2, 39.5, 38.1, 38.1, 
37.3, 30.2, 22.2, 22.2, 20.3, 19.9, 19.2, 13.6; mp 68-69 ºC; LRMS (ESI) (m/z): [M+Na]+ 
calcd for C27H37NO2Na 430.2824, found 430.4; [a]23  D  –44.0º (c 1.00, CHCl3).    
 
(4R,4aS,6aR,9S,11aR,11bS)-N-Butyl-4,9,11b-trimethyl-8-oxotetradecahydro-6a,9-
methanocyclohepta[a]naphthalene-4-carboxamide (I-79j). 
 
oil; 1H NMR (400 MHz, CDCl3): d 5.59 (s, 1H), 3.21 (dt, J = 11.8, 6.7 Hz, 2H), 2.65 (dd, 
J = 18.6, 3.6 Hz, 1H), 2.01 (d, J = 14.3 Hz, 1H), 1.95 (d, J = 13.3 Hz, 1H), 1.77 (dd, J = 
19.9, 14.1 Hz, 4H), 1.71 – 1.65 (m, 2H), 1.63 – 1.57 (m, 1H), 1.56 – 1.52 (m, 1H), 1.51 – 
1.45 (m, 4H), 1.40 (dd, J = 11.8, 3.7 Hz, 1H), 1.37 – 1.30 (m, 3H), 1.25 – 1.18 (m, 2H), 
1.17 (s, 3H), 1.16 – 1.09 (m, 2H), 0.97 (s, 3H), 0.92 (t, J = 7.2 Hz, 4H), 0.77 (s, 3H); 13C 
NMR (125 MHz, CDCl3): d 222.4, 176.5, 57.6, 54.8, 54.3, 48.7, 48.4, 43.6, 41.8, 40.2, 
39.5, 39.2, 38.2, 38.1, 37.3, 31.5, 30.2, 22.3, 20.3, 20.3, 19.9, 19.2, 13.8, 13.5; LRMS 
(ESI) (m/z): [M+H]+ calcd for C24H40NO2 374.2981, found 374.3; [a]23  D  –32.2º (c 0.500, 
CHCl3).    
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Standard procedure for solid-phase bond formation of steviol amide analogs I-80a-k 
(Scheme I-26). To a solution of steviol (I-23, 100 mg, 0.318 mmol, 1.00 equiv) in 
CH2Cl2/DMF (4:1) in a flame-dry reaction vial, was added PS-hydroxybenzotriazole (PS-
HOBt, 1.00 mmol/g, 0.213 mmol, 0.670 equiv), 4-dimethylaminopyridine (55.4 µL, 0.318 
mmol, 0.40 equiv), and then 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (148 mg, 
0.954 mmol, 3.0 equiv). The reaction mixture was shaken slowly for 24 h and then filtered. 
The resins were washed with MeOH (5 mL) and CH2Cl2 (5 mL) thrice to remove excess 
acid. Then, the resin was added to a solution of 4-flurobenzylamine (I-78c, 27.5 mg, 0.220 
mmol, 0.70 equiv) and diisopropylethylamine (55.4 µL, 0.318 mmol, 1.0 equiv) in CH2Cl2 
and shaken slowly for another 24 h. The mixture was filtered again was washed with MeOH 
(5 mL) and CH2Cl2 (5 mL) thrice before the solvent was removed under vacuum.  The 
crude residue was purified by column chromatography with 20% EtOAc:Hex to furnish 
the amide I-80c. 
 
(4R,4aS,6aR,9S,11aR,11bS)-N-(4-Fluorobenzyl)-9-hydroxy-4,11b-dimethyl-8-
methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxamide 
(I-80c). 
 
OH OH
ON
H
RHO O I-80a-kI-23
+ R-NH2
I-78a-k
1) PS-HOBt,    
    DMAP, EDCI,   
    CH2Cl2/DMF
2) I-78, DIPEA, 
    CH2Cl2
OH
ON
H
F
I-80c
    
 
80 
1H NMR (400 MHz, CDCl3): d 8.27 (s, 1H), 7.70 (dd, J = 8.5, 5.7 Hz, 2H), 7.03 (t, J = 8.6 
Hz, 2H), 4.82 (d, J = 67.5 Hz, 2H), 4.69 (s, 2H), 2.13 – 1.93 (m, 4H), 1.88 – 1.63 (m, 6H), 
1.58 – 1.22 (m, 5H), 1.20 – 1.16 (m, 1H), 1.11 (s, 3H), 1.08 – 0.97 (m, 3H), 0.88 (d, J = 
7.9 Hz, 1H), 0.79 (s, 3H), 0.75 (dd, J = 12.7, 3.7 Hz, 1H). 13C NMR (125 MHz, CDCl3): 
d 176.6, 160.6, 156.0, 130.1, 129.6, 129.4, 115.6, 115.4, 103.0, 80.2, 64.2, 57.4, 53.7, 47.4, 
46.9, 43.8, 42.9, 41.7, 40.9, 39.4, 38.2, 30.1, 23.0, 22.4, 20.4, 19.3, 15.7 
 
 
(4R,4aS,6aR,9S,11aR,11bS)-N-Butyl-9-hydroxy-4,11b-dimethyl-8-
methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxamide 
(I-80j). 
 
1H NMR (400 MHz, CDCl3): d 7.99 (s, 1H), 5.58 (s, 1H), 4.88 (d, J = 68.1 Hz, 2H), 3.20 
(dt, J = 12.2, 6.8 Hz, 2H), 2.90 (d, J = 30.2 Hz, 1H), 2.18 (d, J = 17.0 Hz, 1H), 2.14 – 2.09 
(m, 1H), 2.07 – 2.00 (m, 2H), 1.89 (dd, J = 21.7, 5.2 Hz, 3H), 1.82 – 1.71 (m, 3H), 1.63 – 
1.51 (m, 2H), 1.51 – 1.43 (m, 4H), 1.42 – 1.30 (m, 3H), 1.26 (d, J = 10.8 Hz, 1H), 1.13 (s, 
3H), 1.10 – 0.99 (m, 2H), 0.94 – 0.90 (m, 3H), 0.89 (s, 3H), 0.86 – 0.77 (m, 1H); 13C NMR 
(125 MHz, CDCl3): d 176.6, 156.1, 102.9, 80.2, 57.3, 53.8, 47.4, 46.9, 43.7, 41.7, 41.6, 
41.1, 39.4, 39.3, 39.2, 38.3, 31.5, 30.1, 22.4, 20.5, 20.3, 19.4, 15.6, 13.8;  LRMS (m/z): 
[M+H]+ calcd for C24H40NO2 374.2981, found 374.3; [a]23  D  –77.5º (c 1.00, CHCl3). 
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(4R,4aS,6aR,9S,11aR,11bS)-N-(tert-butyl)-9-hydroxy-4,11b-dimethyl-8-
methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxamide 
(I-80m). 
 
oil; 1H NMR (400 MHz, CDCl3): d 5.34 (s, 1H), 4.88 (d, J = 66.6 Hz, 2H), 2.94 (s, 1H), 
2.18 (d, J = 19.5 Hz, 1H), 2.10 (d, J = 17.2 Hz, 1H), 1.99 (d, J = 13.6 Hz, 1H), 1.91 – 1.84 
(m, 4H), 1.82 – 1.73 (m, 4H), 1.60 – 1.50 (m, 2H), 1.49 – 1.37 (m, 3H), 1.33 (s, 3H), 1.31 
(s, 6H), 1.27 (dd, J = 14.7, 3.6 Hz, 1H), 1.12 (s, 3H), 1.08 – 0.98 (m, 2H), 0.95 (s, 3H), 
0.82 (d, J = 4.0 Hz, 1H); 13C NMR (125 MHz, CDCl3): d 175.7, 156.1, 102.9, 80.2, 77.4, 
77.0, 76.7, 57.2, 53.8, 50.7, 47.4, 46.9, 44.1, 41.7, 41.6, 41.2, 39.5, 39.3, 38.5, 30.2, 28.8, 
28.7, 28.7, 22.5, 20.5, 19.3, 15.9; LRMS (ESI) (m/z): [M+H]+ calcd for C24H40NO2 
374.2981, found 374.3; [a]23  D  –102.1º (c 0.750, CHCl3). 
 
 
 
Standard procedure for solid-phase bond formation of isosteviol lactam (I-41) amide 
analogs I-82a-k (Scheme I-26). To a solution of lactam (I-41, 100 mg, 0.333 mmol, 1.00 
equiv) in CH2Cl2/DMF (4:1) in a flame-dry reaction vial, was added PS-
hydroxybenzotriazole (PS-HOBt, 1.00 mmol/g, 0.223 mmol, 0.670 equiv), 4-
OH
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H
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dimethylaminopyridine (58.0 µL, 0.333 mmol, 0.40 equiv), and then 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (155 mg, 1.00 mmol, 3.0 equiv). The reaction mixture 
was shaken slowly for 24 h and then filtered. The resins were washed with MeOH (5 mL) 
and CH2Cl2 (5 mL) thrice to remove excess acid. Then, the resin was added to a solution 
of allylamine (I-78a, 29.1 mg, 0.220 mmol, 0.70 equiv) and diisopropylethylamine (58.0 
µL, 0.333 mmol, 1.0 equiv) in CH2Cl2 and shaken slowly for another 24 h. The mixture 
was filtered again was washed with MeOH (5 mL) and CH2Cl2 (5 mL) thrice before the 
solvent was removed under vacuum.  The crude residue was purified by column 
chromatography with 20% EtOAc:Hex to furnish the amide I-82a. 
 
(3S,6aR,8aS,9R,12aS,12bR)-N-Allyl-3,9,12a-trimethyl-5-oxotetradecahydro-2H-3,6a-
methanonaphtho[2,1-d]azocine-9-carboxamide (I-82a). 
 
oil; 1H NMR (400 MHz, CDCl3): d  5.84 – 5.70 (m, 1H), 5.60 (s, 1H), 5.18 – 5.03 (m, 2H), 
3.87 –  3.71 (m, 2H), 2.82 (d, J = 29.2 Hz, 1H), 2.44 (ddd, J = 52.5, 16.6, 2.1 Hz, 1H), 2.14 
– 1.62 (m, 8H), 1.52 (s, 6H), 1.49 – 1.16 (m, 4H), 1.13 (s, 3H), 1.13 – 0.99 (m, 3H), 0.84 
(dd, J = 13.6, 3.8 Hz, 1H), 0.76 – 0.62 (m, 3H). 13C NMR (125 MHz, CDCl3): d 176.3, 
134.5, 131.4, 120.0, 116.8, 57.9, 52.0, 45.9, 43.8, 42.1, 40.3, 39.5, 38.1, 37.6, 35.4, 33.2, 
30.2, 23.4, 22.4, 20.5, 20.1, 19.4, 14.0; HRMS (ESI) (m/z): [M+Na]+ calcd for 
C23H36O2N2Na 395.2777, found 395.2680; [a]23  D  –10.3º (c 1.20, CHCl3).    
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(3S,6aR,8aS,9R,12aS,12bR)-N-(4-fluorobenzyl)-3,9,12a-trimethyl-5-
oxotetradecahydro-2H-3,6a-methanonaphtho[2,1-d]azocine-9-carboxamide(I-82c). 
 
oil; 1H NMR (400 MHz, CDCl3): d  7.33 – 7.29 (m, 1H), 7.25 – 7.22 (m, 1H), 7.03 – 6.97 
(m, 2H), 6.51 (t, J = 6.0 Hz, 1H), 4.56 (dd, J = 15.0, 6.5 Hz, 1H), 4.49 – 4.33 (m, 2H), 2.40 
(d, J = 12.1 Hz, 1H), 2.31 (d, J = 17.8 Hz, 1H), 2.17 (d, J = 13.4 Hz, 1H), 1.88 (dd, J = 
16.9, 2.7 Hz, 4H), 1.78 (d, J = 13.2 Hz, 1H), 1.73 – 1.67 (m, 2H), 1.64 – 1.56 (m, 2H), 1.51 
– 1.42 (m, 1H), 1.39 (s, 3H), 1.36 – 1.28 (m, 2H), 1.25 (s, 3H), 1.22 – 1.15 (m, 1H), 1.13 
–1.04 (m, 2H), 1.02 – 0.93 (m, 2H), 0.86 (s, 3H); 13C NMR (125 MHz, CDCl3): d 183.0, 
176.1, 171.0, 161.1, 129.5, 129.5, 115.7, 115.5, 77.3, 77.0, 76.7, 59.5, 57.3, 56.6, 51.2, 
43.7, 43.6, 42.8, 42.0, 39.8, 38.0, 37.7, 37.5, 35.0, 28.8, 26.1, 19.5, 19.1, 18.9, 13.8;  LRMS 
(ESI) (m/z): [M+H]+ calcd for C27H38FN2O2 441.2339, found 441; [a]23  D  19.2º (c 1.00, 
CHCl3). 
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Standard procedure for direct amide bond formation from nitrile I-83 (Scheme I-26). To a 
flame-dried reaction flask of the nitrile acid I-83 (1.0 equiv) in CH2Cl2/DMF (4:1) in a 
flame-dry reaction vial, was added PS-hydroxybenzotriazole (PS-HOBt, 1.00 mmol/g, 0.67 
equiv), 4-dimethylaminopyridine (55.4 µL, 0.318 mmol, 0.40 equiv), and then 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (148 mg, 0.954 mmol, 3.0 equiv). The reaction 
mixture was shaken slowly for 24 h and then filtered. The resins were washed with MeOH 
(5 mL) and CH2Cl2 (5 mL) thrice to remove excess acid. Then, the resin was added to a 
solution of amine I-78 (0.220 mmol, 0.70 equiv) and diisopropylethylamine (55.4 µL, 
0.318 mmol, 1.0 equiv) in CH2Cl2 and shaken slowly for another 24 h. The mixture was 
filtered again was washed with MeOH (5 mL) and CH2Cl2 (5 mL) thrice before the solvent 
was removed under vacuum.  The crude residue was purified by column chromatography 
with 20% EtOAc:Hex to furnish the amide I-84. 
 
 
 
  
(1R,4aS,4bR,8aR,10aS)-N-benzyl-8a-(cyanomethyl)-1,4a,7-trimethyl-
1,2,3,4,4a,4b,5,8,8a,9,10,10a-dodecahydrophenanthrene-1-carboxamide (I-84d). 
 
1H NMR (400 MHz, CDCl3): d 7.21 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 5.69 (s, 
1H), 4.36 (d, J = 5.6 Hz, 2H), 3.80 (s, 3H), 2.98 (dd, J = 19.0, 2.5 Hz, 1H), 2.17 (d, J = 
13.1 Hz, 1H), 2.01 (s, 3H), 2.05 – 1.96 (m, 1H), 1.90 – 1.66 (m, 4H), 1.61 (d, J = 13.6 Hz, 
ON
H
MeO I-84d
N
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2H), 1.51 – 1.38 (m, 4H), 1.28 (s, 1H), 1.23 (s, 3H), 1.09 (s, 3H), 1.01 (td, J = 13.5, 3.8 
Hz, 1H), 0.93 – 0.87 (m, 1H), 0.85 (s, 3H13C NMR (125 MHz, CDCl3): d 183.0, 170.6, 
170.0, 159.2, 130.4, 129.4, 129.4, 114.2, 114.2, 77.5, 77.2, 76.8, 57.3, 56.4, 55.5, 55.1, 
44.0, 43.7, 43.4, 40.8, 40.1, 39.6, 38.4, 37.2, 29.2, 23.4, 22.3, 21.7, 20.6, 19.1, 13.6; mp 
63 – 64 ºC;  LRMS (ESI) (m/z): [M+Na]+ calcd for C28H38N2O2 434.2933, found 457.3; 
[a]23  D  3.60º (c 0.600, CHCl3). 
 
 
(1R,4aS,4bR,10aS)-8a-(cyanomethyl)-1,4a,7-trimethyl-N-(pyridin-2-ylmethyl)-
1,2,3,4,4a,4b,5,8,8a,9,10,10a-dodecahydrophenanthrene-1-carboxamide (I-84e). 
 
oil;  1H NMR (400 MHz, CDCl3): d 8.57 (d, J = 4.5 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.27 
(d, J = 7.9 Hz, 1H), 7.25 – 7.17 (m, 1H), 7.11 (s, 1H), 5.35 (s, 1H), 5.31 (s, 1H), 4.53 (tdd, 
J = 16.5, 11.7, 4.7 Hz, 2H), 2.78 – 2.53 (m, 1H), 2.49 – 2.29 (m, 1H), 2.26 – 2.12 (m, 2H), 
2.12 – 1.92 (m, 5H), 1.87 – 1.77 (m, 1H), 1.75 – 1.69 (m, 1H), 1.66 (s, 3H), 1.58 – 1.49 (m, 
1H), 1.35 – 1.27 (m, 1H), 1.23 (s, 3H), 1.22 – 1.12 (m, 3H), 0.92 (dt, J = 16.0, 8.2 Hz, 1H), 
0.65 (s, 3H); 13C NMR (125 MHz, CDCl3): d176.6, 156.4, 149.0, 136.7, 131.2, 122.4, 
122.3, 119.9, 119.0, 77.4, 77.1, 76.8, 57.7, 51.7, 45.7, 44.4, 43.7, 40.2, 39.4, 37.9, 37.4, 
35.3, 29.9, 23.3, 22.2, 20.2, 19.9, 19.1, 13.5; LRMS (m/z): [M+Na]+ calcd for 
C26H35N3ONa 428.2780, found 428.3; [a]23  D  –34.0 º (c 1.00, CHCl3). 
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Standard procedure for direct amide bond formation from amine I-85 (Scheme I-26). 
To a flame-dried reaction flask of the amine I-85 (1.0 equiv) in CH2Cl2/DMF (4:1) in a 
flame-dry reaction vial, was added PS-hydroxybenzotriazole (PS-HOBt, 1.00 mmol/g, 0.67 
equiv), 4-dimethylaminopyridine (55.4 µL, 0.318 mmol, 0.40 equiv), and then 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (148 mg, 0.954 mmol, 3.0 equiv). The reaction 
mixture was shaken slowly for 24 h and then filtered. The resins were washed with MeOH 
(5 mL) and CH2Cl2 (5 mL) thrice to remove excess acid. Then, the resin was added to a 
solution of amine I-78 (0.220 mmol, 0.70 equiv) and diisopropylethylamine (55.4 µL, 
0.318 mmol, 1.0 equiv) in CH2Cl2 and shaken slowly for another 24 h. The mixture was 
filtered again was washed with MeOH (5 mL) and CH2Cl2 (5 mL) thrice before the solvent 
was removed under vacuum.  The crude residue was purified by column chromatography 
with 5% MeOH:DCM to furnish the amide I-86. 
 
(4R,4aS,6aR,8R,9S,11aR,11bS)-8-Amino-N-benzyl-4,9,11b-trimethyltetradecahydro-
6a,9-methanocyclohepta[a]naphthalene-4-carboxamide (I-86b). 
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oil; 1H NMR (400 MHz, CDCl3): d 7.83 (s, 1H), 7.36 (d, J = 6.8 Hz, 2H), 7.34 - 7.30 (m, 
3H), 4.53 (d, J = 6.2 Hz, 2H), 2.18 (d, J = 13.9 Hz, 1H), 1.94 – 1.78 (m, 4H), 1.76 - 1.71 
(m, 3H), 1.69 – 1.58 (m, 3H), 1.49 – 1.41 (m, 3H), 1.40 – 1.33 (m, 2H), 1.30 – 1.26 (m, 
1H), 1.25 (s, 3H), 1.17 – 1.12 (m, 1H), 1.11 – 1.01 (m, 3H), 0.98 (t, J = 7.4 Hz, 1H), 0.93 
(s, 3H), 0.92 – 0.85 (m, 1H), 0.82 (s, 3H); 13C NMR (125 MHz, CDCl3): d 182.3, 159.9, 
136.9, 128.8, 128.8, 127.9, 127.9, 57.6, 56.9, 56.0, 55.6, 43.8, 43.6, 42.6, 42.0, 41.3, 
40.5, 39.9, 38.2, 37.8, 33.9, 29.0, 24.8, 21.6, 20.7, 18.8, 13.5; LRMS (m/z): [M+H]+ 
calcd for C27H40N2O 408.3141, found 409; [a]23  D  –5.25º (c 0.750, CHCl3). 
 
 
  
 
Standard procedure for O-alkylation of steviol ester (I-94) to form ethers I-88a-i (Scheme 
I-27). 
To a solution of steviol ester (100 mg, 0.318 mmol, 1.0 equiv) in DMF (5 mL) in a flame-
dry reaction vial was added slowly via cannula a solution of sodium hydride (38.3 mg in 
60% dispersion in oil, 0.954 mmol, 3.0 equiv) in dry DMF (5 mL). Then, methyl iodide 
(90.3 mg, 0.636 mmol, 2.0 equiv) was added to the reaction flask and the mixture was 
allowed to stir for 2 h at ambient temperature. The reaction was quenched with MTBE and 
the organic phase was washed successively with water. The aqueous phase was extracted 
with MTBE and the combined organic layers were dried over MgSO4, filtered, and 
OH O
OMeOMeO O I-88a-iI-94
NaH, 
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DMF
ROH
HO O I-23
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concentrated in vacuo. Purification by flash column chromatography with 20% EtOAc:Hex 
yielded the product.  
 
 
Methyl (4R,4aS,6aR,9S,11aR,11bS)-9-methoxy-4,11b-dimethyl-8-
methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-
88a). 
 
oil; 1H NMR (400 MHz, CDCl3): d  4.87 (d, J = 6.1 Hz, 2H), 3.64 (s, 3H), 3.22 (s, 3H), 
2.18 (d, J = 13.2 Hz, 1H), 2.14 – 2.00 (m, 2H), 1.89 – 1.80 (m, 4H), 1.79 – 1.71 (m, 3H), 
1.69 – 1.58 (m, 1H), 1.57 – 1.49 (m, 2H), 1.48 – 1.40 (m, 3H), 1.17 (s, 3H), 1.07 – 0.94 
(m, 3H), 0.82 (s, 3H), 0.85 – 0.76 (m, 1H); 13C NMR (125 MHz, CDCl3): d 151.0, 103.7, 
85.2, 77.3, 77.0, 76.7, 57.0, 54.0, 51.2, 50.1, 48.1, 43.8, 41.7, 41.5, 40.7, 40.0, 39.3, 
38.8, 38.0, 28.7, 21.9, 20.2, 19.1, 15.3,  LRMS (ES) (m/z): [M+CH2O2]+ calcd for 
C22H34O3 390.2508, found 390.3; [a]23  D  –93.5º (c 0.800, CHCl3). 
 
 
 
Methyl (4R,4aS,6aR,8R,9S,11aR,11bS)-8-Hydroxy-4,9,11b-trimethyltetradecahydro-
6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-95). 
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To a solution of the isosteviol ester (I-73, 1.00 g, 3.00 mmol) in 25 mL of MeOH at 0 °C 
(ice bath), was slowly added NaBH4 (134 mg, 3.55 mmol). The reaction mixture was stirred 
for 1 h at 0 °C (ice bath), and then solvent was evaporated under reduced pressure. It was 
then diluted with water and extracted with MTBE. Evaporation of the solvent and 
purification of the product on a silica gel column using 10% EtOAc:Hex to give hydroxyl 
ester I-95 (450 mg, 45%). 1H NMR (400 MHz, CDCl3): δ 3.65 (dd, J = 10.6, 4.6 Hz, 1H), 
3.42 (s, 3H), 1.96 (d, J = 13.4 Hz, 1H), 1.73 (s, 1H), 1.68 – 1.47 (m, 6H), 1.45 – 1.27 (m, 
4H), 1.24 – 0.97 (m, 4H), 0.96 (s, 3H), 0.86 – 0.75 (m, 4H), 0.70 (s, 3H), 0.69 – 0.61 (m, 
1H), 0.52 (s, 3H);13C NMR (100 MHz, CDCl3): δ 178.1, 80.4, 57.1, 55.8, 55.2, 51.1, 43.7, 
42.8, 42.0, 42.0, 41.7, 39.9, 38.0, 38.0, 33.7, 28.9, 24.9, 21.7, 20.4, 18.9, 13.1. HRMS (ESI) 
(m/z): [M+Na]+ calcd for C21H34O3Na 357.2406, found 357.2398; [a]23  D  –57.1º (c 0.833, 
CHCl3).    
 
Standard procedure for O-alkylation of isosteviol hydroxyl ester (I-95) to form ethers I-
89a-f (Scheme I-27). To a solution of hydroxyl ester (I-95, 100 mg, 0.345 mmol, 1.0 equiv) 
in DMF (5 mL) in a flame-dry reaction vial was added slowly via cannula a solution of 
sodium hydride (38.3 mg in 60% dispersion in oil, 0.954 mmol, 3.0 equiv) in dry DMF (5 
mL). Then, methyl iodide (90.3 mg, 0.636 mmol, 2.0 equiv) was added to the reaction flask 
and the mixture was allowed to stir for 2 h at ambient temperature. The reaction was 
quenched with MTBE and the organic phase was washed successively with water. The 
aqueous phase was extracted with MTBE and the combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. Purification by flash column chromatography 
with 20% EtOAc:Hex yielded the product I-89. 
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Methyl (4R,4aS,6aR,8S,9S,11aR,11bS)-8-((4-Fluorobenzyl)oxy)-4,9,11b-
trimethyltetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-
89c). 
 
1H NMR (400 MHz, CDCl3): d 7.29 (dd, J = 8.4, 5.7 Hz, 2H), 7.01 (t, J = 8.7 Hz, 2H), 4.45 
(dd, 2H), 3.63 (s, 3H), 3.54 (dd, J = 10.3, 4.1 Hz, 1H), 2.17 (d, J = 13.3 Hz, 1H), 1.96 – 
1.79 (m, 4H), 1.76 – 1.62 (m, 3H), 1.59 – 1.53 (m, 2H), 1.50 – 1.36 (m, 3H), 1.33 – 1.24 
(m, 2H), 1.17 (s, 3H), 1.06 – 0.96 (m, 4H), 0.93 (s, 3H), 0.91 – 0.83 (m, 1H), 0.72 (s, 3H); 
13C NMR (125 MHz, CDCl3): d 178.3, 132.9, 129.0, 128.9, 115.9, 115.2, 115.0, 87.0, 71.3, 
57.3, 56.0, 55.5, 51.3, 43.9, 42.4, 42.2, 42.0, 40.3, 40.0, 38.2, 38.1, 34.5, 29.0, 25.6, 21.9, 
20.6, 19.1, 13.3; mp 151-152 ºC; HRMS (ESI) (m/z): [M+Na]+ calcd for C20H30O3Na 
465.2883, found 465.2795; [a]23  D –103.7º (c 0.655, CHCl3).    
 
 
Methyl (4R,4aS,6aR,8R,9S,11aR,11bS)-8-Butoxy-4,9,11b-trimethyltetradecahydro-
6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-89f). 
 
oil ; 1H NMR (400 MHz, CDCl3): d 3.65 (s, 3H), 3.53 – 3.43 (m, 1H), 3.43 – 3.31 (m, 2H), 
2.17 (d, J = 13.0 Hz, 1H), 1.89 – 1.84 (m, 2H), 1.83 – 1.77 (m, 3H), 1.72 – 1.66 (m, 2H), 
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1.64 – 1.56 (m, 3H), 1.51 (dd, J = 12.2, 6.1 Hz, 3H), 1.44 – 1.37 (m, 4H), 1.32 – 1.24 (m, 
2H), 1.21 (d, J = 4.7 Hz, 1H), 1.18 (s, 3H), 1.12 – 1.03 (m, 2H), 1.02 – 0.97 (m, 2H), 0.94 
(s, 3H), 0.92 – 0.83 (m, 2H), 0.73 (s, 3H); 13C NMR (125 MHz, CDCl3): d 178.2, 87.3, 
69.9, 57.3, 56.0, 55.5, 51.1, 43.8, 42.2, 42.0, 40.5, 39.9, 38.1, 38.0, 34.4, 32.3, 28.9, 25.6, 
21.8, 21.7, 20.4, 19.5, 19.0, 14.0, 13.1; HRMS (ESI) (m/z): [M+Na]+ calcd for C25H42O3Na 
413.3134, found 413.2998; [a]23  D  –42.8º (c 0.850, CHCl3).    
 
 
D: Standard procedure for N-alkylation of lactam I-33 (Scheme I-27). To a solution of the 
lactam (100 mg, 0.347 mmol, 1.0 equiv) in DMF (5 mL) in a flame-dried reaction flask, 
was added sodium hydride (3.0 equiv, pre-washed with hexanes), alkyl halide I-87 (5.0 
equiv) and a catalytic amount of tetrabutylammonium iodide (TBAI, 10 mol%). The 
reaction flask was heated to 90 °C, stirred overnight and then the reaction was carefully 
quenched with water (2 mL). The organic layer was then washed with brine and the 
aqueous layers were re-extracted with Et2O (2 x 10 mL). The combined organic layers were 
then dried over MgSO4, filtered, and the Et2O was removed under reduced pressure, while 
a centrifugal evaporator was used to remove the DMF to give alkylated lactam I-90. 
Column chromatography with 5% MeOH:CH2Cl2 gave the substituted-lactam products.  
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(3S,8aS,9R,12aS,12bR)-Methyl 3,4,9,12a-Tetramethyl-5-oxotetradecahydro-1H-
3,6a-methanonaphtho[2,1-d]azocine-9-carboxylate (I-90a). 
 
To a 50 mL flame-dried round-bottomed flask of lactam I-33 (100 mg, 0.29 mmol) in DMF 
(15 mL) under nitrogen, was added sodium hydride (35 mg, 0.86 mmol, pre-washed with 
hexanes), methyl iodide (90 µL, 1.44 mmol) and a catalytic amount of 
tetrabutylammonium iodide (11 mg, 0.029 mmol). The reaction flask was heated to 90 °C 
and allowed to stir overnight. At this time TLC analysis indicated the consumption of 
starting material and the reaction was carefully quenched with water (2 mL). The organic 
layer was then washed with brine and the aqueous layers were re-extracted with Et2O (2x15 
mL). The combined organic layers were then dried over MgSO4, filtered and the Et2O was 
removed under reduced pressure, while a centrifugal evaporator was used to remove the 
DMF to give methyl alkylated lactam I-90a (90 mg, 86%) as an off-white solid. Rf = 0.2 
(Hex:EtOAc 4:1); mp 168-172 °C; IR (film) 2926, 1722, 1636 cm-1; 1H NMR (400 MHz, 
CDCl3): d 3.62 (s, 3H), 2.98 (dd, J = 18.3, 2.9 Hz, 1H), 2.84 (s, 3H), 2.16 (d, J = 13.3 Hz, 
1 H), 2.04 (d, J = 18.3 Hz, 1H), 1.83-1.92 (m, 2H), 1.55-1.83 (m, 6H), 1.51 (dt, J= 12.9, 
3.2, 3.2 Hz, 1H), 1.40-1.47 (m, 1H), 1.30 (dd, J = 12.8, 2.9 Hz, 1H), 1.25 (s, 3H), 1.18-
1.23 (m, 1H), 1.16 (s, 3H), 1.11 (dd, J = 12.8, 3.8 Hz, 1H), 1.04-1.06 (m, 1H), 1.03-0.95 
(m, 1H), 0.86 (d, J = 17.65, 2H), 0.75 (s, 3H); 13C NMR (100 MHz, CDCl3): d 177.7, 171.9, 
57.4, 56.8, 55.3, 51.1, 51.0, 44.3, 43.7, 41.0, 39.9, 38.0, 37.8, 35.7, 33.9, 28.5, 27.4, 26.8, 
OMeO
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19.7, 18.8, 18.7, 13.5; HRMS (ESI) (m/z): [M+H]+ calcd for C22H36NO3 362.2695; found 
362.2677; [a]23  D 18.9º (c 0.800, CHCl3).   
 
 
Methyl (3S,6aR,8aS,9R,12aS,12bR)-4-(4-Methoxybenzyl)-3,9,12a-trimethyl-5-
oxotetradecahydro-2H-3,6a-methanonaphtho[2,1-d]azocine-9-carboxylate (I-90c). 
  
1H NMR (400 MHz, CDCl3): 7.16 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 4.86 (d, J 
= 15.4 Hz, 1H), 4.20 (d, J = 15.5 Hz, 1H), 3.78 (s, 3H), 3.64 (s, 3H), 3.07 (dd, J = 18.4, 2.7 
Hz, 1H), 2.16 (d, J = 18.2 Hz, 2H), 1.93 – 1.82 (m, 1H), 1.81 – 1.72 (m, 4H), 1.67 (dd, J = 
13.0, 2.8 Hz, 1H), 1.54 (dd, J = 12.9, 3.1 Hz, 2H), 1.48 – 1.39 (m, 1H), 1.31 – 1.19 (m, 
3H), 1.17 (s, 3H), 1.14 (s, 3H), 1.12 – 0.95 (m, 3H), 0.90 – 0.79 (m, 2H), 0.78 (s, 3H); 13C 
NMR (125 MHz, CDCl3): 177.8, 172.3, 158.3, 132.1, 128.3 (2C), 113.7 (2C), 57.5, 56.9, 
56.4, 55.2, 51.7, 51.2, 44.3, 44.0, 43.8, 41.2, 40.0, 38.0, 37.8, 37.1, 34.1, 28.6, 28.1, 19.8, 
18.9, 18.6, 13.7; mp 151-152 ºC;  LRMS (ESI) (m/z): [M+H]+ calcd for C29H42NO4 
468.3036, found 468.3; [a]23  D  –15.6º (c 1.00, CHCl3).    
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Methyl (3S,6aR,8aS,9R,12aS,12bR)-3,9,12a-Trimethyl-5-oxo-4-(4-
(trifluoromethyl)benzyl)tetradecahydro-2H-3,6a-methanonaphtho[2,1-d]azocine-9-
carboxylate (I-90i). 
 
1H NMR (400 MHz, CDCl3): d  7.53 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 5.08 (d, 
J = 16.2 Hz, 1H), 4.15 (d, J = 16.1 Hz, 1H), 3.64 (s, 3H), 3.09 (dd, J = 18.2, 2.5 Hz, 1H), 
2.23 – 2.15 (m, 2H), 1.91 – 1.75 (m, 5H), 1.71 (dd, J = 13.1, 2.5 Hz, 1H), 1.64 – 1.55 (m, 
2H), 1.45 (d, J = 13.7 Hz, 1H), 1.36 – 1.29 (m, 1H), 1.27 – 1.20 (m, 2H), 1.18 (s, 3H), 1.17 
– 1.11 (m, 1H), 1.10 (s, 3H), 1.08 – 0.96 (m, 2H), 0.94 – 0.84 (m, 2H), 0.79 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 177.7, 172.7, 144.0, 127.1, 127.1, 127.1, 125.6, 125.3, 125.3, 
57.4, 56.8, 56.6, 51.5, 51.2, 44.5, 44.2, 43.8, 41.1, 40.0, 38.0, 37.8, 36.9, 34.1, 28.6, 28.0, 
19.7, 18.9, 18.6, 13.7; mp 151-152 ºC; LRMS (ESI) (m/z): [M]+ calcd for C29H38F3NO3 
505.2814, found 506.4; [a]23  D  –-36.6º (c 0.905, CHCl3).    
 
  
 
Standard procedure for N-alkylation of amine I-36 (Scheme I-27). To a flame-dried 
reaction flask of the amine I-36 (100 mg, 0.333 mmol, 1.0 equiv) and trimethylamine (1.5 
equiv) in a 1,4-dioxane-water mixed solvent (1:1, 6 mL), the alkyl halide (I-87, 1.0 equiv) 
was added. The reaction flask was heated to 90 °C and allowed to stir for one day. The 
reaction mixture was quenched with EtOAc and the organic layer was washed with 
saturated aqueous NH4Cl. The organic layer was then washed with brine and the aqueous 
OMeOMeO O I-91a-eI-36
+ R-X
I-87a-e
NH2 N    Et3N, I-87, 
    H2O, dioxane
    90 °C
H
R
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layers were extracted with EtOAc (2 x 10 mL). The combined organic layers were then 
dried over MgSO4, filtered, and concentrated in vacuo to give the crude alkylated-amine 
product I-91. Purification was done by column chromatography with 5% MeOH:DCM. 
 
 
Methyl (4R,4aS,6aR,8R,9S,11aR,11bS)-8-(Benzylamino)-4,9,11b-
trimethyltetradecahydro-6a,9-methanocyclohepta[a]naphthalene-4-carboxylate (I-
91b). 
 
oil; 1H NMR (400 MHz, CDCl3): d 7.35 (d, J = 7.6 Hz, 4H), 7.29 – 7.25 (m, 1H), 3.80 (q, 
J = 46.0, 13.4, 12.4 Hz, 2H), 3.66 (s, 3H), 3.64 (s, 1H), 2.77 (dd, J = 10.6, 5.4 Hz, 1H), 
2.19 (d, J = 13.3 Hz, 1H), 1.86 – 1.80 (m, 2H), 1.74 (d, J = 13.5 Hz, 3H), 1.64 – 1.59 (m, 
3H), 1.57 – 1.51 (m, 2H), 1.46 – 1.40 (m, 1H), 1.38 – 1.31 (m, 2H), 1.19 (s, 3H), 1.10 – 
1.04 (m, 2H), 1.03 – 0.98 (m, 3H), 0.92 (s, 3H), 0.90 – 0.86 (m, 1H), 0.74 (s, 3H); 13C NMR 
(125 MHz, CDCl3): d 178.2, 141.4, 128.3, 128.2, 128.0, 128.0, 126.7, 66.2, 57.3, 57.0, 
55.9, 53.2, 51.1, 43.8, 42.4, 41.8, 41.6, 41.2, 40.0, 38.1, 38.1, 34.3, 28.9, 25.6, 21.8, 20.7, 
19.0, 13.3;  HRMS (ESI) (m/z): [M]+ calcd for C28H41NO2 423.3137, found 424.3; [a]23  D  
–58.5º (c 1.00, CHCl3). 
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Standard procedure for amide bond formation from lactam ester I-90a (Scheme I-28).  
To a solution of methyl-lactam ester I-90 (1.00 g, 2.77 mmol) in THF/H2O (1:1, 10 mL) in 
a round-bottom flask was added 1M aq. LiOH (5 mL) at room temperature. The reaction 
was heated to reflux and stirred overnight. Then, it was cooled to room temperature and 
quenched with 1M aq. HCl to pH 4. The resultant mixture was extracted with EtOAc and 
the combined organic layers were washed with brined and dried over MgSO4. The acid was 
carried on without further purification. To a solution of acid (100 mg, 0.302 mmol, 1.0 
equiv) in CH2Cl2/DMF (4:1) in a flame-dry reaction vial, was added PS-
hydroxybenzotriazole (PS-HOBt, 1.00 mmol/g, 0.67 equiv), 4-dimethylaminopyridine 
(21.1 µL, 0.121 mmol, 0.40 equiv), and then 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (140 mg, 0.905 mmol, 3.0 equiv). The reaction mixture was shaken slowly 
for 24 h and then filtered. The resins were washed with MeOH (5 mL) and CH2Cl2 (5 mL) 
thrice to remove excess acid. Then, the resin was added to a solution of amine I-78 (0.211 
mmol, 0.70 equiv) and diisopropylethylamine (52.6 µL, 0.302 mmol, 1.0 equiv) in CH2Cl2 
and shaken slowly for another 24 h. The mixture was filtered again was washed with MeOH 
(5 mL) and CH2Cl2 (5 mL) thrice before the solvent was removed under vacuum.  The 
crude residue was purified by column chromatography with 20% EtOAc:Hex to furnish 
the lactam amide I-92. 
 
(3S,6aR,8aS,9R,12aS,12bR)-N-(4-fluorobenzyl)-3,4,9,12a-tetramethyl-5-
oxotetradecahydro-2H-3,6a-methanonaphtho[2,1-d]azocine-9-carboxamide(I-92c). 
 
ON
H
N
O
F I-92c
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oil; 1H NMR (400 MHz, CDCl3): d 7.28 – 7.23 (m, 2H), 7.03 (t, J = 8.5 Hz, 2H), 5.24 
(d, J = 15.4 Hz, 1H), 4.69 (s, 1H), 4.47 (d, J = 15.5 Hz, 1H), 3.66 (s, 3H), 2.21 (d, 
J = 13.8 Hz, 1H), 2.15 (d, J = 13.3 Hz, 1H), 1.91 – 1.83 (m, 1H), 1.82 – 1.77 (m, 
1H), 1.73 (s, 3H), 1.71 – 1.60 (m, 3H), 1.58 (s, 3H), 1.49 (h, 1H), 1.44 – 1.32 (m, 
3H), 1.29 (d, J = 6.8 Hz, 2H), 1.26 – 1.21 (m, 1H), 1.19 (s, 3H), 1.08 – 0.94 (m, 
4H), 0.90 (dd, J = 13.0, 4.1 Hz, 1H), 0.85 – 0.76 (m, 1H); LRMS (ESI) (m/z): 
[M+H]+ calcd for C28H40FN2O2 455.2996, found 455; [a]23  D  –74.3º (c 0.450, CHCl3). 
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PART II- RETINOIC ACID RECEPTOR ALPHA ANTAGONIST 
DEVELOPMENT FOR MALE CONTRACEPTION 
Chapter 5. Design and Synthesis of Retinoids for Non-Hormonal Male Contraceptive 
Development 
A. Contraception Background 
Contraception is the prevention of pregnancy with methods that control male or 
female fertility.162 The first reports of contraception date back centuries ago with the 
invention of the condom in 1564.163 This form of birth control was reliant on the male 
counterpart of sexual relationships, but much has changed since then in terms of more 
effective condom development and female contraception.163 Female birth control most 
notably began in the 1950s with the introduction of an oral contraception method, also 
known as “the pill.”164 The birth control pill inhibits ovulation in normal, ovulating women 
by mimicking gonadal hormones: estrogen and progesterone. The first human trials were 
in 1956 with Food and Drug Administration (FDA) approval of the first hormonal 
contraception by 1960.164, 165  
 
1. Unintended Pregnancies and Unmet Need for Contraception 
Despite significant advances in reproductive services since then, a Lancet report in 
2013 estimated that around 146 million women worldwide have an unmet need for 
contraception, or family planning.166 That is to say, that millions of women, especially in 
developing nations, lack access to necessary contraceptive methods.  
Moreover, that global estimate increases to 225 million women for women who do 
not use contraception or employ traditional methods, which include withdrawal or 
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abstinence.167, 168 Table II-1 below displays all the pregnancies from 2008, including the 
percent distribution of intended and unintended pregnancies. In that year alone, over 85 
million pregnancies were unintended with over ten million of those pregnancies coming 
from developed regions in the world, like the United States. The Centers for Disease 
Control and Prevention (CDC) describe an unintended pregnancy as an undesired or mis-
timed pregnancy that occurs.169 Furthermore, of those unintended pregnancies worldwide, 
16%, or over 33 million, resulted in undesired births plus the other 25%, or 52 million, 
pregnancies that ended in abortion or miscarriages.  
 
Table II-1. The number of pregnancies and percent distribution in 2008.170 
Region 
Total # of 
pregnancies 
(millions) 
% distribution of 
pregnancies 
Unintended pregnancy outcomes (%) 
Intended Unintended Births Abortions Miscarriages 
World 208.2 59 41 16 20 5 
More 
developed 
regions 
22.8 53 47 15 25 6 
Less 
developed 
regions 
185.4 60 40 16 19 5 
 
 
We can infer from the number of unintended pregnancies in Table II-1 that there is 
indeed a large unmet need for families all over the world for modern and effective 
contraception that will affect millions of women. Compounded by the number of women 
who experience health problems that prevent them from taking effective contraception,171 
the unmet need has led to more research in both female and male contraception. 
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2. Current Forms of Male Contraception 
Females have a variety of options for contraception, each with potential risks and 
benefits. Aside from the traditional, and at times unsuccessful, methods of natural family 
planning or barrier methods, women also can employ hormonal systemic contraception, 
injectable progestins, long-acting reversible contraception, and permanent sterilization.165 
Male contraceptive research, on the other hand, is underdeveloped, with only two currently 
available options: condoms or a vasectomy.172 Condoms provide a temporary barrier to 
fertilization that is reversible upon removal of its use, while vasectomies, the clamping or 
cutting of the vas deferens to cause male sterilization, can be permanent.173 The following 
chart shows existing contraceptive methods in the developing and developed regions 
worldwide; the majority of the available methods depend on female fulfillment (Chart II-
1).174  
 
 
Chart II-1. Existing contraceptive methods in the developing and develop regions in the 
world.174 
 
Several research projects are under way intended on producing other male 
contraceptive options.172, 173, 175, 176 Potential male contraceptive methods are classified into 
categories based on their target of action: hindering the transport of sperm or suppressing 
spermatogenesis, the maturation of sperm from spermatogonia to spermatozoa.174  Within 
    
 
101 
the past decade, the development of a male contraceptive agents that target 
spermatogenesis is becoming a pharmaceutical option.172 Understanding spermatogenesis 
and its mechanism is paramount for male contraceptive development175 and will be 
discussed throughout this chapter. As noted by Giwercman et al., spermatogenesis is 
probably a more vulnerable process than ovulation.177 Spermatogenesis is the process that 
generates mature sperm in the testes.178 This continuous process takes approximately 75 
days and produces millions of mature haploid sperm.173 Figure II-1, illustrates the 
spermatogenesis process. 
 
 
Figure II-1. The process of Spermatogenesis.179 
 
 Beginning in the seminiferous tubules of the testes, diploid spermatogonia (sg) 
undergo mitosis to produce diploid primary spermatocytes (spc I). These spermatocytes 
can continue to divide mitotically or move on to the next step: meiosis I. The spc I migrate 
toward the lumen to undergo meiosis I and produce haploid secondary spermatocytes (spc 
II). The spc II continue to meiotically divide through meiosis II to generate haploid 
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spermatids (std). The spermatids continue to mature into spermatozoa (spz) in the lumen 
of the seminiferous tubules during spermiogenesis.179 Spermatozoa, or mature sperm cells, 
consist of a head, mid-piece, and flagella tail. Research has been done to inhibit 
spermatogenesis through the exogenesis administration of testosterone derivatives in male 
hormonal contraceptive development.180, 181 All these studies show the effects of injecting 
the androgens subcutaneously, because the oral administration route was not effective.174  
Moreover, aside from the slight pain caused by needle injection, other unwanted side 
effects of supernatural levels of testosterone include negative cardiovascular effects, mood 
changes, acne,182 weight gain,183 and possible prostrate malignancy.184 Altogether, these 
side effects and the type of drug administration have made hormonal contraceptive 
development unattractive.174 Herein lies the need for a non-hormonal male contraceptive 
agent.  
 
3. Areas of Focus for Non-Hormonal Male Contraceptive Development 
A non-hormonal male contraceptive approach can be defined as one that does not 
involve the administration of exogenous hormones or agents that block hormone action or 
secretion.185 This approach will be less likely to have the adverse effects from the hormonal 
treatment.  Non-hormonal male contraception is an unmet need and an attractive area for 
drug development, since this allows men to have power to control their fertility as well as 
take an active role in family planning. Unfortunately, pharmaceutical interest in the male 
contraceptive research arena has died down, probably due to the slow research; the burden 
to provide enough safety, efficacy, and reversibility data; and the assurance of not having 
deleterious effects to future offspring.172, 174 As a result, the NIH has taken this global 
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problem as a major financial contributor.172 Through the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development (NICHD), the Male Contraceptive 
Development Program (MCDP) is an invaluable resource for the future of male birth 
control.  
The MCDP conducts research that can identify mechanisms of sperm maturation 
regulation and new therapeutic targets.186 The main areas of research focus on inhibiting 
spermiogenesis or spermatogenesis, vide supra. Our group received funding through the 
Contraceptive Research Branch to explore multiple areas of potential contraceptive 
development, such as targeting the sperm-specific Na,K-ATPase alpha 4 (a4), 
bromodomain testis-specific protein (BRDT), or retinoic acid receptor alpha (RARa).  
Na,K-ATPase a4 is a specific isoform of a transmembrane protein that is found to control 
motility and hyperactivation in sperm through active sodium and potassium ion 
exchange.187 BRDT is a tissue-restricted protein that is important in spermatogenesis.188 
The RARa target will be discussed in greater detail below.  
 
B. Retinoic Acid Receptor Alpha (RARa) 
While the Georg research group focuses on these and other targets for the 
development of male contraceptive agents, a subset of us (Dr. Rebecca Cuellar, Jillian 
Kyzer, Dr. Narsihmulu Cheryala, and Trinh Holth) have been investigating RARa nuclear 
receptor antagonists. Retinoic acid receptors belong to the nuclear receptor family and are 
composed of three isotypes: RARα, β, and γ.189 They are involved in many significant 
biological processes including embryogenesis, reproduction, vision, growth, inflammation, 
cell differentiation, cell proliferation, and apoptosis.190 Additionally, this family of nuclear 
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receptors also includes retinoid X receptors, which also come in three similar isoforms: a, 
ß, and g.191 RARs exist as heterodimers with RXR, forming RAR-RXR complex, which 
may be responsible for transducing the retinoid signal at the molecular level.192 RARs are 
also required for the mediation of the important vitamin A functions during human 
development.193 In addition to forming heterodimer complexes with retinoic acid receptors, 
RXRs can also exist as homodimers.194 Both RAR and RXR receptors are activated by 
retinoic acid (RA) in the cells.195 Retinoic acid receptors can bind to either all-trans 
RA (ATRA) or 9-cis RA, while retinoid X receptors, only bind to 9-cis RA (Figure II-
2).196, 197  
 
Figure II-2. Structures of all-trans retinoic a, 9-cis RA, and vitamin A. 
 
 
ATRA (II-1) and 9-cis-RA (II-2) belong to a group of compounds called retinoids: 
natural or synthetic analogs of retinol (II-3), also known as vitamin A (Figure II-2).198 
Retinol (II-3) is converted to II-1 through sequential oxidation steps in the body.199 While 
many of the RAR and RXR isoforms are found in spermatocytes and at different 
developmental stages, RA mediates its effects through the action of the RARα in Sertoli 
cells, 195 Sertoli cells are located in the seminiferous tubules and aid in spermatogenesis.200 
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1. Implications in Male Contraception 
Previous research has shown that a knockout mouse model of RARα exhibited 
disrupted spermatogenesis and infertility.201 Additionally, defects in vitamin A-deficient 
(VAD) wild-type mice were reversed after administration of RAR agonists.201 While 
vitamin A-deficiency does occur in humans, not enough information is known regarding 
the effects on reproductive capabilities.202 However, there is some evidence of the effect 
of RA on human male germ cells.203 Reports reveal that germ cells in fetal human testes 
cultured with retinoic acid underwent apoptosis after they were stimulated to proliferate.204 
Additionally, retinoic acid also induces an increase in the gene stimulated by RA gene 8 
(STRA8) for the expression of RA in the human embryonic ovary and testis and the 
postnatal testis.195, 205 While the research is ongoing and these processes are not well 
understood overall, these reports imply the importance of retinoic acid and vitamin A in 
spermatogonial differentiation, meiosis, and the cycle of the seminiferous epithelium. 
The Wolgemuth group at Columbia University first reported on the connection 
between vitamin A and retinoic acid in mammalian male sterility.189, 206  In mouse studies, 
where the Rara gene is removed (Rara-/-), the results showed sterile male mice with specific 
abnormalities in spermatogenesis, as seen in histological cross sections of the tubules.207 
They also observed that the defects in spermatogenesis were similar to those in vitamin A 
deficient testes.208 Chung et al. also reported that disruptions in RARα-mediated retinoid 
signaling in spermatogenesis result in a failure of sperm alignment and release into the 
seminiferous tubular lumen,198 which is similar to the effects observed in VAD mice.189 Of 
note, RARa is required for spermatogenesis and its absence results in progressive 
breakdown of the spermatogenesis process.209 Figure II-3 demonstrates the histological 
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cross sections (A and B) of a seminiferous tubule in the testes and their illustrations below 
(C and D) show the effects on spermatogenesis in normal, fertile mice compared to VAD 
mice.210  
 
 
Figure II-3. Normal spermatogenesis in healthy vs vitamin A deficient mice.210 
 
 
Under normal spermatogenic conditions, spermatogonia differentiate into 
spermatozoa. In between the Sertoli cells, spermatgonia mature to spermatocytes then 
spermatids before they are released into the lumen for spermiation.189, 198 In VAD and 
RARa null mice, the process is completely absent, with no spermatozoa production, which 
causes the sterility. 
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2. Previous Agonist and Antagonist Development 
The reversibility of sterile effects on mice with abnormalities in vitamin A 
deficiency or RARa-deficient testes,206 suggest an opportunity for non-hormonal 
contraceptive development of specific RARa antagonists. A series of compounds have 
been developed that block ATRA binding and activation of transcription of RAR target 
genes by Bristol-Myers Squibb (BMS) (Figure II-4).211 In the 1980s, BMS 189453 (II-4), 
a non-selective RAR antagonist retinoid, acting on all isoforms (a, ß, and g), was shown to 
cause reversible infertility.212 Retinoids are derivatives of vitamin A and are composed of 
three general parts: a hydrophobic ring portion, a linker region, and a carboxylic acid end 
group (Figure II-4). For RARa retinoids, the hydrophobic ring portion imparts antagonism 
with bulky groups inducing antagonistic effects over less bulky hydrophobic moieties. 
When a gem-dimethyl is in place of the phenyl ring in the hydrophobic region, the molecule 
exhibits agonistic activity.213 An amide group in the linker region reveals the greatest 
RARa selectivity. With an alkene linker, II-4 is a pan-antagonist, while II-5 and II-6 are 
RARa selective antagonists. Lastly, the carboxylic acid end group is essential for RAR 
activity. 
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Figure II-4. BMS compounds. 
 
 
Interestingly, the BMS compound BMS-189453 was originally tested on animals 
as a treatment for inflammatory skin diseases. Researchers in the Wolgemuth group at 
Columbia University reported that when doses for the BMS pan-antagonist were decreased 
in fertility experiments, the infertility, that was previously observed, had a reversible effect 
without significant toxicity.208 Additional studies were performed with other retinoids: 
BMS-189532 (II-5) and BMS-195614 (II-6) (Figure II-4).206 These compounds proved to 
be RARa-selective antagonists through competition assays with the other RAR 
isoforms.206  While both retinoids showed great potential in in vitro analyses, they 
demonstrated poor in vivo effects when orally administered to mice.206 We submitted a 
sample of both II-4, the pan antagonist, and II-5, the RARa selective antagonist to Cerep, 
Inc. for evaluation in a variety of assays including aqueous solubility (in phosphate 
buffered saline (PBS), pH 7.4), partition coefficient determination (octanol-PBS buffer, pH 
7.4), cell permeability (Caco-2 cells), plasma protein binding (mouse), and metabolic 
stability (mouse liver microsomes), along with the reference compounds used (Table II-2). 
The partition coefficient (Log D) data shows that II-4 was less favorable than II-5, with a 
value of 3.25 and 3.84, respectively. Ideally, the higher the Log D value, the more lipophilic 
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the compound is and the more the drug is absorbed by the cells.214 Additionally, II-4 had 
lower permeability and was considerably less soluble. However, BMS-189453 (II-4) did 
indeed have a more favorable plasma protein binding value.  While BMS-189532 (II-5) is 
the more ideal candidate for our project because it is a isoform specific, the compound was 
ineffective in vivo. The Cerep data confirms this knowledge: only 0.8% of II-5 was not 
bound to plasma protein and a very small portion of free compound was then metabolized 
at a much faster rate than the pan-antagonist. 
 
Table II-2. Pharmacology of known RARa antagonist and pan-antagonist. 
 
 
Assay (conditions) II-5 II-4 Reference compounds 
Aqueous Solubility (PBS, 
pH 7.4) 
136 µM 3.1 µM 
diethylstilbestrol, haloperidol, 
metoprolol tartrate, 
phenytoin, rifampicin, 
simvastatin, tamoxifen 
Partition Coefficient (Log 
D, n-octanol/PBS, pH 7.4, 
1.0 x 10-4 M) 
3.84 3.25 
diethylstilbestrol, haloperidol, 
ketoconazole, metoprolol 
tartrate, phenytoin, 
rifampicin, simvastatin 
Plasma Protein Binding 
(mouse, CD-1, 1.0´10-5 
M) 
99.2% 
bound; 
99.8% 
recovery 
95.3% 
bound; 
93.3% 
recovery 
acebutolol, quinidine, 
warfarin 
A-B Permeability (TC7, 
pH 6.5/7.4,1.0´10-5 M) 
8.3´10-6 
cm/s; 20% 
recovery 
<0.7´10-6 
cm/s; 14% 
recovery 
colchicines, labetalol, 
propanolol, ranitidine 
Metabolic Stability (liver 
microsomes, mouse, CD-
1, 1.0´10-6 M, 60 min.) 
49% parent 
remaining 
79% parent 
remaining 
imipramine, propanolol, 
terfenadine, verapamil 
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From the results of the biological screening of BMS compounds II-4 and II-5 in 
Table II-2, we determined that the amide linker of II-5, the a selective antagonist, has a 
much larger metabolic liability than the alkene linker of II-4, the pan antagonist. We 
conclude from this data that simultaneously addressing plasma protein binding and 
metabolic stability should yield compounds that are bioavailable in our later animal 
models. We determined that the cause of undesired in vivo effects was most likely due to 
poor bioavailability of the compounds and modifications to their structures could 
circumvent these problems. Given the importance of RARa in sperm maturation and male 
reproduction, the goal of our research is to develop a reversible, non-hormonal therapeutic 
agent that targets and blocks RARa. For this, we pursued the BMS retinoids as a starting 
place for compound development. 
 
C. Design of Retinoids 
The retinoids are made up of three general parts: a hydrophobic ring portion, a 
linker region, and a carboxylic acid end group (Figure II-4). These three general features 
tolerate a wide range of moieties: quinolone, naphthalene, or chromane heterocycles in the 
hydrophobic ring portion; an alkene, an amide, or a heterocyclic isostere for the linker 
region; and benzoic, cyclohexanoic, or naphthoic acid on the end. Table II-3 shows several 
examples of retinoids that are clinically approved or in clinical testing.215 Some of these 
retinoids, including the natural ligands II-1 and II-2, are commercially available as 
treatments for acne, psoriasis, and various types of cancer. All of these approved drugs 
contain a similar structure to our target compounds with a hydrophobic region, a linker 
portion, and a carboxylic end. Additionally, the compounds in Table II-3 all contain a gem-
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dimethyl group in the hydrophobic ring region, which has been show to promote agonism, 
vide supra. 
 
Table II-3. Commercially available retinoids. 
Name (Trade Name) Structure Phase: Indication 
ATRA, Tretinoin 
(Avita) 
 
Launched: acne, warts 
Phase II: breast, brain, and 
renal cancers 
9-cis-RA, Aliretinoin 
(Panretin) 
 
Launched: Karposi’s sarcoma 
Isotretinoin 
(Accutane) 
 
Launched: acne 
Phase II: T-cell malignancies 
Phase III: high grade glioma 
Tazarotene (Tazorac) 
 
Launched: acne, psoriasis 
Pinacolyl-9-cis-
retinoate, MDI 301 
 
Preclinical: acne, cancer, 
psoriasis 
 
 
Since we needed to generate compounds that would address our earlier problems 
with II-4 and II-5 yet also be selective for RARa, we sought to develop compounds with 
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bioisosteres for the amide linker: triazoles, oxadizoles, imidazoles, pyrazoles, oxazoles, 
and other heterocycles. 216, 217 For the hydrophobic ring region, we initially chose to work 
with the same naphthalene ring as the BMS compounds because the synthesis was known 
and modifications at various positions were possible. From bromo-tetralone (II-10), a 
straight forward Grignard reaction followed by elimination provides access to the tetralin 
core of the hydrophobic ring region (Scheme II-1). The tetralin bromide serves as an 
excellent DOS template, vide supra, because many different reactions with the bromide 
will provide multiple different linkers for the retinoids.   
 
 
Scheme II-1. Formation of different tetralin linkers. 
 
 
Path I leads to aniline II-12 possibly through copper catalysis.218 Path II pertains 
the borylation through an organometallic reagent plus a boric ester, followed by acid 
hydrolysis to yield boronic acid II-13.219 Similarly, II-14 and II-15 can be produced 
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through a lithium-halogen exchange to give the corresponding aldehyde,220 followed by a 
sodium azide reaction to give azide II-14 or Bestmann-Ohira reaction conditions to give 
alkyne II-15.221 Hydroxycarbonylation can produce an aryl carboxylic acid II-16 from aryl 
bromide II-11.222  
 Additionally, from the aryl boronic acid derivative II-13, we envisioned 
synthesizing the quinolone linker analogs (Scheme II-2). While quinolone is not a known 
bioisostere for the amide group, the robustness of the quinoline and tetrahydroisoquinoline 
rings could help form tighter or better binding compounds. These heterocycles encompass 
both the linker and carboxylic acid regions so we wanted to explore their potential in our 
tetralin series. 
 
 
Scheme II-2. Quinoline linkers via boronic acid II-13. 
 
On the other hand, we are exploring the triazole heterocycle through the synthesis 
of both aryl azide and aryl alkyne derivatives, II-14 and II-15, respectively, as amide bond 
bioisosteres. Through click chemistry with the corresponding alkyne or azide, we envision 
the formation of triazole linker II-19 or II-20 (Scheme II-3).  
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Scheme II-3. Triazole products from azide II-14 and alkyne II-15. 
 
 
Additionally, my part of this work involves the synthesis of cyclohexanoic acid 
analogs to understand the behavior of the binding pocket and introduce some rigidity into 
the retinoids. The DOS approach for the tetralin core is an excellent way to access multiple 
substituents in the linker region.   
 
D. Computational Modeling of Retinoids 
While the synthesis was underway, we also performed in silico analysis of our 
compounds to assess their potential for a structure-based drug design approach of the 
retinoids. For our investigation, we fortunately had an available crystal structure of a 
RARa heterodimer (PDB:1dkf) bound with a known BMS antagonist II-6 (Figure II-5). 
223   Using the Schrodinger Molecular Modeling suite, we were able generate a grid for the 
binding pocket that was established from the bound II-6. 
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Figure II-5. 1dkf protein structure with proposed docked compounds. 
 
 
With the Maestro program in the suite, docking scores were calculated for our 
retinoids bound within the receptor site. Table II-4 shows the lowest docking scores for a 
sample of our proposed structures; of note, more negative values for docking scores 
indicate better docking within the grid of the binding pocket. Our scores show that the RAR 
a selective compound II-5 did not score as well as our retinoids. Dr. Cuellar from our 
group has previously synthesized RAC-I-163 (II-21) as a triazole analog of II-5, as well 
as its structural isomer (II-22). Within the table, there are Dr. Cuellar’s triazole analogs 
with the benzoic acid moiety, cyclohexanoic acid triazole analogs II-23-II-26, as well as 
the quinoline linker analogs II-27-II-30 (Table II-4). 
 
Table II-4. Docking scores for proposed retinoids plus II-5. 
Compound Docking Score Compound Docking Score 
 
-14.3615 
 
-14.6250 
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-15.3422 
 
-14.6288 
 
-15.3401 
 
-15.4904 
 
-14.5278 
 
-14.9819 
 
-14.8753 
 
-15.4518 
 
-14.7372 
  
 
 
With the 1dkf crystal structure, the quinoline moiety of II-6 computationally 
displayed an ability to fill the antagonist binding pocket in RARa active site, which 
suggests that actual binding of our molecules could produce similar results.  
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 From the Maestro program, we were able to calculate the binding energies of the 
interactions of the retinoids to the amino acids in the binding pocket. Ideally, we want to 
produce molecules that are more energetically favorable, or -∆G, as represented as the bars 
negative from the 0 axis. These purposed retinoids have the most interaction with residues 
220 to 280. This analysis is helping in determining which parts of the molecules are 
interacting with the binding pocket in a positive or negative manner. Future work would 
be to adjust these parts of the molecule to produce favorably interactions. 
 
 
Figure II-6. Binding energies for proposed compounds. 
 
Our computation data suggests that the cyclohexanoic acid moiety could impart 
some rigidity in the retinoids. Research has been ongoing to produce the BMS triazole 
analogs as well as a new group of Eisai Research (ER) analogs. 
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E. Synthesis of Retinoids 
1. BMS Triazole Derivatives  
 For the RARa retinoid synthesis, my work included the cyclohexanoic acid and 
quinolone linkers. To start, the 7-bromo tetralone II-34 was synthesized to serve as a 
building block for the tetralin core (Scheme II-4).  Treatment of ethyl levulinate (II-31) 
with methyl magnesium iodide afforded dimethyl furan II-32, which was followed by 
Friedel–Crafts acylation/intramolecular alkylation of benzene to give tetralone II-33.224 
Bromination of II-33 gave multiple side products (not shown), but the desired II-34 was 
isolated in 20% yield. After attempts to optimize the reaction were unsuccessful, we went 
ahead and bought the commercially available II-34.  
 
Scheme II-4. Synthesis of triazole II-23. 
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A Grignard reaction with tolyl bromide followed by elimination gave the tolyl 
bromide II-35. Sonogashira coupling with TMS acetylene and silyl deprotection produced 
alkyne II-36 (Scheme II-4).  The alkyne was then coupled to azide II-38 with the Huisgen 
1,3-cycloaddition reaction, or click chemistry, to give triazole II-23 after hydrolysis. Azide 
II-38 (Scheme II-4) was made by treating trans amino cyclohexanoic acid with thionyl 
chloride to form the ester in quantitative yield followed by azide formation with sodium 
azide and triflic anhydride. Triazole II-23 was carried on to activity screening, vide infra. 
 
Scheme II-5. Towards the synthesis of triazole II-24. 
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In addition to the II-23 triazole, its structural analog II-24 was produced. Aryl azide 
II-39 was synthesized under mild conditions with a chiral diamine ligand.225  Aryl azide 
II-39 then underwent another click reaction with alkyne II-44 to produce the ester of II-
24. Hydrolysis of the ester under normal basic conditions followed by crystallization in 
methylene chloride and hexanes completed the synthesis of II-24. To access the alkyne 
precursor II-44, we started with tranexamic acid (II-40) and formed its ester II-41. Next, 
the amine was treated with mesyl chloride to give the mesylated amine II-42, then it was 
oxidatively deaminated with N-tert-butylphenylsulfinimidoyl chloride to yield the 
corresponding aldehyde II-43. Lastly, dimethyl (1-diazo-2-oxopropyl) phosphonate, or 
Bestmann-Ohira reagent, was added under basic conditions to afford the alkyne II-44 
(Scheme II-5). 
The synthesis of retinoids isoquinoline II-27 and tetrahydroisoquinoline II-29 were 
also performed (Scheme II-6 and II-7). Boronic acid II-45 was formed from bromide II-
34 with a diboron reagent followed by hydrolysis with sodium periodate. Acid II-45 was 
coupled to chloroquinoline II-47 with a Suzuki coupling protocol.226 To generate 
chloroquinoline II-47, quinolone II-46 was treated with meta-chloroperoxybenzoic acid 
followed by phosphoryl chloride.227 The Suzuki coupling yielded a small amount of II-27 
that was not enough to be biologically tested. We therefore tried coupling with the acid 
derivative II-48 to avoid the final saponification step and potentially another low yield 
(route B, Scheme II-6), but after 24 hours, only starting material was detected.  
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Scheme II-6. Towards the synthesis of quinoline II-27. 
 
Eventually, this route was abandoned when a more simple direct arylation with quinoline 
using the rhodium catalyst was realized.228 After optimizing the conditions, we were able 
to get good yields for both the coupling and saponification steps for the production of II-
27 (Scheme II-6). 
Lastly, synthesis of the quinolone analog II-29 was completed by catalytic 
palladium coupling of tetrahydroisoquinoline II-50 to bromide II-34 to give the desired 
ester. Reaction optimization with BINAP did not produce a yield higher than 28% but the 
product was carried on. Saponification under basic conditions gave quinolone acid II-29 
cleanly without further purification.  
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Scheme II-7. Synthesis of quinoline analog II-29. 
 
 
2. ER Derivatives 
During the synthesis of these BMS-derived retinoids, our group also explored 
quinoline II-51 (ER-50891), another a selective compound (Figure II-7).229 Preliminary 
results from analogs made in our group showed promise, so a cyclohexanoic acid analog 
with a triazole linker was attempted.  
 
 
Figure II-7. ER-50891 (II-52). 
 
 This section covers the brief work I have done towards the synthesis of ER-50891 
derived retinoids. I completed the synthesis of the isopropyl and methoxy quinolone 
analogs II-54 and II-57, respectively, with the aim to convert them to triazole 
cyclohexanoic acid analogs II-58 and II-59 (Scheme II-8).  
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Scheme II-8. Towards the synthesis of ER analogs. 
 
 
For the synthesis of isopropyl quinoline II-55, isopropyl aniline II-52 was first treated with 
butynedioic ester II-53 followed by Eaton’s reagent to generate the quinoline ester II-54.230 
This underwent treatment with triflic anhydride and dimethylaminopyridine (DMAP) to 
yield the triflate intermediate that was then treated with phenyl boronic acid to produce II-
55 in low yield. The triflate intermediate formation followed by the Suzuki reaction was 
done with methoxy quinoline II-56 to give ester II-57 in good yield after two steps.  
Following the production of the esters II-55 and II-57, the initial goal was to produce 
retinoids II-58 and II-59 with the triazole linker by first reducing the respective ester to its 
corresponding aldehyde followed by a Seyferth-Gilbert homologation to give the alkyne 
product that would then be coupled with azide II-39 (from Scheme II-4) via click 
chemistry. However, while the syntheses of these triazole analogs were under way, others 
in our group tested ER analogs with the presence of the triazole linker and found them to 
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be inactive for RARa. With this in mind, new routes are being explored for different linkers 
for the ER analogs.  
  
Scheme II-9. Developing quinoline analogs for hydrophobic pocket exploration. 
 
 
A new route for quinoline analogs are being explored by our group for selective 
aryl- or alkylation of the 4- and 8- positions of the quinoline ring (Scheme II-9). The aim 
of this work is to make different quinoline analogs at the C-4 and C-8 positions to explore 
the hydrophobic pocket of RARa. With 8-bromo-4-chloroquinoline ester II-60, Suzuki 
coupling with phenylboronic acid using Pd(dppf)Cl2 as the catalyst gave the exclusive 
bromo-substituted phenyl quinoline II-61 in good yield. This leaves room to explore 
further substitution at the chloro- position and saves extra steps from having to form the 8-
substituted quinoline exclusively, as in II-54 or II-56. 
 
 
F. Biological Screening of Retinoids 
 Once synthesis of the retinoids has been completed, the compounds were subjected 
to a binding assay and luciferase reporter activity assay.  
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1. Binding Assay 
As a complement to our computational structure-based drug design approach, we 
have also been able to determine where to make structural modifications on our compounds 
to maximize binding interactions to their known targets with the help of our collaborators 
in the Schönbrunn group. They have produced the RARa binding domain with a bacterial 
over-expression system and have used it in isothermal titration calorimetry (ITC) binding 
studies and crystallization screens. ITC is the gold standard technique for determining 
thermodynamic parameters of chemical interactions, especially binding constants. This 
technique is the only experimental method that simultaneously obtains thermodynamic 
parameters, which greatly reduces the potential errors introduced from piggybacking 
calculations. Of note, isothermal titration calorimetry is used for quantifying binding 
constants, while X-ray co-crystallization is used for qualifying those results from binding. 
Additionally, X-ray co-crystallization of our compounds will be used to identify possible 
sites of interest for further modification through structure-activity relationship (SAR) 
analysis. Furthermore, ITC avoids the use of reporter labels including isotopes, 
fluorophores, chromophores, to monitor a reaction; thus, it saves time and money. 
Generally, ITC involves the titration of a ligand into a solution of protein in a closed 
system while monitoring the energy consumption or the generation of heat.  The change in 
heat is then used in the Gibbs’ free energy equation to determine Kd (ΔG = ΔH-TΔS = -
RTlnKa where Ka = 1/Kd). The Kd value, or dissociation constant, is a measurement of 
binding affinity. Binding affinity describes the strength of the interaction between the 
protein and the ligand. In general, smaller Kd values indicate tighter binding and greater 
binding affinity.231 
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For the RAR project, both 9-cis-retinoic acid (II-2) and all-trans-retinoic acid (II-
1) are used as controls, with all tests done in triplicate. Figure II-8 and II-9 shows ITC data 
for all-trans-retinoic acid (II-1) and 9-cis-retinoic acid (II-2) with analysis in both RAR 
and RXR proteins. As mentioned earlier, II-1 binds to RAR but not RXR.197 The Kd value 
of 0.80 µM for the RAR homodimer is similar to 0.82 µM found for the RAR/RXR 
heterodimer (Figure II-8). The similar values could account to exclusive binding to just the 
RAR site. 
 
Figure II-8. ITC data for II-1. 
 
 
On the other hand, 9-cis-retinoic acid (II-2) binds to both RAR and RXR. ITC 
binding assays for II-2 show that binding is lower in RAR by almost two-fold (Figure II-
OH
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9). The Kd values for binding to RAR homodimer and RAR/RXR heterodimer are 1.02 µM 
and 0.63 µM, respectively. Moreover, the natural ligand for RAR is ATRA II-2 and this 
data does indicate that RAR has a better affinity for ATRA vs 9-cis-retinoic acid. 
 
 
Figure II-9. ITC data for II-2. 
  
Many of the compounds in our project have been tested with ITC; my compounds have 
been submitted for ITC analysis. 
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2. Luciferase Reporter Activity Assay 
 We also evaluated our retinoids in a luciferase reporter assay to determine what 
kind of activity they have in RARa, either agonist or antagonist. Our compounds we also 
tested in the RARß and RARg activity assays.  We chose to work with INDIGO 
Biosciences reporter assay kits.232 These kits are all-inclusive cell-based assay systems 
with RAR reporter cells, optimized media, a reference agonist, a luciferase detection 
reagent, and a cell culture-ready assay plate. Their assays utilize proprietary non-human 
mammalian cells engineered to express human RARa (NR1B1), RARß (NR1B2), and 
RARg (NR1B3).232  
 
Scheme II-10. General process for INDIGO activity assay.233 
Reporter Cells
-80 ºC Recovery Media37 ºC 
Cells + Media
37 ºC 
II-23
II-4
II-5
II-2
background
II-23
II-4
II-5
cells + II-2
cells
RAR antagonism by retinoids
log[Antagonist], nMlog[Agonist], nM
RAR agonism by retinoids
Pipet Cells/Media
+ 
Test Compounds
Incubate 24 h at 37 ºC
Discard Media from Plate
Add Luciferase Detection Reagent
Quantify Luminescence with Luminometer
Calculate IC50 values
    
 
129 
 
 
 
The RAR reporter cells include the luciferase reporter gene functionally linked to 
a responsive promoter, which is able to detect small changes in activity through luciferase 
expression in treated reporter cells. The overall process of the assay is shown in Scheme 
II-10.233 First, report cells and the optimized media are mixed and pipetted into the cell 
plate, along with test compounds and controls. After 24 hours of incubation, the luciferase 
reagent is added and the plate is allowed to rest for 30 minutes undisturbed. Then, a 
luminometer is used to quantify the luminescence and the values from this data can be used 
to calculate the IC50 values of the test compounds.  
The BMS compounds: II-23, II-24, II-27, and II-29 were tested for RARa agonism 
and antagonism with concentrations ranging from 0.31 nM to 5000 nM (Figure II-10).    
 
 
Figure II-10. Concentration map of the activity plate. 
 
 
cells/20(nM(9cRA(+(CSM
cells(+(CSM(. ((cells(+(20(nM(9cRA
9cRA(+(CSM ER350891(+(20(nM(9cRA
JLK3e23207(+((20(nM(9cRA
agonist(assay antagonist(assay
cell(+(CSM
TD3VI3235 TD3VI3235(+20(nM(9cRA
TD3VI3283 TD3VI3283(+((20(nM(9cRA
JLK3e23207
TD3VI3261 TD3VI3261(+((20(nM(9cRA
TD3VI3269 TD3VI3269(+((20(nM(9cRA
cells/20(nM(9cRA(+(CSM
cells(+(CSM(. ((cells(+(20(nM(9cRA
9cRA(+(CSM ER350891( (20(nM(9cRA
JLK3e23207(+((20(nM(9cRA
agonist(assay antagonist(assay
cell(+(CSM
TD3VI3235 TD3VI3235(+20(nM(9cRA
83 83
JLK3e2 07
61 61 ((20(nM(9cRA
9 9
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A 5000 0.31 0.31 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31
B 1250 0.31 0.31 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 1.22
C 313 1.22 1.22 1250 1250 1250 1250 1250 1250 1250 1250 1250 1250 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 4.88
D 78 1.22 1.22 1250 1250 1250 1250 1250 1250 1250 1250 1250 1250 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 19.5
E 19.5 4.88 4.88 313 313 313 313 313 313 313 313 313 313 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 78
F 4.88 4.88 4.88 313 313 313 313 313 313 313 313 313 313 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 313
G 1.22 19.5 19.5 78 78 78 78 78 78 78 78 78 78 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 1250
H 0.31 19.5 19.5 78 78 78 78 78 78 78 78 78 78 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 5000
I 0.31 78 78 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 78 78 78 78 78 78 78 78 5000
J 1.22 78 78 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 78 78 78 78 78 78 78 78 1250
K 4.88 313 313 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 313 313 313 313 313 313 313 313 313
L 19.5 313 313 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 4.88 313 313 313 313 313 313 313 313 78
M 78 1250 1250 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1250 1250 1250 1250 1250 1250 1250 1250 19.5
N 313 1250 1250 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1250 1250 1250 1250 1250 1250 1250 1250 4.88
O 1250 5000 5000 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 5000 5000 5000 5000 5000 5000 5000 5000 1.22
P 5000 5000 5000 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 5000 5000 5000 5000 5000 5000 5000 5000 0.31
test$for$agonism test$for$antagonism
1 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 20 21 2 3 4
A 5000 0.31 0.31 5000 5000 0.31 0.31 . . . . . . .
B 1250 0.31 0.31 5000 5000 0.31 0.31 . . . . . . 1.22
C 313 1.22 1.22 1 50 1250 1.22 1.22 . . . . . . 4.88
D 78 1.22 1.22 1 50 1250 1.22 1.22 . . . . . . 9.5
E 19.5 4.88 4.88 313 313 4.88 4.88 . . . . . . 78
F 4.88 4.88 4.88 313 313 4.88 4.88 . . . . . . 313
G 1.22 19.5 19.5 78 78 19.5 19.5 . . . . . . 250
H 0.31 19.5 19.5 78 78 19.5 19.5 . . . . . . 5000
I 0.31 78 78 19.5 19.5 78 78 5000
J 1.22 78 78 19.5 19.5 78 78 1250
K 4.88 313 313 4.88 4.88 313 313
L 19.5 313 313 4.88 4.88 313 313 78
M 78 1250 1250 1.22 1.22 1250 250 19.5
N 313 250 1250 1.22 1.22 1250 250 4.88
O 1250 00 5000 0.31 0.31 5000 5000 1.22
P 5000 5 00 5000 0.31 0.31 5000 5000 .31
test$for$agonism test$for$antagonism
1 2 3 4 5 6 7 8 9 10 11 12 13 4 5 6 7 8 9 20 21 2 3 24
A 5000 .31 0.31 5 00 5 00 50 5 5000 5000 5000 5000 0.31 0.31 . 0 31
B 1250 0.31 0.31 00 5 00 50 5 5000 5000 5000 5000 0.31 0.31 . 1 22
C 313 1.22 1.22 250 1250 1250 1250 1250 1250 1250 1250 .22 1.22 . 4 88
D 78 1.22 1.22 1250 1250 1250 1250 1250 1250 1250 1250 .22 1.22 . 19.5
E 19.5 4 88 4.88 313 313 313 313 313 313 313 313 4.88 4.88 . 78
F 4.88 4. 8 4.88 313 313 313 313 313 313 313 313 4.88 4.88 . 313
G 1.22 19.5 19.5 78 78 78 78 78 78 78 78 19.5 19.5 . 250
H 0.31 19.5 19.5 78 78 78 78 78 78 78 78 19.5 19.5 . 5000
I 0.31 78 78 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 . . 78 78 5000
J 1.22 78 78 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 . . 78 78 1250
K 4.88 313 313 4.88 4.88 4.8 4.8 4.88 4.88 4.88 4.88 . . 313 313 313
L 19.5 313 313 4.88 4.88 4.8 4.8 4.88 4.88 4.88 4.88 . . 313 313 78
M 78 1250 1250 1.22 . 2 1.2 .2 1.22 1.22 1.22 1.22 . . 1250 1250 1 19.5
N 313 1250 1250 .22 . 2 1.2 .2 1.22 1.22 1.22 1.22 . . 1250 1250 1 4.88
O 1250 50 0 5000 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 . . 5 00 5000 1.22
P 5000 5 0 5000 .31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 . . 5 00 5000 .31
test$for$agonism test$for$antagonism
Agonist Assay Antagonist Assay
II-27
II-23
II-24
II-29
II-27
II-23
II-24
II-29
II-27 II-23 II-24 II-29 II-27 II-23 II-24 II-29
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From the activity map below, the BMS analogs demonstrated low to no activity in 
the agonist assay represented by the violet color in the left half of the assay plate (Figure 
II-11). In the assay plate map, a red color indicates high activity with shades of orange, 
yellow, green, and blue in between to designate the decreasing levels of activity, 
respectively. 
Compounds II-23, II-24, and II-29 did not demonstrate any agonism. However, II-
27 showed slight agonism with 25-fold activity over the background, as compared to the 
control (9-cis-retinoic acid), which had greater than 750-fold activity at 2500 nM 
concentration. The antagonist assay showed much more color variation with boxes 
displaying of yellow and green activity colors (Figure II-11).  
 
 
 
Figure II-11. Map of activity plate assay results of BMS retinoids. 
 
 
The antagonism activity data was graphed to calculate the IC50 values of the tested 
compounds (Figure II-12). For the antagonist assay analysis, II-27 and II-29 showed 
activity at 321 nm and 341 nm, respectively. Retinoids II-23 and II-24 did not exhibit any 
Agonist Assay Antagonist Assay
II-27 II-23 II-24 II-29 II-27 II-23 II-24 II-29control control
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antagonism as demonstrated by their non-sigmoidal, flat lines in Figure II-12. The RARb 
and RARg activity assays of these BMS analogs will be performed in the future. There is 
an immediate need to test all the highly active compounds from the RARa activity assays 
first. 
 
  
Figure II-12. Antagonistic assay of BMS RAR analogs. 
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G. Concluding Remarks 
 Male contraceptive research aims to address the unmet need of finding better 
alternatives for men and families to prevent pregnancy. While condoms and vasectomies 
are viable options, the possible ineffectiveness of condoms or the permanency of 
vasectomies are problematic. Additionally, hormonal contraceptive agents have been 
researched but have caused unwanted side effects. Our group is investigating non-
hormonal male contraceptive agents as a solution to tackle these concerns with the help of 
the NIH NICHD. Within the Georg research group, a subset of researchers is focused on 
the discovery of RARα antagonists. This nuclear receptor has been validated as a male 
contraceptive, non-hormonal drug target. RARα is heavily involved in spermatogenesis 
since previous reports showed its gene deletion induced sterility in mice.  
Our work revolves around the design and synthesis of selective, bioavailable RARα 
antagonists based on retinoids composed of three parts: a hydrophobic ring portion, a linker 
region, and a carboxylic acid moiety. We used the scaffold of known BMS antagonists (II-
4, II-5, II-6) to begin our contraceptive development and the first generation of compounds 
contained a tetralin core with various aryl substituents in the ring portion, amide 
bioisosteres in the linker region, and benzoic or cyclohexanoic acids in the carboxylic acid 
moiety. Our compounds were evaluated using in silico analysis with the Schrodinger suite, 
isothermal titration calorimetry, and a luciferase reporter assay.  Evaluation of our first-
generation retinoids determined that additional lipophilic substituents in the ring portion 
and fluoro- groups in the benzoic acid moiety could increase the selectivity. Hence, we are 
pursuing other ring structures, such as a naphthyl ring scaffold similar to ER-50891(II-51), 
and others, for the discovery of second generation of retinoids. 
    
 
133 
Once the synthesis of our compounds is complete, they are subjected to biological 
activity analysis. From the luciferase reporter assay data, my BMS analogs with the 
cyclohexanoic acid moiety (II-23 an II-24) showed no activity in the agonistic or 
antagonistic assays. However, the quinoline analogs (II-27 and II-29) showed sub-
micromolar activity in the antagonistic assay with II-27 exhibiting very slight agonism as 
well.  
 
Chapter 6. Experimental Data  
As previous stated in Chapter 4, vide supra, unless otherwise indicated, reactions 
were carried out open to air with reagent grade solvents directly from the bottle. Purified 
tetrahydrofuran (THF), toluene, diethyl ether (Et2O), and dichloromethane (CH2Cl2) were 
purified by passage through a bed of activated alumina in our solvent system. Purification 
of reaction products was carried out by flash column chromatography using silica gel 60 
(230-400 mesh). Analytical thin layer chromatography (TLC) was performed on 0.25 mm 
silica gel 60-F plates. Visualization was accomplished with UV light and cerium molybdate 
stain followed by heating. Low-resolution mass spectral data were acquired utilizing the 
electrospray ionization technique. 1H NMR spectra were recorded at ambient temperature 
at 400 MHz and are reported in ppm using a solvent as an internal standard (CDCl3 at 7.26 
ppm or CD3OD at 3.31 ppm). Proton-decoupled 13C NMR spectra were recorded at 100 
MHz and are reported in ppm using a solvent as an internal standard (CDCl3 at 77.16 ppm). 
The data are reported as follows: chemical shift on the d scale, multiplicity (b = broad, s = 
singlet, d = doublet, dd= doublet of doublets, t = triplet, q = quartet, m = multiplet), 
coupling constants (Hz), and integration. Melting points were determined with 
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Electrothermal Digital Mel-Temp 3.0 melting point apparatus. High-resolution mass 
spectra were recorded with electron-spray ionization (ESI) or electron ionization (EI). 
 
 
4,4-Dimethyl-3,4-dihydronaphthalen-1(2H)-one (II-33). 
To a stirring solution of AlCl3 (351 mg, 2.63 mmol) in benzene at 5 ºC (dry ice/benzene 
bath), was added lactone (100 mg, 0.876 mmol) in benzene dropwise. The mixture was 
then slowly warmed to 100 ºC and allowed to stir for 3 h. Then an ice-cold solution of 1N 
HCl quenched the reaction before workup in MTBE with dilute HCl, water, and aqueous 
NaHCO3, and brine. The combined organic layers then dried over MgSO4, filtered, and 
concentrated in vacuo. Flash column chromatography with 20% EtOAc/Hex gave UV 
active product. 1H NMR (400 MHz, CDCl3): δ 7.95 (dd, J = 7.8, 1.4 Hz, 1H), 7.47 – 7.42 
(m, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.15 – 7.09 (m, 1H), 2.71 – 2.61 (m, 2H), 1.94 (t, J = 6.6 
Hz, 2H), 1.32 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 198.4, 152.3, 133.9, 128.3, 127.3, 
126.3, 125.8, 37.1, 35.1, 33.9, 29.7, 29.7. 
 
 
7-Bromo-4,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one (II-34). 
OEt
O
O
AlCl3, 
benzene
66%
MeI, Mg, 
Et2O
31%
O
O O
II-31 II-32 II-33
O AlCl3, Br2, 
CH2Cl2
20%
O
Br
II-33 II-34
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To a stirring flask of AlCl3 (1.91 g, 14.3 mmol) in CH2Cl2 was added tetralone (1.0 g, 5.74 
mmol), dropwise at ambient temperature. Then bromine (1.1 g, 6.90 mmol) was slowly 
added, and the mixture was allowed to stir for 2 h at ambient temperature. The reaction 
was then quenched with an ice-cold solution of 6M HCl, followed by extraction with Et2O. 
Combined organic layers washed with water, aqueous NaHCO3, and brine, then dried over 
MgSO4, filtered, and concentrated in vacuo. TLC analysis gave several spots and flash 
column chromatography with 10 % EtOAc/Hex gave a few brominated products. The 
spectra for the desired 7-bromo tetralone is reported here. mp 92-93 °C; 1H NMR (400 
MHz, CDCl3): 8.12 (d, J=3.0 Hz, 1H), 7.60 (dd, J=3.0, 9.0 Hz, 1H), 7.32 (d, J=9.0 Hz, 1H), 
2.72 (t, J=6.0 Hz, 2H), 2.01 (t, J=6.0 Hz, 2H), 1.27 (s, 6H). 13C NMR (125 MHz, CDCl3): 
δ 198.4, 133.9, 128.3, 127.3, 126.3, 125.8, 37.1, 35.1, 29.7, 29.7; [M+Na]+ calcd for 
C12H13OBrNa requires 275.0150, found 275.0044. 
 
 
6-Bromo-1,1-dimethyl-4-(p-tolyl)-1,2-dihydronaphthalene (II-35). 
 
To a flask of Mg (24 mg, 2.66 mmol), tolyl bromide (440 mg, 1.3 mmol) and a couple 
iodine crystals. The flask was heated until bubbles appeared and stirred for 1 h. The 
reaction is then cooled to 0 ºC (ice bath) and a solution of the bromo tetralone (500mg, 
1.97 mmol) in toluene was added. The reaction was allowed to stir overnight at ambient 
temperature. Then, it was quenched with ammonium chloride, extracted with EtOAc, 
washed with brine. The combined organic layers were dried over MgSO4, filtered, and 
Br
1. tolyl bromide,
    Mg, THF
2. pTsOH, 
    toluene
    60%, 2 steps
O
Br
II-34 II-35
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concentrated in vacuo before flash column chromatography with 30% EtOAc:Hex to give 
alcohol intermediate as a yellow oil (74%). Then, to a solution of the alcohol intermediate 
in toluene (10ml), was added a catalytic amount of pTsOH (1 mol%) and molecular sieves. 
The reaction was stirred at reflux for 2 h then worked up with water and MTBE, dried over 
MgSO4, filtered, and concentrated in vacuo followed by flash chromatography with 1 to 
10% EtOAc: Hex to give tolyl bromide. mp 107-109  °C; 1H NMR (400 MHz, CDCl3): δ 
7.37 (dd, J = 8.2, 2.1 Hz, 1H), 7.28 – 7.23 (m, 5H), 7.20 (d, J = 2.0 Hz, 1H), 6.02 (t, J = 4.7 
Hz, 1H), 2.44 (s, 3H), 2.37 (d, J = 4.7 Hz, 2H), 1.35 (s, 6H); 13C NMR (125 MHz, CDCl3): 
δ 144.1, 138.5, 137.3, 137.0, 136.2, 130.2, 129.1, 129.1, 128.8, 128.5, 128.2, 127.3, 125.6, 
119.8, 38.7, 33.5, 28.0, 28.0, 21.2; [M]+ calcd for C19H19Br requires 326.0670, found 
326.0664. 
 
  
 
6-Ethynyl-1,1-dimethyl-4-(p-tolyl)-1,2-dihydronaphthalene (II-36). 
 
A flask of bromide (200 mg, 0.61 mmol), TMS-acetylene (78mg, 0.79 mmol), copper 
iodide (11 mg, 10 mol%), and palladium catalyst (21 mg, 5 mol%) in trimethylamine (2 
mL) was stirred overnight at 70ºC. The solvent was then evaporated and the intermediate 
was purified by column chromatography with 1% EtOAc:Hex to produce 71% product that 
was carried forward to the desilylation step. The silyl intermediate was then dissolved in a 
MeOH:CHCl3 (1:1) mixture and 1N KOH was added. The solution stirred overnight at 
Br
1. TMS-acetylene
    Pd(PPh3)2Cl2, 
    CuI, piperidine,
    DMF, 71%
2. KOH, MeOH, 
    CHCl3, 84%
II-35 II-36
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ambient temperature before work up with DCM. The organic layers were combined, dried 
over MgSO4, filtered, and then concentrated in vacuo.  Flash column chromatography with 
0 to 1% EtOAc:Hex gave pure tolyl naphthyl alkyne II-36 in 84% yield. mp 94-95 °C; 
1H NMR (400 MHz, CDCl3): δ 7.55 (dd, J = 7.9, 1.5 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 
7.45 – 7.38 (m, 4H), 7.37 (d, J = 1.1 Hz, 1H), 6.17 (t, J = 4.7 Hz, 1H), 3.14 (s, 1H), 2.60 
(s, 3H), 2.53 (d, J = 4.7 Hz, 2H), 1.52 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 146.2, 138.7, 
137.5, 136.9, 134.1, 131.2, 129.5, 129.1, 129.1, 128.5, 128.5, 126.7, 123.9, 119.4, 83.9, 
76.3, 38.7, 33.7, 28.0, 28.0, 21.2; GCMS (HREI) m/z calcd for C21H20 [M]+ requires 
272.1565, found 272.1552. 
 
 
Methyl (1r,4r)-4-Azidocyclohexane-1-carboxylate (II-38) 
 
To a solution of acid II-37 (3.00 g, 20.1 mmol) in MeOH (10 mL) was added thionyl 
chloride (1.82 mL, 25.1 mmol) at 0 ºC (ice bath). The mixture was allowed to stir overnight 
at ambient temperature before concentrating in vacuo. Then, the residue was washed with 
hexanes to give the ester salt as a white solid in quantitative yield and carried on without 
further purification. II-37 ester: 1H NMR (400 MHz, CD3OD): δ 3.69 (s, 3H), 3.33 (t, J = 
1.2 Hz, 2H), 3.10 (t, J = 11.4 Hz, 1H), 2.37 (tt, J = 12.0, 2.8 Hz, 1H), 2.11 (d, J = 10.1 Hz, 
4H), 1.61 – 1.38 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 176.7, 52.3, 50.7, 42.8, 30.8, 
30.8, 28.0, 28.0. Then, the triflic azide was formed in situ by adding to a solution of sodium 
azide (1.33 g, 20.4 mmol) in 5 mL water at 0 ºC (ice bath), 5 mL DCM followed by Tf20 
H2N N3
1. SOCl2, MeOH
    quant.
2. NaN3, Tf2O, 
    DMAP, CH2Cl2
    quantII-37 II-38
OH
O
OMe
O
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(700 µL, 4.14 mmol). The mixture was stirred for 2 h in the ice bath. The DCM phase was 
separated, and the aqueous phase was extracted with DCM twice. The combined DCM 
phase was washed with sat. NaHCO3 and water, dried over MgSO4, and set aside. Next, 
amino ester (172 mg, 1.09 mmol) was dissolved in 5 mL dry DCM and stirred at ambient 
temperature. To it was added DMAP (585 mg, 4.80 mmol) and then the above-prepared 
triflic azide in DCM solution was added dropwise. The mixture was stirred for overnight 
and then concentrated in vacuo to give the azide ester II-38 in quantitative yield as an oil. 
1H NMR (400 MHz, CDCl3): δ 3.64 (s, 3H), 3.26 (tt, J = 20.1, 5.7 Hz, 1H), 2.26 (tt, J = 
11.7, 3.0 Hz, 1H), 2.08 – 1.97 (m, 4H), 1.56 – 1.26 (m, 4H); 13C NMR (125 MHz, CDCl3): 
δ 175.5, 59.2, 51.7, 41.8, 30.6, 30.6, 27.1, 27.1. 
 
4-(4-(5,5-Dimethyl-8-(p-tolyl)-5,6-dihydronaphthalen-2-yl)-1H-1,2,3-triazol-1-
yl)cyclohexane-1-carboxylic acid (II-23). 
 
To a suspension of alkyne II-36 (50 mg, 0.18 mmol) and azide II-38 (31 mg, 0.18 mmol) 
in a solution of H2O:tBuOH (1:1), was added sodium ascorbate (3.6 mg, 10 mol%) and 
copper sulfate pentahydrate (1.0 mg, 2 mol%). The mixture was vigorously stirred 
overnight at ambient temperature. Then the reaction was cooled to -5 ºC (aqueous NHCl4 
and ice bath) and a precipitate formed. The precipitate was filtered, washed with ice cold 
water, collected, and dried in vacuo to give triazole ester intermediate. Then, to a round-
bottom flask of the triazole ester intermediate (84 mg, 0.18 mmol) in EtOH (2 mL), was 
added 1M NaOH (1 mL) and the reaction was allowed to stir overnight at ambient 
N
NN
CO2H
1.  II-38, CuSO4•5H2O,
    H2O, Na ascorbate
            98%
 
2. NaOH, EtOH
    
            36%II-36 II-23
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temperature. Then, the mixture was acidified with 1M HCl slowing at 100 µL increments 
and the product was extracted with EtOAc to give desired triazole acid II-23. Further 
recrystallization in MeOH:DCM to give yellowish crystals. mp 128-130 °C; 1H NMR (400 
MHz, CDCl3): δ 7.95 (d, J = 1.6 Hz, 1H), 7.50 – 7.38 (m, 2H), 7.30 – 7.17 (m, 4H), 5.99 
(t, J = 4.7 Hz, 1H), 4.47 (tt, J = 11.9, 3.8 Hz, 1H), 3.70 (s, 1H), 2.51 – 2.40 (m, 1H), 2.39 
(s, 3H), 2.36 (d, J = 4.7 Hz, 2H), 2.30 – 2.25 (m, 2H), 2.20 (d, J = 13.6 Hz, 2H), 1.92 (qd, 
J = 12.7, 3.1 Hz, 2H), 1.66 (qd, J = 13.3, 2.8 Hz, 2H), 1.36 (s, 6H), 1.29 (br s, 1H); 13C 
NMR (125 MHz, CDCl3): δ 187.5, 147.0, 140.5, 139.2, 138.1, 135.9, 130.3, 130.3, 129.8, 
129.8, 129.0, 127.9, 126.2, 125.7, 124.6, 120.0, 60.9, 52.8, 43.1, 40.1, 34.9, 34.9, 33.4, 
33.3, 29.0, 29.0, 28.9, 21.9; LRMS (ESI) m/z calcd for C28H32N3O2 [M+H]+ 442.2, found 
442.9. 
 
 
 
6-Azido-1,1-dimethyl-4-(p-tolyl)-1,2-dihydronaphthalene (II-40). 
 
To a flask of aryl bromide (100 mg, 0.31 mmol) in a solution of EtOH:H2O (7:3), was 
added sodium azide (40 mg, 0.61 mmol), sodium ascorbate (3.0 mg, 5.0 mol%), copper 
iodide (6.0 mg, 5.0 mol%), and diamine ligand (7.0 mg, 15 mol%). The flask was degassed 
with house nitrogen then stirred under reflux for 6 hours, or until consumption of starting 
material. The reaction was then cooled to ambient temperature before work up with EtOAc 
Br N3
II-35 II-40
NaN3, CuI,
Na ascorbate
EtOH/H2O
95%
MeHN NHMe
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and brine. The combined organic layers were dried over MgSO4, filtered, and purified over 
a short silica plug and then concentrated in vacuo to give a dark yellow oil.  
1H NMR (400 MHz, CDCl3): δ 7.34 (d, J = 8.2 Hz, 1H), 7.24 – 7.17 (m, 4H), 6.90 (dd, J = 
8.2, 2.4 Hz, 1H), 6.70 (d, J = 2.4 Hz, 1H), 6.00 (t, J = 4.7 Hz, 1H), 2.40 (s, 3H), 2.34 (d, J 
= 4.7 Hz, 2H), 1.32 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 142.2, 138.8, 137.7, 137.5, 
137.1, 135.8, 129.2, 129.2, 128.6, 128.6, 127.5, 125.3, 117.7, 117.1, 39.0, 33.6, 28.4, 28.4, 
21.3. 
 
 
 
Methyl (1r,4r)-4-(Aminomethyl)cyclohexane-1-carboxylate (II-41). 
 
To a flask of amino acid (1.00 g, 6.36 mmol) in MeOH (150 mL) was added thionyl 
chloride (919 µL, 12.7 mmol) slowly at 0 ºC (ice bath) for 10 min. The suspension was 
allowed to stir at reflux and monitored with TLC. The reaction was then cooled to ambient 
temperature when TLC indicated consumption of starting material. The solvent was 
evaporated and the reaction was worked up with EtOAc and concentrated in vacuo to give 
off white crystals. mp 162-164 °C; 1H NMR (400 MHz, CD3OD) δ 3.68 (s, 3H), 2.81 (d, J 
= 6.9 Hz, 2H), 2.33 (tt, J = 12.3, 3.5 Hz, 1H), 2.12 – 1.87 (m, 4H), 1.65 (ddp, J = 11.3, 7.2, 
3.7 Hz, 1H), 1.47 (qd, J = 13.1, 3.2 Hz, 2H), 1.10 (qd, J = 13.0, 3.2 Hz, 2H); 13C NMR (125 
MHz, CD3OD): δ 177.8, 52.4, 46.2, 43.9, 36.7, 30.3, 30.3, 29.3, 29.3; HRMS (ESI) m/z 
calcd for C9H17NO2 [M+H]+ requires 172.1338, found 172.1328. 
 
NH2NH2
SOCl2, MeOH
75%
II-40 II-41
OH
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OMe
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Methyl (1r,4r)-4-Formylcyclohexane-1-carboxylate (II-43). 
 
 
To a flask of amine ester II-41 (1.00 g, 5.84 mmol) in DCM (10 mL) at 0 ºC (ice bath), 
was added mesyl chloride (452 µL, 5.84 mmol). The mixture was allowed to stir at 0 ºC 
for 1 h. The reaction was quenched with water, washed with DCM, and then cooled to -78 
ºC (dry ice, iPrOH) for the next step without isolation of II-42. DBU (1.78 g, 11.68 mmol) 
was then added to the flask, followed by a solution of the sulfinimidoyl chloride (2.52 g, 
11.68 mmol) in DCM. The reaction stirred at -78 ºC for 2 h before warming to ambient 
temperature and quenching with 1M HCl. Work up was done with Et2O, then the combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. Column 
chromatography with 5-10% MeOH:DCM gave the desired product in 60% after two steps. 
1H NMR (400 MHz, CDCl3): δ 3.82 (d, J = 7.0 Hz, 1H), 3.17 (s, 3H), 2.05 (tt, J = 12.3, 3.5 
Hz, 1H), 1.88 – 1.80 (m, 2H), 1.74 – 1.67 (m, 2H), 1.49 – 1.37 (m, 1H), 1.29 – 1.17 (m, 
2H), 0.87 (qd, J = 13.2, 3.4 Hz, 2H); 13C NMR (125 MHz, CDCl3): d 203.8, 175.7, 49.3, 
42.5, 31.5, 27.9, 25.0, 23.3, 22.6.  
 
 
 
Methyl (1r,4r)-4-Ethynylcyclohexane-1-carboxylate (II-44). 
NH2
MsCl, Et3N,
CH2Cl2 DBU, CH2Cl2
60%, 2 steps
NHMs
S NtBu
Ph
Cl
II-41 II-42
OMe
O
OMe
O
O
II-43
OMe
O
O
Bestmann-Ohira rgt,
K2CO3, MeOH
58%
II-43 II-44
OMe
O
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To a suspension of aldehyde II-43 (500 mg, 2.9 mmol) and K2CO3 (1.4 g, 10 mmol) in dry 
MeOH (10 mL) at ambient temperature, was added the Bestmann-Ohira reagent (790 mg, 
4.1 mmol). The reaction stirred for overnight at ambient temperature and monitored with 
TLC. After consumption of starting material, the solvent was removed and the product was 
washed with DCM and water. The combined organic layers were washed with brine then 
dried over MgSO4, filtered, and concentrated in vacuo. Alkyne II-44 was obtained by 
column chromatography with 25% EtOAc: Hex in 58% yield. 1H NMR (400 MHz, CDCl3): 
δ 3.68 (s, 3H), 2.35 – 2.24 (m, 2H), 2.11 – 1.97 (m, 5H), 1.45 (h, J = 11.0, 10.6 Hz, 4H). 
13C NMR (125 MHz, CDCl3): δ 176.1, 88.2, 68.2, 51.7, 42.2, 31.8, 31.8, 28.7, 28.1, 28.1.  
 
 
4-(1-(5,5-Dimethyl-8-(p-tolyl)-5,6-dihydronaphthalen-2-yl)-1H-1,2,3-triazol-4-
yl)cyclohexane-1-carboxylic Acid (II-24). 
 
 
To a suspension of naphthyl azide II-40 (52 mg, 0.18 mmol) and cyclohexyl alkyne ester 
II-44 (30 mg, 0.18 mmol) in a solution of H2O:tBuOH (1:1), was added sodium ascorbate 
(3.6 mg, 10 mol%) and copper sulfate pentahydrate (1.0 mg, 2 mol%). The mixture was 
vigorously stirred overnight at ambient temperature. Then the reaction was cooled to -5 ºC 
(aqueous NHCl4 and ice bath) and a precipitate formed. The precipitate was filtered, 
washed with ice cold water, collected, and dried in vacuo to give the other triazole ester 
intermediate. Then, to a round-bottom flask of the other triazole ester intermediate (84 mg, 
N3 N
NN
CO2H
1.  II-44, CuSO4•5H2O,
    H2O, Na ascorbate
            20%
 
2. NaOH, EtOH
II-40 II-24
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0.18 mmol) in EtOH (2 mL), was added 1M NaOH (1 mL) and the reaction was allowed 
to stir overnight at ambient temperature. Then, the mixture was acidified with 1M HCl 
slowing at 100 µL increments and the product was extracted with EtOAc to give the other 
desired triazole acid II-24. Further recrystallization in MeOH:DCM to give off-
white/yellow crystals. mp 235-237 °C; 1H NMR (400 MHz, CD3OD): δ 7.69 (s, 1H), 7.55 
(d, J = 2.0 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 2.0 Hz, 1H), 7.22 (q, J = 8.1 Hz, 
4H), 6.06 (t, J = 4.7 Hz, 1H), 2.76 (tt, J = 11.2, 3.1 Hz, 1H), 2.43 – 2.40 (m, 2H), 2.39 (s, 
3H), 2.33 (ddt, J = 14.7, 6.5, 3.7 Hz, 2H), 2.14 (t, J = 13.7 Hz, 4H), 1.63 – 1.47 (m, 4H), 
1.37 (s, 6H); 13C NMR (125 MHz, CD3OD): δ 179.9, 148.6, 147.6, 139.9, 138.5, 137.0, 
133.9, 132.9, 130.5, 130.5, 129.8, 129.8, 129.2, 127.2, 126.6, 121.1, 120.0, 119.5, 44.0, 
40.0, 35.9, 35.0, 33.1, 33.1, 30.0, 30.0, 29.2, 22.2; LRMS (ESI) m/z calcd for C28H32N3O2 
[M+H]+ 442.2, found 442.9. 
 
 
Methyl 2-(5,5-dimethyl-8-(p-tolyl)-5,6-dihydronaphthalen-2-yl)quinoline-6-
carboxylate (II-49). 
 
To a sealable microwave vial of tolyl bromide II-34 (130 mg, 0.400 mmol) and quinoline 
ester II-46 (450 mg, 0.2.40 mmol) in dioxane (2 mL) was added the Rh catalyst (8 mg, 5 
mol %). The reaction was heated to 175 ºC in an oil bath for 24 h and then allowed to warm 
temperature. The reaction was sent through a Celite plug and washed with MTBE and then 
the solvent was removed in vacuo. The product was purified by column chromatography 
N
II-46
Br
II-34
N
[Rh(CO)2Cl]2,
dioxane, 
175 °C, 24 h
61%
OMe
O OMe
O
II-49
+
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with 1-10% EtOAc:Hex and produced the coupled ester product II-49 in 61% yield. mp 
190-191 °C;  1H NMR (400 MHz, CDCl3): d 8.54 (d, J = 1.5 Hz, 1H), 8.27 (dd, J = 8.9, 1.5 
Hz, 1H), 8.20 (d, J = 8.6 Hz, 1H), 8.17 – 8.08 (m, 2H), 7.79 (d, J = 1.7 Hz, 1H), 7.64 (dd, 
J = 72.1, 8.3 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 6.05 (t, J = 4.7 Hz, 
1H), 3.99 (s, 3H), 2.42 (s, 3H), 2.39 (d, J = 4.7 Hz, 2H), 1.39 (s, 6H).; 13C NMR (125 MHz, 
CDCl3): d 166.8, 159.6, 150.1, 147.4, 145.9, 139.2, 137.9, 137.8, 136.9, 134.5, 130.6, 
129.9, 129.1, 129.1, 129.0, 128.6, 128.6, 127.5, 127.1, 126.7, 126.2, 125.3, 124.6, 119.8, 
52.4, 38.9, 33.9, 28.1, 28.1, 21.3; HRMS (ESI) m/z calcd for C30H27NO2 [M+H]+ requires 
434.2121, found 434.2132. 
 
 
 
2-(5,5-Dimethyl-8-(p-tolyl)-5,6-dihydronaphthalen-2-yl)quinoline-6-carboxylic Acid 
(II-27). 
 
To a flask of quinoline ester II-49 (50 mg, 0.12 mmol) in MeOH (3 mL), was added 1N 
NaOH (1 mL). The reaction was heated to 65 ºC and stirred for 2 h. Then, the flask was 
allowed to warm to room temperature and the solvent was removed in vacuo. The reaction 
was diluted with water and acidified to pH 4 with 1N HCl. The product precipitated and 
was collected via filtration and recrystallized with DCM:MeOH to give desired quinoline 
acid II-27 in 38% yield after two steps. mp 268-269 °C;  1H NMR (400 MHz, CDCl3): d 
3.82 (d, J = 7.0 Hz, 1H), 3.17 (s, 3H), 2.05 (tt, J = 12.3, 3.5 Hz, 1H), 1.88 – 1.80 (m, 2H), 
N N
1. NaOH, 
    MeOH
    65 °C, 
2. HCl 
    38%
OH
O
OMe
O
II-49 II-27
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1.74 – 1.67 (m, 2H), 1.49 – 1.37 (m, 1H), 1.29 – 1.17 (m, 2H), 0.87 (qd, J = 13.2, 3.4 Hz, 
2H).13C NMR (125 MHz, CDCl3): δ 176.7, 51.7, 43.3, 39.5, 28.4, 28.4, 27.1, 27.1; 
LRMS (ESI) m/z calcd for C29H26NO2 [M+H]+ 420.2, found 420.8. 
 
 
 
Methyl 2-(5,5-dimethyl-8-(p-tolyl)-5,6-dihydronaphthalen-2-yl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxylate (II-51). 
 
To a two-neck round-bottom flask was added Xantphos (53 mg, 0.092 mmol, 10 mol%) 
and Pd catalyst (42 mg, 0.046 mmol, 5 mol%) in toluene (2 mL). The reaction was purged 
with nitrogen for 10-15 min then heated to 110 ºC for 15 min. After it reaction vessel was 
cooled to ambient temperature, NaOtBu (180 mg, 1.8 mmol) was added followed by the 
tolyl bromide II-34 (300 mg, 0.92 mmol), then the quinoline analog II-50 (350 mg, 1.8 
mmol). The reaction was purged again with nitrogen for 10-15 min then heated to 110 ºC 
and allowed to stir for 36 h. After the flask had cooled to ambient temperature, the reaction 
was filtered through a Celite plug and the solvent was removed in vacuo. Column 
chromatography with 1% EtOAc:Hex gave the desired coupled ester II-51 in 38% yield. 
*Previous attempts with rac-BINAP gave less than 20% product after 24 or 48 h. mp 187-
190 °C;  1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.26 – 7.12 (m, 6H), 7.10 (d, J = 8.4 
Hz, 1H), 6.83 (dd, J = 8.4, 2.6 Hz, 1H), 6.70 (d, J = 2.6 Hz, 1H), 5.94 (t, J = 4.7 Hz, 1H), 
4.25 (s, 2H), 3.87 (s, 3H), 3.37 (t, J = 5.8 Hz, 2H), 2.91 (t, J = 5.7 Hz, 2H), 2.38 (s, 3H), 
N
Pd2dba3, Xantphos, 
NaOtBu, toluene,
110 °C, 36 h
   28%
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2.28 (d, J = 4.7 Hz, 2H), 1.28 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 167.2, 148.6, 140.1, 
139.6, 138.3, 136.7, 136.7, 135.2, 134.8, 130.0, 129.0, 129.0, 128.7, 128.7, 128.2, 127.1, 
126.8, 126.7, 124.7, 114.8, 114.6, 52.1, 51.6, 47.0, 39.3, 33.2, 29.0, 28.5, 28.5, 21.3. 
 
 
2-(5,5-Dimethyl-8-(p-tolyl)-5,6-dihydronaphthalen-2-yl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxylic Acid (II-29). 
 
To a flask of quinoline ester II-51 (50 mg, 0.12 mmol) in THF:H2O (1:1, 3 mL), was added 
1N NaOH (1 mL). The reaction was heated to 60 ºC and stirred for 24 h. Then, the flask 
was allowed to warm to room temperature and the solvent was removed in vacuo. The 
reaction was diluted with water and acidified to pH 4 with 1N HCl. The product 
precipitated and was collected via filtration and recrystallized with DCM:MeOH to give 
desired tetrahydroisoquinoline acid II-29 in 75% after two steps. mp 243-244 °C;  1H NMR 
(400 MHz, CD3OD): d 7.87 (s, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.39 
(d, J = 8.4 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 2.0 Hz, 4H), 6.97 (d, J = 2.4 Hz, 
1H), 6.02 (t, J = 4.6 Hz, 1H), 4.60 (s, 2H), 3.75 (t, J = 6.2 Hz, 2H), 3.19 (d, J = 5.7 Hz, 2H), 
2.33 (d, J = 4.7 Hz, 2H), 2.30 (s, 3H), 1.30 (s, 6H). LRMS (ESI) m/z calcd for C29H30NO2 
[M+H]+ 424.2, found 424.9. 
 
 
N
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Methyl 8-isopropyl-4-oxo-1,4-dihydroquinoline-2-carboxylate (II-54). 
 
 
To a flask of aniline (1.0 g, 8.1 mmol) in MeOH (5 mL) at 5 ºC (ice bath), was added 
dicarboxylate (1.4 g, 9.7 mmol). The reaction stirred for 2 h at ambient temperature. 
Evaporation of solvent gave a dark yellow solid that was carried on to next step. To a flask 
of intermediate diester (1.8g, 6.6 mmol), was added Eaton's reagent (7 mL). The reaction 
was heated to 50 ºC and stirred for 2-3 h, until TLC revealed consumption of starting 
material. Then, the reaction mixture was cooled to 5 ºC (ice bath) and poured into an ice 
cold saturated NaHCO3 solution, as precipitate formed. The solid was filtered and washed 
with water and dried in vacuo to give yellowish oil. 1H NMR (400 MHz, CDCl3): d 9.10 
(s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.60 (dd, J = 7.4, 0.9 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 
6.98 (d, J = 1.7 Hz, 1H), 4.07 (s, 3H), 3.30 (p, J = 6.8 Hz, 1H), 1.43 (d, J = 6.8 Hz, 6H); 
13C NMR (125 MHz, CDCl3): d 180.0, 163.8, 136.4, 135.6, 135.6, 129.1, 126.7, 124.4, 
124.1, 111.2, 53.9, 27.7, 22.7. 
 
 
Methyl 8-methoxy-4-phenylquinoline-2-carboxylate (II-57). 
 
NH2
II-52
CO2Me
CO2Me
+
II-53
1.MeOH,
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22%, 2 steps
H
N
O
CO2Me
II-54
H
N
O
CO2Me
OMe
1. DMAP, Tf2O,
    pyridine
2. PhB(OH)2
    Pd(PPh3)4
    DMF
90% crude, 
2 steps
N CO2Me
OMe
II-56
II-57
    
 
148 
 
To a flask of quinoline (200 mg, 0.86 mmol) dissolved in dry DCM (5 mL), was added 
DMAP (41 mg, 0.34 mmol) and 2,6-lutidine (303 µL, 2.6 mmol). Then, the flask was 
cooled to 0 ºC (ice bath) and triflic anhydride (440 µL, 2.6 mmol) was added dropwise. 
The reaction was warmed to ambient temperature and allowed to stir overnight. The solvent 
was then evaporated the next day and the residue was washed with MeOH and concentrated 
in vacuo to give an off-white product. Then, the triflate product (100 mg, 0.27 mmol) was 
then dissolved in DMF (5 mL) and phenyl boronic acid (50mg, 0.41 mmol), trimethylamine 
(75 µL, 0.54 mmol) was added. The flask was degassed with house argon, then palladium 
tetrakis (10 mg, 30 mol%) was added and the reaction stirred for 4 h at reflux. The reaction 
was extracted with DCM, washed with brine, and dried over MgSO4. After filtration, the 
product was concentrated in vacuo and then purified by flash column chromatography with 
30% EtOAc/Hex. 1H NMR (400 MHz, CDCl3): δ 8.24 (d, J = 7.1 Hz, 1H), 8.16 (s, 1H), 
7.54-7.52 (m, 4H), 7.36 – 7.29 (m, 2H), 7.14-7.10 (m, 1H), 4.10 (s, 3H), 4.05 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 183.4, 155.7, 148.7, 138.3, 133.6, 132.1, 129.6, 129.5, 129.5, 
128.7, 128.6, 128.5, 128.5, 128.4, 122.0, 117.7, 56.1, 53.1. 
 
 
Methyl 4-chloro-8-phenylquinoline-2-carboxylate (II-61) 
 
To a two-neck round-bottom flask was added quinoline II-60 (500 mg, 1.66 mmol), 
phenylboronic acid (305 mg, 2.50 mmol, 1.50 equiv), and potassium carbonate (688 mg, 
4.98, 3.00 equiv) in 1,4-dioxane (5 mL). The solution was purged with nitrogen for 5-20 
N
Br
Cl
OMe
O
II-60
N
Cl
OMe
O
PhB(OH)2
Pd(dppf)Cl2
K2CO3
1,4-dioxane
57%
II-61
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min, then Pd(ddpf)Cl2 (136 mg, 0.166 mmol) was added. The reaction was heated to 100 
ºC (oil bath) and allowed to stir overnight. After cooling to room temperature, the reaction 
was diluted with EtOAc and washed with water. The reaction was then filtered and the 
filtrate was washed again with water and brine. The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. Column chromatography with 0 to 10% 
EtOAc:Hex, gave the 4-phenyl quinoline ester II-61 in 57% yield. 1H NMR (400 MHz, 
CDCl3) δ 8.38 – 8.25 (m, 2H), 7.92 (d, J = 7.1 Hz, 1H), 7.85 – 7.78 (m, 3H), 7.51 (t, J = 
7.6 Hz, 2H), 7.45 (d, J = 7.0 Hz, 1H), 3.98 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 165.5, 
147.3, 146.1, 144.1, 142.3, 138.3, 132.0, 131.4, 129.6, 128.9, 128.1, 128.0, 128.0, 123.7, 
121.3, 77.5, 53.2; [M+Na]+ calcd for C17H12ClNO2Na requires 320.0557, found 320.0456. 
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APPENDIX A 
Full Chart I-4: Pairwise similarity coefficients for I-23 and I-25 library compounds
 
Compound 79m 93 25 54 79k 79q 79t 79u 79z 79r 79s 79n 79x 79o 79v 79l 79y 80a 79a 82a 80a 79b 82b 80c 79c 82c 80d
79m 1.0000 0.4091 0.4839 0.6552 0.7308 0.6364 0.6364 0.6034 0.5645 0.6364 0.7170 0.7547 0.6230 0.7037 0.6333 0.6786 0.6032 0.4545 0.6786 0.4697 0.4286 0.6441 0.4493 0.4167 0.6230 0.4366 0.4054
93 0.4091 1.0000 0.7925 0.3750 0.4091 0.4091 0.4091 0.3913 0.3699 0.4091 0.4030 0.3913 0.3600 0.3971 0.3649 0.3857 0.3506 0.4559 0.4058 0.3889 0.4306 0.3699 0.3553 0.4189 0.3600 0.3462 0.4459
25 0.4839 0.7925 1.0000 0.4412 0.4839 0.4839 0.4839 0.4615 0.4348 0.4839 0.4762 0.4615 0.4225 0.4688 0.4286 0.4545 0.4110 0.3803 0.4545 0.3944 0.3600 0.4348 0.3784 0.3506 0.4225 0.3684 0.3766
54 0.6552 0.3750 0.4412 1.0000 0.6552 0.5738 0.5738 0.5469 0.5606 0.5738 0.6441 0.6230 0.7500 0.6333 0.6250 0.6129 0.5970 0.4167 0.6129 0.4306 0.4324 0.6349 0.4521 0.4211 0.6154 0.4400 0.4103
79k 0.7308 0.4091 0.4839 0.6552 1.0000 0.6364 0.6364 0.6034 0.5645 0.6981 0.7170 0.6909 0.6230 0.7037 0.6333 0.6786 0.6032 0.4545 0.6786 0.4697 0.4286 0.6441 0.4493 0.4167 0.6230 0.4366 0.4054
79q 0.6364 0.4091 0.4839 0.5738 0.6364 1.0000 0.6364 0.6034 0.7321 0.7308 0.6250 0.6316 0.5714 0.6429 0.5806 0.6207 0.5538 0.4118 0.6207 0.4265 0.3889 0.5902 0.4085 0.3784 0.5714 0.3973 0.3684
79t 0.6364 0.4091 0.4839 0.5738 0.6364 0.6364 1.0000 0.8235 0.5645 0.6364 0.6545 0.6034 0.5469 0.6140 0.5556 0.5932 0.5303 0.3913 0.5932 0.4058 0.3699 0.5645 0.3889 0.3600 0.5469 0.3784 0.3506
79u 0.6034 0.3913 0.4615 0.5469 0.6034 0.6034 0.8235 1.0000 0.5385 0.6034 0.5932 0.5738 0.5224 0.5833 0.5303 0.5645 0.5072 0.3750 0.5645 0.3889 0.3553 0.5385 0.3733 0.3462 0.5224 0.3636 0.3375
79z 0.5645 0.3699 0.4348 0.5606 0.5645 0.7321 0.5645 0.5385 1.0000 0.6441 0.5556 0.5625 0.5821 0.5714 0.5909 0.5538 0.5652 0.3733 0.5538 0.3867 0.4861 0.7049 0.5070 0.3974 0.5821 0.4156 0.3875
79r 0.6364 0.4091 0.4839 0.5738 0.6981 0.7308 0.6364 0.6034 0.6441 1.0000 0.6250 0.6034 0.5469 0.6140 0.5556 0.5932 0.5303 0.3913 0.5932 0.4058 0.3699 0.5645 0.3889 0.3600 0.5469 0.3784 0.3506
79s 0.7170 0.4030 0.4762 0.6441 0.7170 0.6250 0.6545 0.5932 0.5556 0.6250 1.0000 0.6786 0.6129 0.6909 0.6230 0.6667 0.5938 0.4478 0.6667 0.4627 0.4225 0.6333 0.4429 0.4110 0.6129 0.4306 0.4000
79n 0.7547 0.3913 0.4615 0.6230 0.6909 0.6316 0.6034 0.5738 0.5625 0.6034 0.6786 1.0000 0.6721 0.7593 0.6833 0.7321 0.6508 0.5000 0.7321 0.5152 0.4714 0.6949 0.4928 0.4583 0.6721 0.4789 0.4459
79x 0.6230 0.3600 0.4225 0.7500 0.6230 0.5714 0.5469 0.5224 0.5821 0.5469 0.6129 0.6721 1.0000 0.6833 0.8448 0.6613 0.6923 0.4583 0.6613 0.4722 0.5797 0.8276 0.6029 0.5857 0.8305 0.6087 0.5694
79o 0.7037 0.3971 0.4688 0.6333 0.7037 0.6429 0.6140 0.5833 0.5714 0.6140 0.6909 0.7593 0.6833 1.0000 0.6949 0.7455 0.6613 0.5077 0.7455 0.5231 0.4783 0.7069 0.5000 0.4648 0.6833 0.4857 0.4521
79v 0.6333 0.3649 0.4286 0.6250 0.6333 0.5806 0.5556 0.5303 0.5909 0.5556 0.6230 0.6833 0.8448 0.6949 1.0000 0.6721 0.7031 0.4648 0.6721 0.4789 0.5882 0.8421 0.6119 0.5942 0.8448 0.6176 0.5775
79l 0.6786 0.3857 0.4545 0.6129 0.6786 0.6207 0.5932 0.5645 0.5538 0.5932 0.6667 0.7321 0.6613 0.7455 0.6721 1.0000 0.6406 0.4925 0.7193 0.5075 0.4648 0.6833 0.4857 0.4521 0.6613 0.4722 0.4400
79y 0.6032 0.3506 0.4110 0.5970 0.6032 0.5538 0.5303 0.5072 0.5652 0.5303 0.5938 0.6508 0.6923 0.6613 0.7031 0.6406 1.0000 0.4459 0.6406 0.4595 0.4800 0.6875 0.5000 0.5915 0.8333 0.6143 0.4744
80a 0.4545 0.4559 0.3803 0.4167 0.4545 0.4118 0.3913 0.3750 0.3733 0.3913 0.4478 0.5000 0.4583 0.5077 0.4648 0.4925 0.4459 1.0000 0.6949 0.6613 0.7097 0.4714 0.4521 0.6875 0.4583 0.4400 0.6667
79a 0.6786 0.4058 0.4545 0.6129 0.6786 0.6207 0.5932 0.5645 0.5538 0.5932 0.6667 0.7321 0.6613 0.7455 0.6721 0.7193 0.6406 0.6949 1.0000 0.7119 0.4857 0.6833 0.4857 0.4722 0.6613 0.4722 0.4595
82a 0.4697 0.3889 0.3944 0.4306 0.4697 0.4265 0.4058 0.3889 0.3867 0.4058 0.4627 0.5152 0.4722 0.5231 0.4789 0.5075 0.4595 0.6613 0.7119 1.0000 0.4658 0.4857 0.6984 0.4533 0.4722 0.6769 0.4416
80a 0.4286 0.4306 0.3600 0.4324 0.4286 0.3889 0.3699 0.3553 0.4861 0.3699 0.4225 0.4714 0.5797 0.4783 0.5882 0.4648 0.4800 0.7097 0.4857 0.4658 1.0000 0.6984 0.6667 0.8361 0.5797 0.5556 0.8095
79b 0.6441 0.3699 0.4348 0.6349 0.6441 0.5902 0.5645 0.5385 0.7049 0.5645 0.6333 0.6949 0.8276 0.7069 0.8421 0.6833 0.6875 0.4714 0.6833 0.4857 0.6984 1.0000 0.7258 0.5797 0.8276 0.6029 0.5634
82b 0.4493 0.3553 0.3784 0.4521 0.4493 0.4085 0.3889 0.3733 0.5070 0.3889 0.4429 0.4928 0.6029 0.5000 0.6119 0.4857 0.5000 0.4521 0.4857 0.6984 0.6667 0.7258 1.0000 0.5556 0.6029 0.8361 0.5405
80c 0.4167 0.4189 0.3506 0.4211 0.4167 0.3784 0.3600 0.3462 0.3974 0.3600 0.4110 0.4583 0.5857 0.4648 0.5942 0.4521 0.5915 0.6875 0.4722 0.4533 0.8361 0.5797 0.5556 1.0000 0.7077 0.6765 0.8125
79c 0.6230 0.3600 0.4225 0.6154 0.6230 0.5714 0.5469 0.5224 0.5821 0.5469 0.6129 0.6721 0.8305 0.6833 0.8448 0.6613 0.8333 0.4583 0.6613 0.4722 0.5797 0.8276 0.6029 0.7077 1.0000 0.7344 0.5694
82c 0.4366 0.3462 0.3684 0.4400 0.4366 0.3973 0.3784 0.3636 0.4156 0.3784 0.4306 0.4789 0.6087 0.4857 0.6176 0.4722 0.6143 0.4400 0.4722 0.6769 0.5556 0.6029 0.8361 0.6765 0.7344 1.0000 0.5467
80d 0.4054 0.4459 0.3766 0.4103 0.4054 0.3684 0.3506 0.3375 0.3875 0.3506 0.4000 0.4459 0.5694 0.4521 0.5775 0.4400 0.4744 0.6667 0.4595 0.4416 0.8095 0.5634 0.5405 0.8125 0.5694 0.5467 1.0000
89d 0.6032 0.3867 0.4507 0.5970 0.6032 0.5538 0.5303 0.5072 0.5652 0.5303 0.5938 0.6508 0.8033 0.6613 0.8167 0.6406 0.6716 0.4459 0.6406 0.4595 0.5634 0.8000 0.5857 0.5694 0.8033 0.5915 0.7164
82d 0.4247 0.3718 0.3947 0.4286 0.4247 0.3867 0.3684 0.3544 0.4051 0.3684 0.4189 0.4658 0.5915 0.4722 0.6000 0.4595 0.4935 0.4286 0.4595 0.6567 0.5405 0.5857 0.8095 0.5467 0.5915 0.8125 0.6857
80e 0.4000 0.4026 0.3375 0.4051 0.4000 0.3636 0.3462 0.3333 0.4000 0.3462 0.3947 0.4400 0.4805 0.4459 0.4868 0.4342 0.4321 0.6567 0.4533 0.4359 0.7692 0.5342 0.5132 0.6957 0.4805 0.4625 0.6761
79e 0.5938 0.3462 0.4054 0.5882 0.5938 0.5455 0.5224 0.5000 0.5797 0.5224 0.5846 0.6406 0.6818 0.6508 0.6923 0.6308 0.6143 0.4400 0.6308 0.4533 0.5342 0.7581 0.5556 0.4805 0.6818 0.5000 0.4684
82e 0.4189 0.3333 0.3544 0.4231 0.4189 0.3816 0.3636 0.3500 0.4177 0.3636 0.4133 0.4595 0.5000 0.4658 0.5067 0.4533 0.4500 0.4231 0.4533 0.6471 0.5132 0.5556 0.7692 0.4625 0.5000 0.6957 0.4512
80f 0.3947 0.3974 0.3333 0.4000 0.3947 0.3590 0.3418 0.3293 0.4125 0.3418 0.3896 0.4342 0.5132 0.4400 0.5200 0.4286 0.4444 0.6471 0.4474 0.4304 0.8125 0.5694 0.5467 0.7353 0.5132 0.4937 0.7143
79f 0.5846 0.3418 0.4000 0.5797 0.5846 0.5373 0.5147 0.4930 0.5942 0.5147 0.5758 0.6308 0.7231 0.6406 0.7344 0.6212 0.6286 0.4342 0.6212 0.4474 0.5694 0.8033 0.5915 0.5132 0.7231 0.5333 0.5000
82f 0.4133 0.3293 0.3500 0.4177 0.4133 0.3766 0.3590 0.3457 0.4304 0.3590 0.4079 0.4533 0.5333 0.4595 0.5405 0.4474 0.4625 0.4177 0.4474 0.6377 0.5467 0.5915 0.8125 0.4937 0.5333 0.7353 0.4815
80k 0.4762 0.4769 0.3971 0.4348 0.6607 0.4091 0.4091 0.3913 0.3699 0.4531 0.4688 0.4545 0.4167 0.4615 0.4225 0.4478 0.4054 0.7069 0.4697 0.4493 0.6613 0.4286 0.4110 0.6406 0.4167 0.4000 0.6212
82k 0.5000 0.3913 0.4179 0.4559 0.6909 0.4308 0.4308 0.4118 0.3889 0.4762 0.4921 0.4769 0.4366 0.4844 0.4429 0.4697 0.4247 0.4348 0.4697 0.6949 0.4110 0.4493 0.6613 0.4000 0.4366 0.6406 0.3896
80g 0.4054 0.4079 0.3418 0.4103 0.4054 0.3684 0.3506 0.3544 0.3875 0.3506 0.4000 0.4459 0.4868 0.4521 0.4933 0.4400 0.4375 0.6667 0.4595 0.4416 0.7538 0.5205 0.5000 0.7059 0.4868 0.4684 0.6857
79g 0.6032 0.3506 0.4110 0.5970 0.6032 0.5538 0.5303 0.5294 0.5652 0.5303 0.5938 0.6508 0.6923 0.6613 0.7031 0.6406 0.6232 0.4459 0.6406 0.4595 0.5205 0.7419 0.5417 0.4868 0.6923 0.5067 0.4744
82g 0.4247 0.3375 0.3590 0.4286 0.4247 0.3867 0.3684 0.3718 0.4051 0.3684 0.4189 0.4658 0.5067 0.4722 0.5135 0.4595 0.4557 0.4286 0.4595 0.6567 0.5000 0.5417 0.7538 0.4684 0.5067 0.7059 0.4568
80h 0.4412 0.4638 0.3889 0.4054 0.4412 0.4203 0.3803 0.3649 0.3636 0.3803 0.4348 0.4853 0.4459 0.4925 0.4521 0.4783 0.4342 0.7333 0.5000 0.4789 0.6875 0.4583 0.4400 0.6667 0.4459 0.4286 0.6716
79h 0.6667 0.4000 0.4697 0.6032 0.6667 0.6379 0.5833 0.5556 0.5455 0.5833 0.6552 0.7193 0.6508 0.7321 0.6613 0.7069 0.6308 0.4853 0.7069 0.5000 0.4583 0.6721 0.4789 0.4459 0.6508 0.4658 0.4533
82h 0.4627 0.3836 0.4085 0.4247 0.4627 0.4412 0.4000 0.3836 0.3816 0.4000 0.4559 0.5075 0.4658 0.5152 0.4722 0.5000 0.4533 0.4648 0.5000 0.7213 0.4400 0.4789 0.6875 0.4286 0.4658 0.6667 0.4359
80i 0.4286 0.4306 0.3600 0.3947 0.4286 0.4085 0.3699 0.3553 0.3718 0.3889 0.4225 0.4714 0.4342 0.4783 0.4400 0.4648 0.4605 0.7097 0.4857 0.4658 0.6667 0.4459 0.4286 0.6471 0.4342 0.4177 0.6286
79i 0.6441 0.3699 0.4348 0.5846 0.6441 0.6167 0.5645 0.5385 0.5522 0.5902 0.6333 0.6949 0.6308 0.7069 0.6406 0.6833 0.6615 0.4714 0.6833 0.4857 0.4459 0.6508 0.4658 0.4342 0.6308 0.4533 0.4231
82i 0.4493 0.3553 0.3784 0.4133 0.4493 0.4286 0.3889 0.3733 0.3896 0.4085 0.4429 0.4928 0.4533 0.5000 0.4595 0.4857 0.4800 0.4521 0.4857 0.6984 0.4286 0.4658 0.6667 0.4177 0.4533 0.6471 0.4074
80j 0.4478 0.4493 0.3750 0.4110 0.4478 0.4265 0.3857 0.3699 0.3684 0.3857 0.4412 0.4925 0.4521 0.5000 0.4583 0.4853 0.4795 0.7458 0.5075 0.4857 0.6984 0.4648 0.4459 0.6769 0.4521 0.4342 0.6567
79j 0.6786 0.3857 0.4545 0.6129 0.6786 0.6491 0.5932 0.5645 0.5538 0.5932 0.6667 0.7321 0.6613 0.7455 0.6721 0.7193 0.6935 0.4925 0.7193 0.5075 0.4648 0.6833 0.4857 0.4521 0.6613 0.4722 0.4400
82j 0.4697 0.3699 0.3944 0.4306 0.4697 0.4478 0.4058 0.3889 0.3867 0.4058 0.4627 0.5152 0.4722 0.5231 0.4789 0.5075 0.5000 0.4714 0.5075 0.7333 0.4459 0.4857 0.6984 0.4342 0.4722 0.6769 0.4231
32 0.4516 0.5763 0.6140 0.4118 0.4516 0.4516 0.4516 0.4531 0.4058 0.4516 0.4444 0.4308 0.3944 0.4375 0.4000 0.4242 0.3836 0.3913 0.4242 0.4058 0.3699 0.4058 0.3889 0.3600 0.3944 0.3784 0.3867
30 0.3333 0.3582 0.3235 0.3056 0.3333 0.3333 0.3333 0.3188 0.3014 0.3333 0.3284 0.3188 0.2933 0.3235 0.2973 0.3143 0.2857 0.4242 0.3333 0.3194 0.4000 0.3014 0.2895 0.3889 0.2933 0.2821 0.3784
88b 0.3649 0.6774 0.5606 0.3718 0.3649 0.3836 0.3649 0.3506 0.4795 0.3649 0.3600 0.3684 0.3924 0.3733 0.3974 0.3636 0.3827 0.4267 0.3816 0.3671 0.5417 0.4795 0.4605 0.4487 0.3924 0.3780 0.4744
88a 0.4286 0.8235 0.6727 0.3913 0.4286 0.4286 0.4286 0.4091 0.3857 0.4286 0.4219 0.4091 0.3750 0.4154 0.3803 0.4030 0.3649 0.4769 0.4242 0.4058 0.4493 0.3857 0.3699 0.4366 0.3750 0.3600 0.4648
88d 0.3553 0.6563 0.5441 0.3625 0.3553 0.3733 0.3553 0.3418 0.3924 0.3553 0.3506 0.3590 0.4000 0.3636 0.4051 0.3544 0.3902 0.4156 0.3718 0.3580 0.4487 0.3924 0.3780 0.4557 0.4000 0.3855 0.5811
88c 0.3553 0.6563 0.5441 0.3625 0.3553 0.3733 0.3553 0.3418 0.3924 0.3553 0.3506 0.3590 0.4000 0.3636 0.4051 0.3544 0.4805 0.4156 0.3718 0.3580 0.4487 0.3924 0.3780 0.5541 0.4933 0.4744 0.4810
88f 0.3418 0.6269 0.5211 0.3494 0.3418 0.3590 0.3418 0.3293 0.3951 0.3418 0.3375 0.3457 0.3529 0.3500 0.3571 0.3415 0.3448 0.4000 0.3580 0.3452 0.4500 0.3951 0.3810 0.4048 0.3529 0.3409 0.4286
88e 0.3803 0.7119 0.5873 0.3506 0.3803 0.4203 0.3803 0.3649 0.3636 0.3803 0.3750 0.3836 0.3544 0.3889 0.3590 0.3784 0.3457 0.4444 0.3973 0.3816 0.4211 0.3636 0.3500 0.4103 0.3544 0.3415 0.4359
88i 0.3590 0.6269 0.5211 0.3494 0.3418 0.3590 0.3418 0.3293 0.3780 0.3418 0.3375 0.3625 0.3855 0.3500 0.3902 0.3415 0.3929 0.4000 0.3580 0.3452 0.4321 0.3780 0.3647 0.4568 0.4024 0.3882 0.4634
88h 0.3462 0.6364 0.5286 0.3537 0.3462 0.3636 0.3462 0.3333 0.3827 0.3462 0.3418 0.3500 0.3902 0.3544 0.3951 0.3457 0.5065 0.4051 0.3625 0.3494 0.4375 0.3827 0.3690 0.5395 0.4805 0.4625 0.4691
88j 0.3375 0.6176 0.5139 0.3452 0.3375 0.3544 0.3375 0.3253 0.4074 0.3375 0.3333 0.3415 0.3647 0.3457 0.3690 0.3373 0.4048 0.3951 0.3537 0.3412 0.4625 0.4074 0.3929 0.4691 0.4146 0.4000 0.4405
79p 0.6786 0.3857 0.4545 0.6129 0.6786 0.6207 0.6207 0.5645 0.5538 0.5932 0.7273 0.7321 0.6613 0.9200 0.6721 0.7193 0.6406 0.4925 0.7193 0.5075 0.4648 0.6833 0.4857 0.4521 0.6613 0.4722 0.4400
89h 0.3205 0.4324 0.4384 0.3293 0.3205 0.3377 0.3205 0.3086 0.3580 0.3205 0.3165 0.3250 0.3659 0.3291 0.3704 0.3210 0.4805 0.3133 0.3210 0.3095 0.3452 0.3580 0.3452 0.4375 0.4545 0.4375 0.3765
89i 0.3333 0.4267 0.4324 0.3253 0.3165 0.3333 0.3165 0.3049 0.3537 0.3165 0.3125 0.3375 0.3614 0.3250 0.3659 0.3171 0.3690 0.3095 0.3171 0.3059 0.3412 0.3537 0.3412 0.3647 0.3780 0.3647 0.3721
89g 0.3125 0.4211 0.4267 0.3214 0.3125 0.3291 0.3125 0.3012 0.3827 0.3125 0.3086 0.3171 0.3412 0.3210 0.3452 0.3133 0.3810 0.3059 0.3133 0.3023 0.3690 0.3827 0.3690 0.3765 0.3902 0.3765 0.3523
86a 0.4030 0.3472 0.3333 0.3699 0.4030 0.3623 0.3429 0.3288 0.3289 0.3429 0.3971 0.4478 0.4110 0.4545 0.4167 0.4412 0.4000 0.6129 0.6333 0.6032 0.4247 0.4225 0.4054 0.4133 0.4110 0.3947 0.4026
86b 0.4000 0.3289 0.3333 0.4054 0.4000 0.3611 0.3425 0.3289 0.4583 0.3425 0.3944 0.4429 0.5507 0.4493 0.5588 0.4366 0.4533 0.4247 0.4366 0.4189 0.6364 0.6667 0.6364 0.5278 0.5507 0.5278 0.5135
86c 0.3889 0.3205 0.3247 0.3947 0.3889 0.3514 0.3333 0.3205 0.3718 0.3333 0.3836 0.4306 0.5571 0.4366 0.5652 0.4247 0.5634 0.4133 0.4247 0.4079 0.5278 0.5507 0.5278 0.6471 0.6769 0.6471 0.5200
86d 0.3784 0.3462 0.3506 0.3846 0.3784 0.3421 0.3247 0.3125 0.3625 0.3247 0.3733 0.4189 0.5417 0.4247 0.5493 0.4133 0.4487 0.4026 0.4133 0.3974 0.5135 0.5352 0.5135 0.5200 0.5417 0.5200 0.6571
86e 0.3733 0.3086 0.3125 0.3797 0.3733 0.3377 0.3205 0.3086 0.3750 0.3205 0.3684 0.4133 0.4545 0.4189 0.4605 0.4079 0.4074 0.3974 0.4079 0.3924 0.4868 0.5068 0.4868 0.4375 0.4545 0.4375 0.4268
84a 0.3289 0.2840 0.2716 0.3210 0.3289 0.2949 0.2785 0.2683 0.2857 0.2785 0.3247 0.3684 0.3580 0.3733 0.3797 0.3816 0.3494 0.5070 0.5217 0.5000 0.3704 0.3671 0.3537 0.3614 0.3580 0.3452 0.3529
84b 0.3205 0.2619 0.2651 0.3293 0.3205 0.2875 0.2716 0.2619 0.3750 0.2716 0.3165 0.3590 0.4545 0.3636 0.4800 0.3718 0.3735 0.3457 0.3544 0.3415 0.5270 0.5493 0.5270 0.4375 0.4545 0.4375 0.4268
84c 0.3125 0.2558 0.2588 0.3214 0.3125 0.2805 0.2651 0.2558 0.3023 0.2651 0.3086 0.3500 0.4615 0.3544 0.4868 0.3625 0.4684 0.3373 0.3457 0.3333 0.4375 0.4545 0.4375 0.5395 0.5616 0.5395 0.4337
84d 0.3049 0.2791 0.2824 0.3140 0.3049 0.2738 0.2588 0.2500 0.2955 0.2588 0.3012 0.3415 0.4500 0.3457 0.4744 0.3537 0.3721 0.3294 0.3373 0.3256 0.4268 0.4430 0.4268 0.4337 0.4500 0.4337 0.5513
84e 0.3012 0.2472 0.2500 0.3103 0.3012 0.2706 0.2558 0.2472 0.3068 0.2558 0.2976 0.3373 0.3765 0.3415 0.3976 0.3494 0.3371 0.3256 0.3333 0.3218 0.4048 0.4198 0.4048 0.3636 0.3765 0.3636 0.3556
89a 0.3810 0.5254 0.5345 0.3478 0.3810 0.3810 0.3810 0.3636 0.3429 0.3810 0.3750 0.3636 0.3333 0.3692 0.3380 0.3582 0.3243 0.3478 0.3582 0.3429 0.3288 0.3429 0.3288 0.3200 0.3333 0.3200 0.3467
89b 0.3378 0.4571 0.4638 0.3462 0.3378 0.3562 0.3378 0.3247 0.4521 0.3378 0.3333 0.3421 0.3671 0.3467 0.3718 0.3377 0.3580 0.3291 0.3377 0.3250 0.4342 0.4521 0.4342 0.3537 0.3671 0.3537 0.3780
89c 0.3289 0.4444 0.4507 0.3375 0.3289 0.3467 0.3289 0.3165 0.3671 0.3289 0.3247 0.3333 0.3750 0.3377 0.3797 0.3291 0.4545 0.3210 0.3291 0.3171 0.3537 0.3671 0.3537 0.4487 0.4667 0.4487 0.3855
89d 0.3289 0.4444 0.4507 0.3375 0.3289 0.3467 0.3289 0.3165 0.3671 0.3289 0.3247 0.3333 0.3750 0.3377 0.3797 0.3291 0.3659 0.3210 0.3291 0.3171 0.3537 0.3671 0.3537 0.3614 0.3750 0.3614 0.4744
89e 0.3380 0.4627 0.4697 0.3117 0.3380 0.3768 0.3380 0.3243 0.3247 0.3380 0.3333 0.3425 0.3165 0.3472 0.3205 0.3378 0.3086 0.3289 0.3378 0.3247 0.3125 0.3247 0.3125 0.3049 0.3165 0.3049 0.3293
89f 0.3165 0.4267 0.4324 0.3253 0.3165 0.3333 0.3165 0.3049 0.3704 0.3165 0.3125 0.3210 0.3294 0.3250 0.3333 0.3171 0.3218 0.3095 0.3171 0.3059 0.3571 0.3704 0.3571 0.3182 0.3294 0.3182 0.3409
90a 0.4444 0.5667 0.6034 0.4058 0.4444 0.4444 0.4677 0.4462 0.4000 0.4444 0.4375 0.4242 0.3889 0.4308 0.3944 0.4179 0.3784 0.3857 0.4179 0.4000 0.3649 0.4000 0.3836 0.3553 0.3889 0.3733 0.3816
90b 0.3836 0.4857 0.5147 0.3896 0.3836 0.4028 0.4028 0.3867 0.5000 0.3836 0.3784 0.3867 0.4103 0.3919 0.4156 0.3816 0.4000 0.3544 0.3816 0.3671 0.4605 0.5000 0.4800 0.3780 0.4103 0.3951 0.4024
90c 0.3733 0.4722 0.5000 0.3797 0.3733 0.3919 0.3919 0.3766 0.4103 0.3733 0.3684 0.3766 0.4177 0.3816 0.4231 0.3718 0.5000 0.3457 0.3718 0.3580 0.3780 0.4103 0.3951 0.4744 0.5135 0.4935 0.4096
90d 0.3733 0.4722 0.5000 0.3797 0.3733 0.3919 0.3919 0.3766 0.4103 0.3733 0.3684 0.3766 0.4177 0.3816 0.4231 0.3718 0.4074 0.3457 0.3718 0.3580 0.3780 0.4103 0.3951 0.3855 0.4177 0.4024 0.5000
90e 0.4000 0.5075 0.5385 0.3684 0.4000 0.4412 0.4203 0.4028 0.3816 0.4000 0.3944 0.4028 0.3718 0.4085 0.3766 0.3973 0.3625 0.3684 0.3973 0.3816 0.3500 0.3816 0.3671 0.3415 0.3718 0.3580 0.3659
90f 0.3590 0.4533 0.4795 0.3659 0.3590 0.3766 0.3766 0.3625 0.4125 0.3590 0.3544 0.3625 0.3690 0.3671 0.3735 0.3580 0.3605 0.3333 0.3580 0.3452 0.3810 0.4125 0.3976 0.3409 0.3690 0.3563 0.3636
90g 0.3544 0.4474 0.4730 0.3614 0.3544 0.3718 0.3718 0.3580 0.4250 0.3544 0.3500 0.3580 0.3810 0.3625 0.3855 0.3537 0.4217 0.3294 0.3537 0.3412 0.3929 0.4250 0.4096 0.4000 0.4321 0.4167 0.3750
90h 0.3636 0.4595 0.4861 0.3704 0.3636 0.3816 0.3816 0.3671 0.4000 0.3636 0.3590 0.3671 0.4074 0.3718 0.4125 0.3625 0.5263 0.3373 0.3625 0.3494 0.3690 0.4000 0.3855 0.4625 0.5000 0.4810 0.4000
90i 0.3766 0.4533 0.4795 0.3659 0.3590 0.3766 0.3766 0.3625 0.3951 0.3590 0.3544 0.3797 0.4024 0.3671 0.4074 0.3580 0.4096 0.3333 0.3580 0.3452 0.3647 0.3951 0.3810 0.3882 0.4198 0.4048 0.3953
91b 0.2118 0.2771 0.2805 0.2247 0.2118 0.2262 0.1977 0.1910 0.2941 0.1977 0.2093 0.2184 0.2727 0.2209 0.2759 0.2159 0.2391 0.2111 0.2159 0.2088 0.3294 0.3415 0.3294 0.2637 0.2727 0.2637 0.2857
91c 0.3421 0.4384 0.4444 0.3500 0.3421 0.3421 0.3247 0.3125 0.3625 0.3247 0.3377 0.3462 0.4231 0.3506 0.4286 0.3418 0.4675 0.3333 0.3418 0.3293 0.4000 0.4156 0.4000 0.5000 0.5205 0.5000 0.4321
91d 0.3421 0.4384 0.4444 0.3500 0.3421 0.3421 0.3247 0.3125 0.3625 0.3247 0.3377 0.3462 0.4231 0.3506 0.4286 0.3418 0.3780 0.3333 0.3418 0.3293 0.4000 0.4156 0.4000 0.4074 0.4231 0.4074 0.5263
91e 0.3521 0.4559 0.4627 0.3247 0.3521 0.3714 0.3333 0.3200 0.3205 0.3333 0.3472 0.3562 0.3291 0.3611 0.3333 0.3514 0.3375 0.3421 0.3514 0.3377 0.3250 0.3377 0.3250 0.3171 0.3291 0.3171 0.3415
91a 0.3906 0.5082 0.5167 0.3571 0.3906 0.3692 0.3692 0.3529 0.3333 0.3692 0.3846 0.3731 0.3425 0.3788 0.3472 0.3676 0.3333 0.3571 0.3676 0.3521 0.3378 0.3521 0.3378 0.3289 0.3425 0.3289 0.3553
92a 0.4627 0.3836 0.3889 0.4247 0.4627 0.4203 0.4203 0.4028 0.3816 0.4000 0.4559 0.5075 0.4658 0.5152 0.4722 0.5000 0.4533 0.6508 0.7000 0.6667 0.4595 0.4789 0.4595 0.4474 0.4658 0.4474 0.4359
92b 0.4429 0.3506 0.3733 0.4459 0.4429 0.4028 0.4028 0.3867 0.5000 0.3836 0.4366 0.4857 0.5942 0.4928 0.6029 0.4789 0.4933 0.4459 0.4789 0.4595 0.6567 0.7143 0.6818 0.5479 0.5942 0.5694 0.5333
92c 0.4306 0.3418 0.3636 0.4342 0.4306 0.3919 0.3919 0.3766 0.4103 0.3733 0.4247 0.4722 0.6000 0.4789 0.6087 0.4658 0.6056 0.4342 0.4658 0.4474 0.5479 0.5942 0.5694 0.6667 0.7231 0.6912 0.5395
92d 0.4189 0.3671 0.3896 0.4231 0.4189 0.3816 0.3816 0.3671 0.4000 0.3636 0.4133 0.4595 0.5833 0.4658 0.5915 0.4533 0.4872 0.4231 0.4533 0.4359 0.5333 0.5775 0.5541 0.5395 0.5833 0.5600 0.6761
67 0.3913 0.7368 0.7500 0.3600 0.3913 0.3913 0.3913 0.3750 0.3553 0.3913 0.3857 0.3750 0.3462 0.3803 0.3506 0.3699 0.3375 0.3784 0.3699 0.3553 0.3590 0.3553 0.3418 0.3500 0.3462 0.3333 0.3750
66 0.4918 0.5667 0.5763 0.4478 0.4918 0.4918 0.4918 0.4688 0.4412 0.4918 0.4839 0.4688 0.4286 0.4762 0.4348 0.4615 0.4167 0.4058 0.4615 0.3803 0.3836 0.4412 0.3649 0.3733 0.4286 0.3553 0.4000
31 0.3538 0.3582 0.3433 0.3239 0.3538 0.3538 0.3538 0.3382 0.3194 0.3538 0.3485 0.3382 0.3108 0.3433 0.3151 0.3333 0.3026 0.4242 0.3529 0.3380 0.4000 0.3194 0.3067 0.3889 0.3108 0.2987 0.3784
90j 0.4000 0.5303 0.5385 0.3684 0.4000 0.4203 0.4203 0.4028 0.3816 0.4000 0.3944 0.4028 0.3718 0.4085 0.3766 0.3973 0.3625 0.4444 0.4783 0.4583 0.3671 0.3816 0.3671 0.3580 0.3718 0.3580 0.3827
36 0.3810 0.5254 0.5345 0.3478 0.3810 0.3810 0.3810 0.3636 0.3429 0.3810 0.3750 0.3636 0.3333 0.3692 0.3380 0.3582 0.3243 0.3478 0.3582 0.3429 0.3288 0.3429 0.3288 0.3200 0.3333 0.3200 0.3467
33 0.4516 0.5763 0.6140 0.4118 0.4516 0.4516 0.4516 0.4308 0.4058 0.4516 0.4444 0.4308 0.3944 0.4375 0.4000 0.4242 0.3836 0.3913 0.4242 0.6441 0.3699 0.4058 0.6129 0.3600 0.3944 0.5938 0.3867
35 0.3014 0.4203 0.4265 0.2949 0.3014 0.3194 0.3014 0.2895 0.3077 0.3014 0.2973 0.3067 0.3000 0.3108 0.3205 0.3200 0.2927 0.2949 0.3026 0.2911 0.2963 0.3077 0.2963 0.2892 0.3000 0.2892 0.3133
25 0.7000 0.4426 0.5263 0.6250 0.7000 0.7000 0.7000 0.6604 0.6140 0.7000 0.6863 0.6604 0.5932 0.6731 0.6034 0.6481 0.5738 0.4444 0.6481 0.4375 0.4179 0.6140 0.4179 0.4058 0.5932 0.4058 0.3944
23 0.4500 0.5254 0.4355 0.4091 0.4500 0.4500 0.4500 0.4286 0.4030 0.4500 0.4426 0.4286 0.3913 0.4355 0.3971 0.4219 0.3803 0.6909 0.4444 0.4242 0.6441 0.4030 0.3857 0.6230 0.3913 0.3750 0.6032
    
 
180  
80d Compound 89d 82d 80e 79e 82e 80f 79f 82f 80k 82k 80g 79g 82g 80h 79h 82h 80i 79i 82i 80j 79j 82j 32 30 88b 88a 88d 88c
0.4054 79m 0.6032 0.4247 0.4000 0.5938 0.4189 0.3947 0.5846 0.4133 0.4762 0.5000 0.4054 0.6032 0.4247 0.4412 0.6667 0.4627 0.4286 0.6441 0.4493 0.4478 0.6786 0.4697 0.4516 0.3333 0.3649 0.4286 0.3553 0.3553
0.4459 93 0.3867 0.3718 0.4026 0.3462 0.3333 0.3974 0.3418 0.3293 0.4769 0.3913 0.4079 0.3506 0.3375 0.4638 0.4000 0.3836 0.4306 0.3699 0.3553 0.4493 0.3857 0.3699 0.5763 0.3582 0.6774 0.8235 0.6563 0.6563
0.3766 25 0.4507 0.3947 0.3375 0.4054 0.3544 0.3333 0.4000 0.3500 0.3971 0.4179 0.3418 0.4110 0.3590 0.3889 0.4697 0.4085 0.3600 0.4348 0.3784 0.3750 0.4545 0.3944 0.6140 0.3235 0.5606 0.6727 0.5441 0.5441
0.4103 54 0.5970 0.4286 0.4051 0.5882 0.4231 0.4000 0.5797 0.4177 0.4348 0.4559 0.4103 0.5970 0.4286 0.4054 0.6032 0.4247 0.3947 0.5846 0.4133 0.4110 0.6129 0.4306 0.4118 0.3056 0.3718 0.3913 0.3625 0.3625
0.4054 79k 0.6032 0.4247 0.4000 0.5938 0.4189 0.3947 0.5846 0.4133 0.6607 0.6909 0.4054 0.6032 0.4247 0.4412 0.6667 0.4627 0.4286 0.6441 0.4493 0.4478 0.6786 0.4697 0.4516 0.3333 0.3649 0.4286 0.3553 0.3553
0.3684 79q 0.5538 0.3867 0.3636 0.5455 0.3816 0.3590 0.5373 0.3766 0.4091 0.4308 0.3684 0.5538 0.3867 0.4203 0.6379 0.4412 0.4085 0.6167 0.4286 0.4265 0.6491 0.4478 0.4516 0.3333 0.3836 0.4286 0.3733 0.3733
0.3506 79t 0.5303 0.3684 0.3462 0.5224 0.3636 0.3418 0.5147 0.3590 0.4091 0.4308 0.3506 0.5303 0.3684 0.3803 0.5833 0.4000 0.3699 0.5645 0.3889 0.3857 0.5932 0.4058 0.4516 0.3333 0.3649 0.4286 0.3553 0.3553
0.3375 79u 0.5072 0.3544 0.3333 0.5000 0.3500 0.3293 0.4930 0.3457 0.3913 0.4118 0.3544 0.5294 0.3718 0.3649 0.5556 0.3836 0.3553 0.5385 0.3733 0.3699 0.5645 0.3889 0.4531 0.3188 0.3506 0.4091 0.3418 0.3418
0.3875 79z 0.5652 0.4051 0.4000 0.5797 0.4177 0.4125 0.5942 0.4304 0.3699 0.3889 0.3875 0.5652 0.4051 0.3636 0.5455 0.3816 0.3718 0.5522 0.3896 0.3684 0.5538 0.3867 0.4058 0.3014 0.4795 0.3857 0.3924 0.3924
0.3506 79r 0.5303 0.3684 0.3462 0.5224 0.3636 0.3418 0.5147 0.3590 0.4531 0.4762 0.3506 0.5303 0.3684 0.3803 0.5833 0.4000 0.3889 0.5902 0.4085 0.3857 0.5932 0.4058 0.4516 0.3333 0.3649 0.4286 0.3553 0.3553
0.4000 79s 0.5938 0.4189 0.3947 0.5846 0.4133 0.3896 0.5758 0.4079 0.4688 0.4921 0.4000 0.5938 0.4189 0.4348 0.6552 0.4559 0.4225 0.6333 0.4429 0.4412 0.6667 0.4627 0.4444 0.3284 0.3600 0.4219 0.3506 0.3506
0.4459 79n 0.6508 0.4658 0.4400 0.6406 0.4595 0.4342 0.6308 0.4533 0.4545 0.4769 0.4459 0.6508 0.4658 0.4853 0.7193 0.5075 0.4714 0.6949 0.4928 0.4925 0.7321 0.5152 0.4308 0.3188 0.3684 0.4091 0.3590 0.3590
0.5694 79x 0.8033 0.5915 0.4805 0.6818 0.5000 0.5132 0.7231 0.5333 0.4167 0.4366 0.4868 0.6923 0.5067 0.4459 0.6508 0.4658 0.4342 0.6308 0.4533 0.4521 0.6613 0.4722 0.3944 0.2933 0.3924 0.3750 0.4000 0.4000
0.4521 79o 0.6613 0.4722 0.4459 0.6508 0.4658 0.4400 0.6406 0.4595 0.4615 0.4844 0.4521 0.6613 0.4722 0.4925 0.7321 0.5152 0.4783 0.7069 0.5000 0.5000 0.7455 0.5231 0.4375 0.3235 0.3733 0.4154 0.3636 0.3636
0.5775 79v 0.8167 0.6000 0.4868 0.6923 0.5067 0.5200 0.7344 0.5405 0.4225 0.4429 0.4933 0.7031 0.5135 0.4521 0.6613 0.4722 0.4400 0.6406 0.4595 0.4583 0.6721 0.4789 0.4000 0.2973 0.3974 0.3803 0.4051 0.4051
0.4400 79l 0.6406 0.4595 0.4342 0.6308 0.4533 0.4286 0.6212 0.4474 0.4478 0.4697 0.4400 0.6406 0.4595 0.4783 0.7069 0.5000 0.4648 0.6833 0.4857 0.4853 0.7193 0.5075 0.4242 0.3143 0.3636 0.4030 0.3544 0.3544
0.4744 79y 0.6716 0.4935 0.4321 0.6143 0.4500 0.4444 0.6286 0.4625 0.4054 0.4247 0.4375 0.6232 0.4557 0.4342 0.6308 0.4533 0.4605 0.6615 0.4800 0.4795 0.6935 0.5000 0.3836 0.2857 0.3827 0.3649 0.3902 0.4805
0.6667 80a 0.4459 0.4286 0.6567 0.4400 0.4231 0.6471 0.4342 0.4177 0.7069 0.4348 0.6667 0.4459 0.4286 0.7333 0.4853 0.4648 0.7097 0.4714 0.4521 0.7458 0.4925 0.4714 0.3913 0.4242 0.4267 0.4769 0.4156 0.4156
0.4595 79a 0.6406 0.4595 0.4533 0.6308 0.4533 0.4474 0.6212 0.4474 0.4697 0.4697 0.4595 0.6406 0.4595 0.5000 0.7069 0.5000 0.4857 0.6833 0.4857 0.5075 0.7193 0.5075 0.4242 0.3333 0.3816 0.4242 0.3718 0.3718
0.4416 82a 0.4595 0.6567 0.4359 0.4533 0.6471 0.4304 0.4474 0.6377 0.4493 0.6949 0.4416 0.4595 0.6567 0.4789 0.5000 0.7213 0.4658 0.4857 0.6984 0.4857 0.5075 0.7333 0.4058 0.3194 0.3671 0.4058 0.3580 0.3580
0.8095 80a 0.5634 0.5405 0.7692 0.5342 0.5132 0.8125 0.5694 0.5467 0.6613 0.4110 0.7538 0.5205 0.5000 0.6875 0.4583 0.4400 0.6667 0.4459 0.4286 0.6984 0.4648 0.4459 0.3699 0.4000 0.5417 0.4493 0.4487 0.4487
0.5634 79b 0.8000 0.5857 0.5342 0.7581 0.5556 0.5694 0.8033 0.5915 0.4286 0.4493 0.5205 0.7419 0.5417 0.4583 0.6721 0.4789 0.4459 0.6508 0.4658 0.4648 0.6833 0.4857 0.4058 0.3014 0.4795 0.3857 0.3924 0.3924
0.5405 82b 0.5857 0.8095 0.5132 0.5556 0.7692 0.5467 0.5915 0.8125 0.4110 0.6613 0.5000 0.5417 0.7538 0.4400 0.4789 0.6875 0.4286 0.4658 0.6667 0.4459 0.4857 0.6984 0.3889 0.2895 0.4605 0.3699 0.3780 0.3780
0.8125 80c 0.5694 0.5467 0.6957 0.4805 0.4625 0.7353 0.5132 0.4937 0.6406 0.4000 0.7059 0.4868 0.4684 0.6667 0.4459 0.4286 0.6471 0.4342 0.4177 0.6769 0.4521 0.4342 0.3600 0.3889 0.4487 0.4366 0.4557 0.5541
0.5694 79c 0.8033 0.5915 0.4805 0.6818 0.5000 0.5132 0.7231 0.5333 0.4167 0.4366 0.4868 0.6923 0.5067 0.4459 0.6508 0.4658 0.4342 0.6308 0.4533 0.4521 0.6613 0.4722 0.3944 0.2933 0.3924 0.3750 0.4000 0.4933
0.5467 82c 0.5915 0.8125 0.4625 0.5000 0.6957 0.4937 0.5333 0.7353 0.4000 0.6406 0.4684 0.5067 0.7059 0.4286 0.4658 0.6667 0.4177 0.4533 0.6471 0.4342 0.4722 0.6769 0.3784 0.2821 0.3780 0.3600 0.3855 0.4744
1.0000 80d 0.7164 0.6857 0.6761 0.4684 0.4512 0.7143 0.5000 0.4815 0.6212 0.3896 0.6857 0.4744 0.4568 0.6716 0.4533 0.4359 0.6286 0.4231 0.4074 0.6567 0.4400 0.4231 0.3867 0.3784 0.4744 0.4648 0.5811 0.4810
0.7164 89d 1.0000 0.7424 0.4684 0.6618 0.4872 0.5000 0.7015 0.5195 0.4054 0.4247 0.4744 0.6716 0.4935 0.4533 0.6563 0.4730 0.4231 0.6119 0.4416 0.4400 0.6406 0.4595 0.4225 0.2857 0.4177 0.4028 0.5200 0.4250
0.6857 82d 0.7424 1.0000 0.4512 0.4872 0.6761 0.4815 0.5195 0.7143 0.3896 0.6212 0.4568 0.4935 0.6857 0.4359 0.4730 0.6716 0.4074 0.4416 0.6286 0.4231 0.4595 0.6567 0.4054 0.2750 0.4024 0.3867 0.5000 0.4096
0.6761 80e 0.4684 0.4512 1.0000 0.7206 0.6901 0.7286 0.5128 0.4938 0.6119 0.3846 0.7000 0.4872 0.4691 0.6377 0.4286 0.4125 0.6197 0.4177 0.4024 0.6471 0.4342 0.4177 0.3462 0.3733 0.4500 0.4189 0.4048 0.4048
0.4684 79e 0.6618 0.4872 0.7206 1.0000 0.7463 0.5128 0.7164 0.5325 0.4000 0.4189 0.4872 0.6866 0.5065 0.4286 0.6212 0.4474 0.4177 0.6029 0.4359 0.4342 0.6308 0.4533 0.3784 0.2821 0.3951 0.3600 0.3529 0.3529
0.4512 82e 0.4872 0.6761 0.6901 0.7463 1.0000 0.4938 0.5325 0.7286 0.3846 0.6119 0.4691 0.5065 0.7000 0.4125 0.4474 0.6377 0.4024 0.4359 0.6197 0.4177 0.4533 0.6471 0.3636 0.2716 0.3810 0.3462 0.3409 0.3409
0.7143 80f 0.5000 0.4815 0.7286 0.5128 0.4938 1.0000 0.7246 0.6944 0.6029 0.3797 0.6901 0.4810 0.4634 0.6286 0.4231 0.4074 0.6111 0.4125 0.3976 0.6377 0.4286 0.4125 0.3418 0.3684 0.4625 0.4133 0.4167 0.4167
0.5000 79f 0.7015 0.5195 0.5128 0.7164 0.5325 0.7246 1.0000 0.7500 0.3947 0.4133 0.4810 0.6765 0.5000 0.4231 0.6119 0.4416 0.4125 0.5942 0.4304 0.4286 0.6212 0.4474 0.3733 0.2785 0.4074 0.3553 0.3647 0.3647
0.4815 82f 0.5195 0.7143 0.4938 0.5325 0.7286 0.6944 0.7500 1.0000 0.3797 0.6029 0.4634 0.5000 0.6901 0.4074 0.4416 0.6286 0.3976 0.4304 0.6111 0.4125 0.4474 0.6377 0.3590 0.2683 0.3929 0.3418 0.3523 0.3523
0.6212 80k 0.4054 0.3896 0.6119 0.4000 0.3846 0.6029 0.3947 0.3797 1.0000 0.6271 0.6212 0.4054 0.3896 0.6833 0.4412 0.4225 0.6613 0.4286 0.4110 0.6949 0.4478 0.4286 0.4091 0.4444 0.4247 0.5000 0.4133 0.4133
0.3896 82k 0.4247 0.6212 0.3846 0.4189 0.6119 0.3797 0.4133 0.6029 0.6271 1.0000 0.3896 0.4247 0.6212 0.4225 0.4627 0.6833 0.4110 0.4493 0.6613 0.4286 0.4697 0.6949 0.4308 0.3188 0.3506 0.4091 0.3418 0.3418
0.6857 80g 0.4744 0.4568 0.7000 0.4872 0.4691 0.6901 0.4810 0.4634 0.6212 0.3896 1.0000 0.7164 0.6857 0.6471 0.4342 0.4177 0.6286 0.4231 0.4074 0.6567 0.4400 0.4231 0.3684 0.3784 0.4375 0.4247 0.4096 0.4096
0.4744 79g 0.6716 0.4935 0.4872 0.6866 0.5065 0.4810 0.6765 0.5000 0.4054 0.4247 0.7164 1.0000 0.7424 0.4342 0.6308 0.4533 0.4231 0.6119 0.4416 0.4400 0.6406 0.4595 0.4028 0.2857 0.3827 0.3649 0.3571 0.3571
0.4568 82g 0.4935 0.6857 0.4691 0.5065 0.7000 0.4634 0.5000 0.6901 0.3896 0.6212 0.6857 0.7424 1.0000 0.4177 0.4533 0.6471 0.4074 0.4416 0.6286 0.4231 0.4595 0.6567 0.3867 0.2750 0.3690 0.3506 0.3448 0.3448
0.6716 80h 0.4533 0.4359 0.6377 0.4286 0.4125 0.6286 0.4231 0.4074 0.6833 0.4225 0.6471 0.4342 0.4177 1.0000 0.6885 0.6563 0.6875 0.4583 0.4400 0.7500 0.5000 0.4789 0.4000 0.4118 0.4342 0.4848 0.4231 0.4231
0.4533 79h 0.6563 0.4730 0.4286 0.6212 0.4474 0.4231 0.6119 0.4416 0.4412 0.4627 0.4342 0.6308 0.4533 0.6885 1.0000 0.7167 0.4583 0.6721 0.4789 0.5000 0.7368 0.5224 0.4394 0.3099 0.3766 0.4179 0.3671 0.3671
0.4359 82h 0.4730 0.6716 0.4125 0.4474 0.6377 0.4074 0.4416 0.6286 0.4225 0.6833 0.4177 0.4533 0.6471 0.6563 0.7167 1.0000 0.4400 0.4789 0.6875 0.4789 0.5224 0.7500 0.4203 0.2973 0.3625 0.4000 0.3537 0.3537
0.6286 80i 0.4231 0.4074 0.6197 0.4177 0.4024 0.6111 0.4125 0.3976 0.6613 0.4110 0.6286 0.4231 0.4074 0.6875 0.4583 0.4400 1.0000 0.6984 0.6667 0.8136 0.5522 0.5286 0.3699 0.4000 0.4051 0.4493 0.3951 0.3951
0.4231 79i 0.6119 0.4416 0.4177 0.6029 0.4359 0.4125 0.5942 0.4304 0.4286 0.4493 0.4231 0.6119 0.4416 0.4583 0.6721 0.4789 0.6984 1.0000 0.7258 0.5522 0.8036 0.5758 0.4058 0.3014 0.3500 0.3857 0.3415 0.3415
0.4074 82i 0.4416 0.6286 0.4024 0.4359 0.6197 0.3976 0.4304 0.6111 0.4110 0.6613 0.4074 0.4416 0.6286 0.4400 0.4789 0.6875 0.6667 0.7258 1.0000 0.5286 0.5758 0.8136 0.3889 0.2895 0.3373 0.3699 0.3294 0.3294
0.6567 80j 0.4400 0.4231 0.6471 0.4342 0.4177 0.6377 0.4286 0.4125 0.6949 0.4286 0.6567 0.4400 0.4231 0.7500 0.5000 0.4789 0.8136 0.5522 0.5286 1.0000 0.6833 0.6508 0.3857 0.4179 0.4211 0.4697 0.4103 0.4103
0.4400 79j 0.6406 0.4595 0.4342 0.6308 0.4533 0.4286 0.6212 0.4474 0.4478 0.4697 0.4400 0.6406 0.4595 0.5000 0.7368 0.5224 0.5522 0.8036 0.5758 0.6833 1.0000 0.7119 0.4242 0.3143 0.3636 0.4030 0.3544 0.3544
0.4231 82j 0.4595 0.6567 0.4177 0.4533 0.6471 0.4125 0.4474 0.6377 0.4286 0.6949 0.4231 0.4595 0.6567 0.4789 0.5224 0.7500 0.5286 0.5758 0.8136 0.6508 0.7119 1.0000 0.4058 0.3014 0.3500 0.3857 0.3415 0.3415
0.3867 32 0.4225 0.4054 0.3462 0.3784 0.3636 0.3418 0.3733 0.3590 0.4091 0.4308 0.3684 0.4028 0.3867 0.4000 0.4394 0.4203 0.3699 0.4058 0.3889 0.3857 0.4242 0.4058 1.0000 0.3333 0.5075 0.6071 0.4928 0.4928
0.3784 30 0.2857 0.2750 0.3733 0.2821 0.2716 0.3684 0.2785 0.2683 0.4444 0.3188 0.3784 0.2857 0.2750 0.4118 0.3099 0.2973 0.4000 0.3014 0.2895 0.4179 0.3143 0.3014 0.3333 1.0000 0.3200 0.3750 0.3117 0.3117
0.4744 88b 0.4177 0.4024 0.4500 0.3951 0.3810 0.4625 0.4074 0.3929 0.4247 0.3506 0.4375 0.3827 0.3690 0.4342 0.3766 0.3625 0.4051 0.3500 0.3373 0.4211 0.3636 0.3500 0.5075 0.3200 1.0000 0.7119 0.8387 0.8387
0.4648 88a 0.4028 0.3867 0.4189 0.3600 0.3462 0.4133 0.3553 0.3418 0.5000 0.4091 0.4247 0.3649 0.3506 0.4848 0.4179 0.4000 0.4493 0.3857 0.3699 0.4697 0.4030 0.3857 0.6071 0.3750 0.7119 1.0000 0.6885 0.6885
0.5811 88d 0.5200 0.5000 0.4048 0.3529 0.3409 0.4167 0.3647 0.3523 0.4133 0.3418 0.4096 0.3571 0.3448 0.4231 0.3671 0.3537 0.3951 0.3415 0.3294 0.4103 0.3544 0.3415 0.4928 0.3117 0.8387 0.6885 1.0000 0.8413
0.4810 88c 0.4250 0.4096 0.4048 0.3529 0.3409 0.4167 0.3647 0.3523 0.4133 0.3418 0.4096 0.3571 0.3448 0.4231 0.3671 0.3537 0.3951 0.3415 0.3294 0.4103 0.3544 0.3415 0.4928 0.3117 0.8387 0.6885 0.8413 1.0000
0.4286 88f 0.3765 0.3636 0.5714 0.5128 0.4938 0.4353 0.3837 0.3708 0.3974 0.3293 0.4118 0.3605 0.3483 0.4074 0.3537 0.3412 0.3810 0.3294 0.3182 0.3951 0.3415 0.3294 0.4722 0.3000 0.7727 0.6563 0.7000 0.7000
0.4359 88e 0.3797 0.3659 0.3951 0.3415 0.3294 0.3902 0.3373 0.3256 0.4429 0.3649 0.4000 0.3457 0.3333 0.4722 0.4110 0.3947 0.4400 0.3816 0.3671 0.5217 0.4571 0.4384 0.5313 0.3333 0.7031 0.7500 0.6818 0.6818
0.4634 88i 0.4096 0.3953 0.3908 0.3409 0.3297 0.4023 0.3523 0.3407 0.3974 0.3293 0.3953 0.3448 0.3333 0.4074 0.3537 0.3412 0.3810 0.3294 0.3182 0.3951 0.3415 0.3294 0.4722 0.3000 0.8000 0.6563 0.8030 0.8308
0.4691 88h 0.4146 0.4000 0.3953 0.3448 0.3333 0.4070 0.3563 0.3444 0.4026 0.3333 0.4000 0.3488 0.3371 0.4125 0.3580 0.3452 0.3855 0.3333 0.3218 0.4000 0.3457 0.3333 0.4789 0.3038 0.7059 0.6667 0.7101 0.8438
0.4405 88j 0.3882 0.3750 0.4023 0.3523 0.3407 0.4302 0.3793 0.3667 0.3924 0.3253 0.4070 0.3563 0.3444 0.4024 0.3494 0.3372 0.3765 0.3256 0.3146 0.3902 0.3373 0.3256 0.4658 0.2963 0.8154 0.6462 0.7391 0.8182
0.4400 79p 0.6406 0.4595 0.4342 0.6308 0.4533 0.4286 0.6212 0.4474 0.4478 0.4697 0.4400 0.6406 0.4595 0.4783 0.7069 0.5000 0.4648 0.6833 0.4857 0.4853 0.7193 0.5075 0.4242 0.3143 0.3636 0.4030 0.3544 0.3544
0.3765 89h 0.3902 0.3765 0.3111 0.3218 0.3111 0.3222 0.3333 0.3222 0.3086 0.3086 0.3146 0.3256 0.3146 0.3214 0.3333 0.3214 0.2989 0.3095 0.2989 0.3095 0.3210 0.3095 0.4507 0.2785 0.4615 0.4507 0.4684 0.5676
0.3721 89i 0.3855 0.3721 0.3077 0.3182 0.3077 0.3187 0.3295 0.3187 0.3049 0.3049 0.3111 0.3218 0.3111 0.3176 0.3293 0.3176 0.2955 0.3059 0.2955 0.3059 0.3171 0.3059 0.4444 0.2750 0.4935 0.4444 0.5000 0.5195
0.3523 89g 0.3647 0.3523 0.3187 0.3295 0.3187 0.3444 0.3563 0.3444 0.3012 0.3012 0.3222 0.3333 0.3222 0.3140 0.3253 0.3140 0.2921 0.3023 0.2921 0.3023 0.3133 0.3023 0.4384 0.2716 0.5065 0.4384 0.4568 0.5128
0.4026 86a 0.4000 0.3846 0.3974 0.3947 0.3797 0.3924 0.3896 0.3750 0.4058 0.3857 0.4026 0.4000 0.3846 0.4366 0.4348 0.4167 0.4247 0.4225 0.4054 0.4429 0.4412 0.4225 0.3429 0.3143 0.3291 0.3623 0.3210 0.3210
0.5135 86b 0.5352 0.5135 0.4868 0.5068 0.4868 0.5200 0.5417 0.5200 0.3836 0.3836 0.4737 0.4932 0.4737 0.4133 0.4306 0.4133 0.4026 0.4189 0.4026 0.4189 0.4366 0.4189 0.3425 0.2973 0.4342 0.3425 0.3537 0.3537
0.5200 86c 0.5417 0.5200 0.4375 0.4545 0.4375 0.4684 0.4868 0.4684 0.3733 0.3733 0.4430 0.4605 0.4430 0.4026 0.4189 0.4026 0.3924 0.4079 0.3924 0.4079 0.4247 0.4079 0.3333 0.2895 0.3537 0.3333 0.3614 0.4487
0.6571 86d 0.6866 0.6571 0.4268 0.4430 0.4268 0.4568 0.4744 0.4568 0.3636 0.3636 0.4321 0.4487 0.4321 0.4103 0.4267 0.4103 0.3827 0.3974 0.3827 0.3974 0.4133 0.3974 0.3600 0.2821 0.3780 0.3600 0.4744 0.3855
0.4268 86e 0.4430 0.4268 0.6620 0.6912 0.6620 0.4691 0.4872 0.4691 0.3590 0.3590 0.4444 0.4615 0.4444 0.3875 0.4026 0.3875 0.3780 0.3924 0.3780 0.3924 0.4079 0.3924 0.3205 0.2785 0.3571 0.3205 0.3182 0.3182
0.3529 84a 0.3494 0.3372 0.3488 0.3452 0.3333 0.3448 0.3412 0.3295 0.3333 0.3165 0.3529 0.3494 0.3372 0.3625 0.3590 0.3457 0.3537 0.3500 0.3373 0.3671 0.3636 0.3500 0.2785 0.2857 0.2874 0.2949 0.2809 0.2809
0.4268 84b 0.4430 0.4268 0.4048 0.4198 0.4048 0.4337 0.4500 0.4337 0.3086 0.3086 0.3929 0.4074 0.3929 0.3373 0.3500 0.3373 0.3294 0.3415 0.3294 0.3415 0.3544 0.3415 0.2716 0.2625 0.3571 0.2716 0.2889 0.2889
0.4337 84c 0.4500 0.4337 0.3636 0.3765 0.3636 0.3908 0.4048 0.3908 0.3012 0.3012 0.3678 0.3810 0.3678 0.3294 0.3415 0.3294 0.3218 0.3333 0.3218 0.3333 0.3457 0.3333 0.2651 0.2561 0.2889 0.2651 0.2967 0.3721
0.5513 84d 0.5733 0.5513 0.3556 0.3678 0.3556 0.3820 0.3953 0.3820 0.2941 0.2941 0.3596 0.3721 0.3596 0.3372 0.3494 0.3372 0.3146 0.3256 0.3146 0.3256 0.3373 0.3256 0.2892 0.2500 0.3111 0.2892 0.3953 0.3187
0.3556 84e 0.3678 0.3556 0.5570 0.5789 0.5570 0.3933 0.4070 0.3933 0.2907 0.2907 0.3708 0.3837 0.3708 0.3182 0.3294 0.3182 0.3111 0.3218 0.3111 0.3218 0.3333 0.3218 0.2558 0.2471 0.2935 0.2558 0.2604 0.2604
0.3467 89a 0.3611 0.3467 0.3077 0.3200 0.3077 0.3038 0.3158 0.3038 0.3636 0.3636 0.3117 0.3243 0.3117 0.3571 0.3731 0.3571 0.3288 0.3429 0.3288 0.3429 0.3582 0.3429 0.5536 0.3281 0.4627 0.5536 0.4493 0.4493
0.3780 89b 0.3924 0.3780 0.3571 0.3704 0.3571 0.3690 0.3827 0.3690 0.3247 0.3247 0.3452 0.3580 0.3452 0.3375 0.3506 0.3375 0.3133 0.3250 0.3133 0.3250 0.3377 0.3250 0.4776 0.2933 0.6176 0.4776 0.5135 0.5135
0.3855 89c 0.4000 0.3855 0.3182 0.3294 0.3182 0.3295 0.3412 0.3295 0.3165 0.3165 0.3218 0.3333 0.3218 0.3293 0.3418 0.3293 0.3059 0.3171 0.3059 0.3171 0.3291 0.3171 0.4638 0.2857 0.5135 0.4638 0.5200 0.6286
0.4744 89d 0.4933 0.4744 0.3182 0.3294 0.3182 0.3295 0.3412 0.3295 0.3165 0.3165 0.3218 0.3333 0.3218 0.3293 0.3418 0.3293 0.3059 0.3171 0.3059 0.3171 0.3291 0.3171 0.4638 0.2857 0.5135 0.4638 0.6286 0.5200
0.3293 89e 0.3418 0.3293 0.2941 0.3049 0.2941 0.2907 0.3012 0.2907 0.3243 0.3243 0.2976 0.3086 0.2976 0.3553 0.3699 0.3553 0.3291 0.3421 0.3291 0.3973 0.4143 0.3973 0.4844 0.2917 0.4324 0.4844 0.4211 0.4211
0.3409 89f 0.3529 0.3409 0.4691 0.4872 0.4691 0.3483 0.3605 0.3483 0.3049 0.3049 0.3258 0.3372 0.3258 0.3176 0.3293 0.3176 0.2955 0.3059 0.2955 0.3059 0.3171 0.3059 0.4444 0.2750 0.4935 0.4444 0.4444 0.4444
0.3816 90a 0.4167 0.4000 0.3418 0.3733 0.3590 0.3375 0.3684 0.3544 0.4030 0.4242 0.3462 0.3784 0.3636 0.3944 0.4328 0.4143 0.3649 0.4000 0.3836 0.3803 0.4179 0.4000 0.6250 0.3284 0.5000 0.5965 0.4857 0.4857
0.4024 90b 0.4359 0.4198 0.3810 0.4125 0.3976 0.3929 0.4250 0.4096 0.3506 0.3684 0.3690 0.4000 0.3855 0.3625 0.3947 0.3797 0.3373 0.3671 0.3537 0.3500 0.3816 0.3671 0.5303 0.2857 0.6000 0.5075 0.5000 0.5000
0.4096 90c 0.4430 0.4268 0.3409 0.3690 0.3563 0.3523 0.3810 0.3678 0.3418 0.3590 0.3448 0.3735 0.3605 0.3537 0.3846 0.3704 0.3294 0.3580 0.3452 0.3415 0.3718 0.3580 0.5147 0.2785 0.5000 0.4928 0.5065 0.6111
0.5000 90d 0.5405 0.5195 0.3409 0.3690 0.3563 0.3523 0.3810 0.3678 0.3418 0.3590 0.3448 0.3735 0.3605 0.3537 0.3846 0.3704 0.3294 0.3580 0.3452 0.3415 0.3718 0.3580 0.5147 0.2785 0.5000 0.4928 0.6111 0.5065
0.3659 90e 0.3974 0.3827 0.3294 0.3580 0.3452 0.3256 0.3537 0.3412 0.3649 0.3836 0.3333 0.3625 0.3494 0.3947 0.4306 0.4133 0.3671 0.4000 0.3846 0.4384 0.4783 0.4583 0.5556 0.2973 0.4730 0.5313 0.4605 0.4605
0.3636 90f 0.3929 0.3793 0.4938 0.5325 0.5125 0.3708 0.4000 0.3864 0.3293 0.3457 0.3483 0.3765 0.3636 0.3412 0.3704 0.3571 0.3182 0.3452 0.3333 0.3294 0.3580 0.3452 0.4930 0.2683 0.5000 0.4722 0.4512 0.4512
0.3750 90g 0.4048 0.3908 0.3407 0.3678 0.3556 0.3667 0.3953 0.3820 0.3253 0.3415 0.3444 0.3721 0.3596 0.3372 0.3659 0.3529 0.3146 0.3412 0.3295 0.3256 0.3537 0.3412 0.4861 0.2651 0.5128 0.4658 0.4634 0.5190
0.4000 90h 0.4321 0.4167 0.3333 0.3605 0.3483 0.3444 0.3721 0.3596 0.3333 0.3500 0.3371 0.3647 0.3523 0.3452 0.3750 0.3614 0.3218 0.3494 0.3372 0.3333 0.3625 0.3494 0.5000 0.2716 0.4872 0.4789 0.4937 0.5946
0.3953 90i 0.4268 0.4118 0.3297 0.3563 0.3444 0.3407 0.3678 0.3556 0.3293 0.3457 0.3333 0.3605 0.3483 0.3412 0.3704 0.3571 0.3182 0.3452 0.3333 0.3294 0.3580 0.3452 0.4930 0.2683 0.4810 0.4722 0.4875 0.5063
0.2857 91b 0.2955 0.2857 0.2553 0.2637 0.2553 0.2660 0.2747 0.2660 0.2045 0.2045 0.2447 0.2527 0.2447 0.2333 0.2414 0.2333 0.2021 0.2088 0.2021 0.2222 0.2299 0.2222 0.2875 0.2024 0.3735 0.2875 0.3034 0.3034
0.4321 91c 0.4487 0.4321 0.3448 0.3571 0.3448 0.3563 0.3690 0.3563 0.3291 0.3291 0.3488 0.3614 0.3488 0.3415 0.3544 0.3415 0.3176 0.3293 0.3176 0.3293 0.3418 0.3293 0.4571 0.2821 0.4675 0.4571 0.4744 0.5753
0.5263 91d 0.5479 0.5263 0.3448 0.3571 0.3448 0.3563 0.3690 0.3563 0.3291 0.3291 0.3488 0.3614 0.3488 0.3415 0.3544 0.3415 0.3176 0.3293 0.3176 0.3293 0.3418 0.3293 0.4571 0.2821 0.4675 0.4571 0.5753 0.4744
0.3415 91e 0.3544 0.3415 0.3059 0.3171 0.3059 0.3023 0.3133 0.3023 0.3378 0.3378 0.3095 0.3210 0.3095 0.3684 0.3836 0.3684 0.3590 0.3733 0.3590 0.4507 0.4706 0.4507 0.4769 0.2877 0.4267 0.4769 0.4156 0.4156
0.3553 91a 0.3699 0.3553 0.3165 0.3289 0.3165 0.3125 0.3247 0.3125 0.3731 0.3731 0.3205 0.3333 0.3205 0.3662 0.3824 0.3662 0.3378 0.3521 0.3378 0.3521 0.3676 0.3521 0.5345 0.3182 0.4493 0.5345 0.4366 0.4366
0.4359 92a 0.4533 0.4359 0.4304 0.4474 0.4304 0.4250 0.4416 0.4250 0.4429 0.4429 0.4359 0.4533 0.4359 0.4722 0.4928 0.4722 0.4595 0.4789 0.4595 0.4789 0.5000 0.4789 0.4000 0.3151 0.3625 0.4000 0.3537 0.3537
0.5333 92b 0.5775 0.5541 0.5065 0.5479 0.5263 0.5395 0.5833 0.5600 0.4054 0.4247 0.4935 0.5342 0.5132 0.4342 0.4722 0.4533 0.4231 0.4595 0.4416 0.4400 0.4789 0.4595 0.3836 0.2857 0.4545 0.3649 0.3735 0.3735
0.5395 92c 0.5833 0.5600 0.4568 0.4935 0.4750 0.4875 0.5263 0.5063 0.3947 0.4133 0.4625 0.5000 0.4810 0.4231 0.4595 0.4416 0.4125 0.4474 0.4304 0.4286 0.4658 0.4474 0.3733 0.2785 0.3735 0.3553 0.3810 0.4684
0.6761 92d 0.7313 0.7000 0.4458 0.4810 0.4634 0.4756 0.5128 0.4938 0.3846 0.4026 0.4512 0.4872 0.4691 0.4304 0.4667 0.4487 0.4024 0.4359 0.4198 0.4177 0.4533 0.4359 0.4000 0.2716 0.3976 0.3816 0.4937 0.4048
0.3750 67 0.3718 0.3580 0.3373 0.3333 0.3214 0.3333 0.3293 0.3176 0.3944 0.3750 0.3415 0.3375 0.3253 0.3867 0.3836 0.3684 0.3590 0.3553 0.3418 0.3733 0.3699 0.3553 0.5484 0.3239 0.5286 0.6271 0.5139 0.5139
0.4000 66 0.4571 0.3816 0.3590 0.4110 0.3418 0.3544 0.4054 0.3375 0.4242 0.4030 0.3636 0.4167 0.3462 0.4143 0.4769 0.3944 0.3836 0.4412 0.3649 0.4000 0.4615 0.3803 0.5965 0.3485 0.5000 0.5965 0.4857 0.4857
0.3784 31 0.3026 0.2911 0.3733 0.2987 0.2875 0.3684 0.2949 0.2840 0.4444 0.3382 0.3784 0.3026 0.2911 0.4118 0.3286 0.3151 0.4000 0.3194 0.3067 0.4179 0.3333 0.3194 0.3538 0.5926 0.3200 0.3750 0.3117 0.3117
0.3827 90j 0.3974 0.3827 0.3452 0.3580 0.3452 0.3412 0.3537 0.3412 0.3836 0.3836 0.3494 0.3625 0.3494 0.3947 0.4110 0.3947 0.3671 0.3816 0.3671 0.3816 0.3973 0.3816 0.5556 0.3151 0.4932 0.5556 0.4800 0.4800
0.3467 36 0.3611 0.3467 0.3077 0.3200 0.3077 0.3038 0.3158 0.3038 0.3636 0.3636 0.3117 0.3243 0.3117 0.3571 0.3731 0.3571 0.3288 0.3429 0.3288 0.3429 0.3582 0.3429 0.5536 0.3281 0.4627 0.5536 0.4493 0.4493
0.3867 33 0.4225 0.6250 0.3462 0.3784 0.5672 0.3418 0.3733 0.5588 0.4091 0.6909 0.3506 0.3836 0.5758 0.4000 0.4394 0.6610 0.3699 0.4058 0.6129 0.3857 0.4242 0.6441 0.6364 0.3333 0.5075 0.6071 0.4928 0.4928
0.3133 35 0.3250 0.3133 0.2791 0.2892 0.2791 0.2759 0.2857 0.2759 0.2895 0.2895 0.2824 0.2927 0.2824 0.3038 0.3158 0.3038 0.2805 0.2911 0.2805 0.2911 0.3026 0.2911 0.4394 0.2917 0.4133 0.4394 0.4026 0.4026
0.3944 25 0.5738 0.3944 0.3889 0.5645 0.3889 0.3836 0.5556 0.3836 0.4667 0.4667 0.3944 0.5738 0.3944 0.4308 0.6364 0.4308 0.4179 0.6140 0.4179 0.4375 0.6481 0.4375 0.4912 0.4821 0.3913 0.4655 0.3803 0.3803
0.6032 23 0.3803 0.3649 0.5938 0.3750 0.3600 0.5846 0.3699 0.3553 0.7308 0.4286 0.6032 0.3803 0.3649 0.6667 0.4154 0.3971 0.6441 0.4030 0.3857 0.6786 0.4219 0.4030 0.4500 0.6038 0.4627 0.5536 0.4493 0.4493
    
 
181  
88c Compound 88f 88e 88i 88h 88j 79p 89h 89i 89g 86a 86b 86c 86d 86e 84a 84b 84c 84d 84e 89a 89b 89c 8 89e 89f 90a 90b 90c
0.3553 79m 0.3418 0.3803 0.3590 0.3462 0.3375 0.6786 0.3205 0.3333 0.3125 0.4030 0.4000 0.3889 0.3784 0.3733 0.3289 0.3205 0.3125 0.3049 0.3012 0.3810 0.3378 0.3289 0.3289 0.3380 0.3165 0.4444 0.3836 0.3733
0.6563 93 0.6269 0.7119 0.6269 0.6364 0.6176 0.3857 0.4324 0.4267 0.4211 0.3472 0.3289 0.3205 0.3462 0.3086 0.2840 0.2619 0.2558 0.2791 0.2472 0.5254 0.4571 0.4444 0.4444 0.4627 0.4267 0.5667 0.4857 0.4722
0.5441 25 0.5211 0.5873 0.5211 0.5286 0.5139 0.4545 0.4384 0.4324 0.4267 0.3333 0.3333 0.3247 0.3506 0.3125 0.2716 0.2651 0.2588 0.2824 0.2500 0.5345 0.4638 0.4507 0.4507 0.4697 0.4324 0.6034 0.5147 0.5000
0.3625 54 0.3494 0.3506 0.3494 0.3537 0.3452 0.6129 0.3293 0.3253 0.3214 0.3699 0.4054 0.3947 0.3846 0.3797 0.3210 0.3293 0.3214 0.3140 0.3103 0.3478 0.3462 0.3375 0.3375 0.3117 0.3253 0.4058 0.3896 0.3797
0.3553 79k 0.3418 0.3803 0.3418 0.3462 0.3375 0.6786 0.3205 0.3165 0.3125 0.4030 0.4000 0.3889 0.3784 0.3733 0.3289 0.3205 0.3125 0.3049 0.3012 0.3810 0.3378 0.3289 0.3289 0.3380 0.3165 0.4444 0.3836 0.3733
0.3733 79q 0.3590 0.4203 0.3590 0.3636 0.3544 0.6207 0.3377 0.3333 0.3291 0.3623 0.3611 0.3514 0.3421 0.3377 0.2949 0.2875 0.2805 0.2738 0.2706 0.3810 0.3562 0.3467 0.3467 0.3768 0.3333 0.4444 0.4028 0.3919
0.3553 79t 0.3418 0.3803 0.3418 0.3462 0.3375 0.6207 0.3205 0.3165 0.3125 0.3429 0.3425 0.3333 0.3247 0.3205 0.2785 0.2716 0.2651 0.2588 0.2558 0.3810 0.3378 0.3289 0.3289 0.3380 0.3165 0.4677 0.4028 0.3919
0.3418 79u 0.3293 0.3649 0.3293 0.3333 0.3253 0.5645 0.3086 0.3049 0.3012 0.3288 0.3289 0.3205 0.3125 0.3086 0.2683 0.2619 0.2558 0.2500 0.2472 0.3636 0.3247 0.3165 0.3165 0.3243 0.3049 0.4462 0.3867 0.3766
0.3924 79z 0.3951 0.3636 0.3780 0.3827 0.4074 0.5538 0.3580 0.3537 0.3827 0.3289 0.4583 0.3718 0.3625 0.3750 0.2857 0.3750 0.3023 0.2955 0.3068 0.3429 0.4521 0.3671 0.3671 0.3247 0.3704 0.4000 0.5000 0.4103
0.3553 79r 0.3418 0.3803 0.3418 0.3462 0.3375 0.5932 0.3205 0.3165 0.3125 0.3429 0.3425 0.3333 0.3247 0.3205 0.2785 0.2716 0.2651 0.2588 0.2558 0.3810 0.3378 0.3289 0.3289 0.3380 0.3165 0.4444 0.3836 0.3733
0.3506 79s 0.3375 0.3750 0.3375 0.3418 0.3333 0.7273 0.3165 0.3125 0.3086 0.3971 0.3944 0.3836 0.3733 0.3684 0.3247 0.3165 0.3086 0.3012 0.2976 0.3750 0.3333 0.3247 0.3247 0.3333 0.3125 0.4375 0.3784 0.3684
0.3590 79n 0.3457 0.3836 0.3625 0.3500 0.3415 0.7321 0.3250 0.3375 0.3171 0.4478 0.4429 0.4306 0.4189 0.4133 0.3684 0.3590 0.3500 0.3415 0.3373 0.3636 0.3421 0.3333 0.3333 0.3425 0.3210 0.4242 0.3867 0.3766
0.4000 79x 0.3529 0.3544 0.3855 0.3902 0.3647 0.6613 0.3659 0.3614 0.3412 0.4110 0.5507 0.5571 0.5417 0.4545 0.3580 0.4545 0.4615 0.4500 0.3765 0.3333 0.3671 0.3750 0.3750 0.3165 0.3294 0.3889 0.4103 0.4177
0.3636 79o 0.3500 0.3889 0.3500 0.3544 0.3457 0.9200 0.3291 0.3250 0.3210 0.4545 0.4493 0.4366 0.4247 0.4189 0.3733 0.3636 0.3544 0.3457 0.3415 0.3692 0.3467 0.3377 0.3377 0.3472 0.3250 0.4308 0.3919 0.3816
0.4051 79v 0.3571 0.3590 0.3902 0.3951 0.3690 0.6721 0.3704 0.3659 0.3452 0.4167 0.5588 0.5652 0.5493 0.4605 0.3797 0.4800 0.4868 0.4744 0.3976 0.3380 0.3718 0.3797 0.3797 0.3205 0.3333 0.3944 0.4156 0.4231
0.3544 79l 0.3415 0.3784 0.3415 0.3457 0.3373 0.7193 0.3210 0.3171 0.3133 0.4412 0.4366 0.4247 0.4133 0.4079 0.3816 0.3718 0.3625 0.3537 0.3494 0.3582 0.3377 0.3291 0.3291 0.3378 0.3171 0.4179 0.3816 0.3718
0.4805 79y 0.3448 0.3457 0.3929 0.5065 0.4048 0.6406 0.4805 0.3690 0.3810 0.4000 0.4533 0.5634 0.4487 0.4074 0.3494 0.3735 0.4684 0.3721 0.3371 0.3243 0.3580 0.4545 0.3659 0.3086 0.3218 0.3784 0.4000 0.5000
0.4156 80a 0.4000 0.4444 0.4000 0.4051 0.3951 0.4925 0.3133 0.3095 0.3059 0.6129 0.4247 0.4133 0.4026 0.3974 0.5070 0.3457 0.3373 0.3294 0.3256 0.3478 0.3291 0.3210 0.3210 0.3289 0.3095 0.3857 0.3544 0.3457
0.3718 79a 0.3580 0.3973 0.3580 0.3625 0.3537 0.7193 0.3210 0.3171 0.3133 0.6333 0.4366 0.4247 0.4133 0.4079 0.5217 0.3544 0.3457 0.3373 0.3333 0.3582 0.3377 0.3291 0.3291 0.3378 0.3171 0.4179 0.3816 0.3718
0.3580 82a 0.3452 0.3816 0.3452 0.3494 0.3412 0.5075 0.3095 0.3059 0.3023 0.6032 0.4189 0.4079 0.3974 0.3924 0.5000 0.3415 0.3333 0.3256 0.3218 0.3429 0.3250 0.3171 0.3171 0.3247 0.3059 0.4000 0.3671 0.3580
0.4487 80a 0.4500 0.4211 0.4321 0.4375 0.4625 0.4648 0.3452 0.3412 0.3690 0.4247 0.6364 0.5278 0.5135 0.4868 0.3704 0.5270 0.4375 0.4268 0.4048 0.3288 0.4342 0.3537 0.3537 0.3125 0.3571 0.3649 0.4605 0.3780
0.3924 79b 0.3951 0.3636 0.3780 0.3827 0.4074 0.6833 0.3580 0.3537 0.3827 0.4225 0.6667 0.5507 0.5352 0.5068 0.3671 0.5493 0.4545 0.4430 0.4198 0.3429 0.4521 0.3671 0.3671 0.3247 0.3704 0.4000 0.5000 0.4103
0.3780 82b 0.3810 0.3500 0.3647 0.3690 0.3929 0.4857 0.3452 0.3412 0.3690 0.4054 0.6364 0.5278 0.5135 0.4868 0.3537 0.5270 0.4375 0.4268 0.4048 0.3288 0.4342 0.3537 0.3537 0.3125 0.3571 0.3836 0.4800 0.3951
0.5541 80c 0.4048 0.4103 0.4568 0.5395 0.4691 0.4521 0.4375 0.3647 0.3765 0.4133 0.5278 0.6471 0.5200 0.4375 0.3614 0.4375 0.5395 0.4337 0.3636 0.3200 0.3537 0.4487 0.3614 0.3049 0.3182 0.3553 0.3780 0.4744
0.4933 79c 0.3529 0.3544 0.4024 0.4805 0.4146 0.6613 0.4545 0.3780 0.3902 0.4110 0.5507 0.6769 0.5417 0.4545 0.3580 0.4545 0.5616 0.4500 0.3765 0.3333 0.3671 0.4667 0.3750 0.3165 0.3294 0.3889 0.4103 0.5135
0.4744 82c 0.3409 0.3415 0.3882 0.4625 0.4000 0.4722 0.4375 0.3647 0.3765 0.3947 0.5278 0.6471 0.5200 0.4375 0.3452 0.4375 0.5395 0.4337 0.3636 0.3200 0.3537 0.4487 0.3614 0.3049 0.3182 0.3733 0.3951 0.4935
0.4810 80d 0.4286 0.4359 0.4634 0.4691 0.4405 0.4400 0.3765 0.3721 0.3523 0.4026 0.5135 0.5200 0.6571 0.4268 0.3529 0.4268 0.4337 0.5513 0.3556 0.3467 0.3780 0.3855 0.4744 0.3293 0.3409 0.3816 0.4024 0.4096
0.4250 89d 0.3765 0.3797 0.4096 0.4146 0.3882 0.6406 0.3902 0.3855 0.3647 0.4000 0.5352 0.5417 0.6866 0.4430 0.3494 0.4430 0.4500 0.5733 0.3678 0.3611 0.3924 0.4000 0.4933 0.3418 0.3529 0.4167 0.4359 0.4430
0.4096 82d 0.3636 0.3659 0.3953 0.4000 0.3750 0.4595 0.3765 0.3721 0.3523 0.3846 0.5135 0.5200 0.6571 0.4268 0.3372 0.4268 0.4337 0.5513 0.3556 0.3467 0.3780 0.3855 0.4744 0.3293 0.3409 0.4000 0.4198 0.4268
0.4048 80e 0.5714 0.3951 0.3908 0.3953 0.4023 0.4342 0.3111 0.3077 0.3187 0.3974 0.4868 0.4375 0.4268 0.6620 0.3488 0.4048 0.3636 0.3556 0.5570 0.3077 0.3571 0.3182 0.3182 0.2941 0.4691 0.3418 0.3810 0.3409
0.3529 79e 0.5128 0.3415 0.3409 0.3448 0.3523 0.6308 0.3218 0.3182 0.3295 0.3947 0.5068 0.4545 0.4430 0.6912 0.3452 0.4198 0.3765 0.3678 0.5789 0.3200 0.3704 0.3294 0.3294 0.3049 0.4872 0.3733 0.4125 0.3690
0.3409 82e 0.4938 0.3294 0.3297 0.3333 0.3407 0.4533 0.3111 0.3077 0.3187 0.3797 0.4868 0.4375 0.4268 0.6620 0.3333 0.4048 0.3636 0.3556 0.5570 0.3077 0.3571 0.3182 0.3182 0.2941 0.4691 0.3590 0.3976 0.3563
0.4167 80f 0.4353 0.3902 0.4023 0.4070 0.4302 0.4286 0.3222 0.3187 0.3444 0.3924 0.5200 0.4684 0.4568 0.4691 0.3448 0.4337 0.3908 0.3820 0.3933 0.3038 0.3690 0.3295 0.3295 0.2907 0.3483 0.3375 0.3929 0.3523
0.3647 79f 0.3837 0.3373 0.3523 0.3563 0.3793 0.6212 0.3333 0.3295 0.3563 0.3896 0.5417 0.4868 0.4744 0.4872 0.3412 0.4500 0.4048 0.3953 0.4070 0.3158 0.3827 0.3412 0.3412 0.3012 0.3605 0.3684 0.4250 0.3810
0.3523 82f 0.3708 0.3256 0.3407 0.3444 0.3667 0.4474 0.3222 0.3187 0.3444 0.3750 0.5200 0.4684 0.4568 0.4691 0.3295 0.4337 0.3908 0.3820 0.3933 0.3038 0.3690 0.3295 0.3295 0.2907 0.3483 0.3544 0.4096 0.3678
0.4133 80k 0.3974 0.4429 0.3974 0.4026 0.3924 0.4478 0.3086 0.3049 0.3012 0.4058 0.3836 0.3733 0.3636 0.3590 0.3333 0.3086 0.3012 0.2941 0.2907 0.3636 0.3247 0.3165 0.3165 0.3243 0.3049 0.4030 0.3506 0.3418
0.3418 82k 0.3293 0.3649 0.3293 0.3333 0.3253 0.4697 0.3086 0.3049 0.3012 0.3857 0.3836 0.3733 0.3636 0.3590 0.3165 0.3086 0.3012 0.2941 0.2907 0.3636 0.3247 0.3165 0.3165 0.3243 0.3049 0.4242 0.3684 0.3590
0.4096 80g 0.4118 0.4000 0.3953 0.4000 0.4070 0.4400 0.3146 0.3111 0.3222 0.4026 0.4737 0.4430 0.4321 0.4444 0.3529 0.3929 0.3678 0.3596 0.3708 0.3117 0.3452 0.3218 0.3218 0.2976 0.3258 0.3462 0.3690 0.3448
0.3571 79g 0.3605 0.3457 0.3448 0.3488 0.3563 0.6406 0.3256 0.3218 0.3333 0.4000 0.4932 0.4605 0.4487 0.4615 0.3494 0.4074 0.3810 0.3721 0.3837 0.3243 0.3580 0.3333 0.3333 0.3086 0.3372 0.3784 0.4000 0.3735
0.3448 82g 0.3483 0.3333 0.3333 0.3371 0.3444 0.4595 0.3146 0.3111 0.3222 0.3846 0.4737 0.4430 0.4321 0.4444 0.3372 0.3929 0.3678 0.3596 0.3708 0.3117 0.3452 0.3218 0.3218 0.2976 0.3258 0.3636 0.3855 0.3605
0.4231 80h 0.4074 0.4722 0.4074 0.4125 0.4024 0.4783 0.3214 0.3176 0.3140 0.4366 0.4133 0.4026 0.4103 0.3875 0.3625 0.3373 0.3294 0.3372 0.3182 0.3571 0.3375 0.3293 0.3293 0.3553 0.3176 0.3944 0.3625 0.3537
0.3671 79h 0.3537 0.4110 0.3537 0.3580 0.3494 0.7069 0.3333 0.3293 0.3253 0.4348 0.4306 0.4189 0.4267 0.4026 0.3590 0.3500 0.3415 0.3494 0.3294 0.3731 0.3506 0.3418 0.3418 0.3699 0.3293 0.4328 0.3947 0.3846
0.3537 82h 0.3412 0.3947 0.3412 0.3452 0.3372 0.5000 0.3214 0.3176 0.3140 0.4167 0.4133 0.4026 0.4103 0.3875 0.3457 0.3373 0.3294 0.3372 0.3182 0.3571 0.3375 0.3293 0.3293 0.3553 0.3176 0.4143 0.3797 0.3704
0.3951 80i 0.3810 0.4400 0.3810 0.3855 0.3765 0.4648 0.2989 0.2955 0.2921 0.4247 0.4026 0.3924 0.3827 0.3780 0.3537 0.3294 0.3218 0.3146 0.3111 0.3288 0.3133 0.3059 0.3059 0.3291 0.2955 0.3649 0.3373 0.3294
0.3415 79i 0.3294 0.3816 0.3294 0.3333 0.3256 0.6833 0.3095 0.3059 0.3023 0.4225 0.4189 0.4079 0.3974 0.3924 0.3500 0.3415 0.3333 0.3256 0.3218 0.3429 0.3250 0.3171 0.3171 0.3421 0.3059 0.4000 0.3671 0.3580
0.3294 82i 0.3182 0.3671 0.3182 0.3218 0.3146 0.4857 0.2989 0.2955 0.2921 0.4054 0.4026 0.3924 0.3827 0.3780 0.3373 0.3294 0.3218 0.3146 0.3111 0.3288 0.3133 0.3059 0.3059 0.3291 0.2955 0.3836 0.3537 0.3452
0.4103 80j 0.3951 0.5217 0.3951 0.4000 0.3902 0.4853 0.3095 0.3059 0.3023 0.4429 0.4189 0.4079 0.3974 0.3924 0.3671 0.3415 0.3333 0.3256 0.3218 0.3429 0.3250 0.3171 0.3171 0.3973 0.3059 0.3803 0.3500 0.3415
0.3544 79j 0.3415 0.4571 0.3415 0.3457 0.3373 0.7193 0.3210 0.3171 0.3133 0.4412 0.4366 0.4247 0.4133 0.4079 0.3636 0.3544 0.3457 0.3373 0.3333 0.3582 0.3377 0.3291 0.3291 0.4143 0.3171 0.4179 0.3816 0.3718
0.3415 82j 0.3294 0.4384 0.3294 0.3333 0.3256 0.5075 0.3095 0.3059 0.3023 0.4225 0.4189 0.4079 0.3974 0.3924 0.3500 0.3415 0.3333 0.3256 0.3218 0.3429 0.3250 0.3171 0.3171 0.3973 0.3059 0.4000 0.3671 0.3580
0.4928 32 0.4722 0.5313 0.4722 0.4789 0.4658 0.4242 0.4507 0.4444 0.4384 0.3429 0.3425 0.3333 0.3600 0.3205 0.2785 0.2716 0.2651 0.2892 0.2558 0.5536 0.4776 0.4638 0.4638 0.4844 0.4444 0.6250 0.5303 0.5147
0.3117 30 0.3000 0.3333 0.3000 0.3038 0.2963 0.3143 0.2785 0.2750 0.2716 0.3143 0.2973 0.2895 0.2821 0.2785 0.2857 0.2625 0.2561 0.2500 0.2471 0.3281 0.2933 0.2857 0.2857 0.2917 0.2750 0.3284 0.2857 0.2785
0.8387 88b 0.7727 0.7031 0.8000 0.7059 0.8154 0.3636 0.4615 0.4935 0.5065 0.3291 0.4342 0.3537 0.3780 0.3571 0.2874 0.3571 0.2889 0.3111 0.2935 0.4627 0.6176 0.5135 0.5135 0.4324 0.4935 0.5000 0.6000 0.5000
0.6885 88a 0.6563 0.7500 0.6563 0.6667 0.6462 0.4030 0.4507 0.4444 0.4384 0.3623 0.3425 0.3333 0.3600 0.3205 0.2949 0.2716 0.2651 0.2892 0.2558 0.5536 0.4776 0.4638 0.4638 0.4844 0.4444 0.5965 0.5075 0.4928
0.8413 88d 0.7000 0.6818 0.8030 0.7101 0.7391 0.3544 0.4684 0.5000 0.4568 0.3210 0.3537 0.3614 0.4744 0.3182 0.2809 0.2889 0.2967 0.3953 0.2604 0.4493 0.5135 0.5200 0.6286 0.4211 0.4444 0.4857 0.5000 0.5065
1.0000 88c 0.7000 0.6818 0.8308 0.8438 0.8182 0.3544 0.5676 0.5195 0.5128 0.3210 0.3537 0.4487 0.3855 0.3182 0.2809 0.2889 0.3721 0.3187 0.2604 0.4493 0.5135 0.6286 0.5200 0.4211 0.4444 0.4857 0.5000 0.6111
0.7000 88f 1.0000 0.6522 0.6712 0.6351 0.6849 0.3415 0.4167 0.4286 0.4405 0.3095 0.3571 0.3182 0.3409 0.4691 0.2717 0.2935 0.2604 0.2813 0.3933 0.4306 0.4935 0.4444 0.4444 0.4051 0.6438 0.4658 0.5000 0.4512
0.6818 88e 0.6522 1.0000 0.6522 0.7121 0.6429 0.3784 0.4416 0.4177 0.4125 0.3421 0.3250 0.3171 0.3415 0.3059 0.2824 0.2614 0.2556 0.2778 0.2473 0.4844 0.4459 0.4342 0.4342 0.5846 0.4177 0.5231 0.4730 0.4605
0.8308 88i 0.6712 0.6522 1.0000 0.7042 0.7324 0.3415 0.4691 0.6438 0.4578 0.3095 0.3412 0.3647 0.3721 0.3077 0.2717 0.2796 0.3011 0.3085 0.2525 0.4306 0.4935 0.5195 0.5000 0.4051 0.4286 0.4658 0.4810 0.5063
0.8438 88h 0.6351 0.7121 0.7042 1.0000 0.7183 0.3457 0.6389 0.4691 0.4815 0.3133 0.3452 0.4375 0.3765 0.3111 0.2747 0.2826 0.3636 0.3118 0.2551 0.4366 0.4615 0.5676 0.4684 0.4286 0.4167 0.4722 0.4872 0.5946
0.8182 88j 0.6849 0.6429 0.7324 0.7183 1.0000 0.3373 0.4815 0.4578 0.6486 0.3059 0.3690 0.3765 0.3523 0.3187 0.2688 0.3043 0.3118 0.2917 0.2626 0.4247 0.5065 0.5128 0.4568 0.4000 0.4405 0.4595 0.5128 0.5190
0.3544 79p 0.3415 0.3784 0.3415 0.3457 0.3373 1.0000 0.3210 0.3171 0.3133 0.4412 0.4366 0.4247 0.4133 0.4079 0.3636 0.3544 0.3457 0.3373 0.3333 0.3582 0.3377 0.3291 0.3291 0.3378 0.3171 0.4179 0.3816 0.3718
0.5676 89h 0.4167 0.4416 0.4691 0.6389 0.4815 0.3210 1.0000 0.6957 0.7101 0.3896 0.4416 0.5479 0.4744 0.3976 0.2527 0.2747 0.3563 0.3043 0.2474 0.6393 0.6970 0.8387 0.7015 0.6875 0.6250 0.4444 0.4615 0.5676
0.5195 89i 0.4286 0.4177 0.6438 0.4691 0.4578 0.3171 0.6957 1.0000 0.7246 0.3846 0.4359 0.4615 0.4684 0.3929 0.2500 0.2717 0.2935 0.3011 0.2449 0.6290 0.7937 0.8254 0.7969 0.6269 0.6620 0.4384 0.4557 0.4810
0.5128 89g 0.4405 0.4125 0.4578 0.4815 0.6486 0.3133 0.7101 0.7246 1.0000 0.3797 0.4675 0.4744 0.4444 0.4048 0.2473 0.2967 0.3043 0.2842 0.2551 0.6190 0.8095 0.8125 0.7313 0.6176 0.6761 0.4324 0.4872 0.4937
0.3210 86a 0.3095 0.3421 0.3095 0.3133 0.3059 0.4412 0.3896 0.3846 0.3797 1.0000 0.6721 0.6508 0.6308 0.6212 0.4789 0.3210 0.3133 0.3059 0.3023 0.4677 0.4110 0.4000 0.4000 0.4348 0.3846 0.3380 0.3125 0.3049
0.3537 86b 0.3571 0.3250 0.3412 0.3452 0.3690 0.4366 0.4416 0.4359 0.4675 0.6721 1.0000 0.8305 0.8033 0.7619 0.3457 0.5205 0.4304 0.4198 0.3976 0.4394 0.5507 0.4533 0.4533 0.4110 0.4545 0.3378 0.4342 0.3537
0.4487 86c 0.3182 0.3171 0.3647 0.4375 0.3765 0.4247 0.5479 0.4615 0.4744 0.6508 0.8305 1.0000 0.8065 0.6866 0.3373 0.4304 0.5333 0.4268 0.3563 0.4265 0.4533 0.5634 0.4605 0.4000 0.4074 0.3289 0.3537 0.4487
0.3855 86d 0.3409 0.3415 0.3721 0.3765 0.3523 0.4133 0.4744 0.4684 0.4444 0.6308 0.8033 0.8065 1.0000 0.6667 0.3294 0.4198 0.4268 0.5455 0.3483 0.4559 0.4800 0.4868 0.5915 0.4267 0.4321 0.3553 0.3780 0.3855
0.3182 86e 0.4691 0.3059 0.3077 0.3111 0.3187 0.4079 0.3976 0.3929 0.4048 0.6212 0.7619 0.6866 0.6667 1.0000 0.3256 0.3976 0.3563 0.3483 0.5513 0.4085 0.4545 0.4074 0.4074 0.3846 0.5811 0.3165 0.3571 0.3182
0.2809 84a 0.2717 0.2824 0.2717 0.2747 0.2688 0.3636 0.2527 0.2500 0.2473 0.4789 0.3457 0.3373 0.3294 0.3256 1.0000 0.7273 0.7059 0.6857 0.6761 0.2564 0.2644 0.2584 0.2584 0.2471 0.2500 0.2750 0.2727 0.2667
0.2889 84b 0.2935 0.2614 0.2796 0.2826 0.3043 0.3544 0.2747 0.2717 0.2967 0.3210 0.5205 0.4304 0.4198 0.3976 0.7273 1.0000 0.8438 0.8182 0.7794 0.2500 0.3494 0.2809 0.2809 0.2414 0.2857 0.2683 0.3571 0.2889
0.3721 84c 0.2604 0.2556 0.3011 0.3636 0.3118 0.3457 0.3563 0.2935 0.3043 0.3133 0.4304 0.5333 0.4268 0.3563 0.7059 0.8438 1.0000 0.8209 0.7083 0.2439 0.2809 0.3647 0.2889 0.2360 0.2526 0.2619 0.2889 0.3721
0.3187 84d 0.2813 0.2778 0.3085 0.3118 0.2917 0.3373 0.3043 0.3011 0.2842 0.3059 0.4198 0.4268 0.5455 0.3483 0.6857 0.8182 0.8209 1.0000 0.6892 0.2683 0.3034 0.3111 0.3882 0.2584 0.2737 0.2857 0.3111 0.3187
0.2604 84e 0.3933 0.2473 0.2525 0.2551 0.2626 0.3333 0.2474 0.2449 0.2551 0.3023 0.3976 0.3563 0.3483 0.5513 0.6761 0.7794 0.7083 0.6892 1.0000 0.2353 0.2857 0.2526 0.2526 0.2283 0.3864 0.2529 0.2935 0.2604
0.4493 89a 0.4306 0.4844 0.4306 0.4366 0.4247 0.3582 0.6393 0.6290 0.6190 0.4677 0.4394 0.4265 0.4559 0.4085 0.2564 0.2500 0.2439 0.2683 0.2353 1.0000 0.6842 0.6610 0.6610 0.7358 0.6290 0.5439 0.4627 0.4493
0.5135 89b 0.4935 0.4459 0.4935 0.4615 0.5065 0.3377 0.6970 0.7937 0.8095 0.4110 0.5507 0.4533 0.4800 0.4545 0.2644 0.3494 0.2809 0.3034 0.2857 0.6842 1.0000 0.8333 0.8333 0.6774 0.7656 0.4706 0.5714 0.4737
0.6286 89c 0.4444 0.4342 0.5195 0.5676 0.5128 0.3291 0.8387 0.8254 0.8125 0.4000 0.4533 0.5634 0.4868 0.4074 0.2584 0.2809 0.3647 0.3111 0.2526 0.6610 0.8333 1.0000 0.8361 0.6563 0.6912 0.4571 0.4737 0.5833
0.5200 89d 0.4444 0.4342 0.5000 0.4684 0.4568 0.3291 0.7015 0.7969 0.7313 0.4000 0.4533 0.4605 0.5915 0.4074 0.2584 0.2809 0.2889 0.3882 0.2526 0.6610 0.8333 0.8361 1.0000 0.6563 0.6912 0.4571 0.4737 0.4805
0.4211 89e 0.4051 0.5846 0.4051 0.4286 0.4000 0.3378 0.6875 0.6269 0.6176 0.4348 0.4110 0.4000 0.4267 0.3846 0.2471 0.2414 0.2360 0.2584 0.2283 0.7358 0.6774 0.6563 0.6563 1.0000 0.6269 0.4769 0.4324 0.4211
0.4444 89f 0.6438 0.4177 0.4286 0.4167 0.4405 0.3171 0.6250 0.6620 0.6761 0.3846 0.4545 0.4074 0.4321 0.5811 0.2500 0.2857 0.2526 0.2737 0.3864 0.6290 0.7656 0.6912 0.6912 0.6269 1.0000 0.4384 0.4744 0.4268
0.4857 90a 0.4658 0.5231 0.4658 0.4722 0.4595 0.4179 0.4444 0.4384 0.4324 0.3380 0.3378 0.3289 0.3553 0.3165 0.2750 0.2683 0.2619 0.2857 0.2529 0.5439 0.4706 0.4571 0.4571 0.4769 0.4384 1.0000 0.6721 0.6508
0.5000 90b 0.5000 0.4730 0.4810 0.4872 0.5128 0.3816 0.4615 0.4557 0.4872 0.3125 0.4342 0.3537 0.3780 0.3571 0.2727 0.3571 0.2889 0.3111 0.2935 0.4627 0.5714 0.4737 0.4737 0.4324 0.4744 0.6721 1.0000 0.8387
0.6111 90c 0.4512 0.4605 0.5063 0.5946 0.5190 0.3718 0.5676 0.4810 0.4937 0.3049 0.3537 0.4487 0.3855 0.3182 0.2667 0.2889 0.3721 0.3187 0.2604 0.4493 0.4737 0.5833 0.4805 0.4211 0.4268 0.6508 0.8387 1.0000
0.5065 90d 0.4512 0.4605 0.4875 0.4937 0.4634 0.3718 0.4684 0.4625 0.4390 0.3049 0.3537 0.3614 0.4744 0.3182 0.2667 0.2889 0.2967 0.3953 0.2604 0.4493 0.4737 0.4805 0.5833 0.4211 0.4268 0.6508 0.8387 0.8413
0.4605 90e 0.4430 0.5821 0.4430 0.4487 0.4375 0.3973 0.4231 0.4177 0.4125 0.3247 0.3250 0.3171 0.3415 0.3059 0.2674 0.2614 0.2556 0.2778 0.2473 0.4844 0.4459 0.4342 0.4342 0.5373 0.4177 0.7069 0.7031 0.6818
0.4512 90f 0.6267 0.4430 0.4353 0.4405 0.4471 0.3580 0.4167 0.4118 0.4235 0.2941 0.3571 0.3182 0.3409 0.4691 0.2581 0.2935 0.2604 0.2813 0.3933 0.4306 0.4744 0.4268 0.4268 0.4051 0.6000 0.6212 0.7727 0.7000
0.5190 90g 0.4471 0.4375 0.4643 0.5062 0.6316 0.3537 0.4815 0.4405 0.6053 0.2907 0.3690 0.3765 0.3523 0.3187 0.2553 0.3043 0.3118 0.2917 0.2626 0.4247 0.4872 0.4937 0.4390 0.4000 0.4235 0.6119 0.8154 0.8182
0.5946 90h 0.4405 0.4487 0.4938 0.6216 0.5062 0.3625 0.5946 0.4691 0.4815 0.2976 0.3452 0.4375 0.3765 0.3111 0.2609 0.2826 0.3636 0.3118 0.2551 0.4366 0.4615 0.5676 0.4684 0.4103 0.4167 0.6308 0.7059 0.8438
0.5063 90i 0.4353 0.4430 0.6267 0.4938 0.4643 0.3580 0.4691 0.6000 0.4405 0.2941 0.3412 0.3647 0.3721 0.3077 0.2581 0.2796 0.3011 0.3085 0.2525 0.4306 0.4557 0.4810 0.4625 0.4051 0.4118 0.6212 0.8000 0.8308
0.3034 91b 0.3077 0.2907 0.2935 0.2967 0.3187 0.2159 0.3488 0.3448 0.3721 0.2442 0.3875 0.3140 0.3372 0.3034 0.2128 0.3182 0.2553 0.2766 0.2474 0.3333 0.4359 0.3571 0.3571 0.3333 0.3605 0.2840 0.3735 0.3034
0.5753 91c 0.4217 0.4286 0.4750 0.5600 0.4875 0.3418 0.6912 0.5890 0.6027 0.4133 0.5068 0.6232 0.5405 0.4375 0.2697 0.3218 0.4096 0.3523 0.2766 0.5714 0.5857 0.7121 0.5915 0.5286 0.5263 0.4507 0.4675 0.5753
0.4744 91d 0.4217 0.4286 0.4568 0.4625 0.4337 0.3418 0.5753 0.5676 0.5395 0.4133 0.5068 0.5135 0.6522 0.4375 0.2697 0.3218 0.3295 0.4337 0.2766 0.5714 0.5857 0.5915 0.7121 0.5286 0.5263 0.4507 0.4675 0.4744
0.4156 91e 0.4000 0.5294 0.4000 0.4051 0.3951 0.3514 0.5139 0.5068 0.5000 0.4493 0.4247 0.4133 0.4400 0.3974 0.2588 0.2529 0.2472 0.2697 0.2391 0.6316 0.5441 0.5286 0.5286 0.6833 0.5068 0.4697 0.4267 0.4156
0.4366 91a 0.4189 0.4697 0.4189 0.4247 0.4133 0.3676 0.5455 0.5373 0.5294 0.4762 0.4478 0.4348 0.4638 0.4167 0.2658 0.2593 0.2530 0.2771 0.2442 0.7200 0.5806 0.5625 0.5625 0.6207 0.5373 0.5254 0.4493 0.4366
0.3537 92a 0.3412 0.3766 0.3412 0.3452 0.3372 0.5000 0.3059 0.3023 0.2989 0.5938 0.4133 0.4026 0.3924 0.3875 0.4932 0.3373 0.3294 0.3218 0.3182 0.3380 0.3210 0.3133 0.3133 0.3205 0.3023 0.6500 0.4730 0.4605
0.3735 92b 0.3765 0.3457 0.3605 0.3647 0.3882 0.4789 0.3412 0.3372 0.3647 0.4000 0.6269 0.5205 0.5067 0.4805 0.3494 0.5200 0.4321 0.4217 0.4000 0.3243 0.4286 0.3494 0.3494 0.3086 0.3529 0.6190 0.6000 0.5000
0.4684 92c 0.3371 0.3373 0.3837 0.4568 0.3953 0.4658 0.4321 0.3605 0.3721 0.3896 0.5205 0.6377 0.5132 0.4321 0.3412 0.4321 0.5325 0.4286 0.3596 0.3158 0.3494 0.4430 0.3571 0.3012 0.3146 0.6000 0.5000 0.6111
0.4048 92d 0.3596 0.3614 0.3908 0.3953 0.3708 0.4533 0.3721 0.3678 0.3483 0.3797 0.5067 0.5132 0.6479 0.4217 0.3333 0.4217 0.4286 0.5443 0.3516 0.3421 0.3735 0.3810 0.4684 0.3253 0.3371 0.6308 0.5263 0.5325
0.5139 67 0.4933 0.5522 0.4933 0.5000 0.4868 0.3699 0.4156 0.4103 0.4051 0.3158 0.3165 0.3086 0.3333 0.2976 0.2588 0.2529 0.2472 0.2697 0.2391 0.5000 0.4384 0.4267 0.4267 0.4429 0.4103 0.5397 0.4658 0.4533
0.4857 66 0.4658 0.5231 0.4658 0.4722 0.4595 0.4615 0.4444 0.4384 0.4324 0.3380 0.3378 0.3289 0.3553 0.3165 0.2750 0.2683 0.2619 0.2857 0.2529 0.5439 0.4706 0.4571 0.4571 0.4769 0.4384 0.5862 0.5000 0.4857
0.3117 31 0.3000 0.3333 0.3000 0.3038 0.2963 0.3333 0.2785 0.2750 0.2716 0.3143 0.2973 0.2895 0.2821 0.2785 0.2857 0.2625 0.2561 0.2500 0.2471 0.3281 0.2933 0.2857 0.2857 0.2917 0.2750 0.3485 0.3026 0.2949
0.4800 90j 0.4615 0.5143 0.4615 0.4675 0.4557 0.3973 0.4231 0.4177 0.4125 0.3973 0.3250 0.3171 0.3415 0.3059 0.3293 0.2614 0.2556 0.2778 0.2473 0.4844 0.4459 0.4342 0.4342 0.4507 0.4177 0.7069 0.7031 0.6818
0.4493 36 0.4306 0.4844 0.4306 0.4366 0.4247 0.3582 0.5625 0.5538 0.5455 0.6250 0.5833 0.5645 0.5968 0.5385 0.2564 0.2500 0.2439 0.2683 0.2353 0.7500 0.6000 0.5806 0.5806 0.6429 0.5538 0.5439 0.4627 0.4493
0.4928 33 0.4722 0.5313 0.4722 0.4789 0.4658 0.4242 0.4507 0.4444 0.4384 0.3429 0.3425 0.3333 0.3600 0.3205 0.2785 0.2716 0.2651 0.2892 0.2558 0.5536 0.4776 0.4638 0.4638 0.4844 0.4444 0.6250 0.5303 0.5147
0.4026 35 0.3875 0.4110 0.3875 0.3924 0.3827 0.3026 0.3846 0.3797 0.3750 0.2692 0.2875 0.2805 0.3049 0.2706 0.6825 0.6615 0.6418 0.6716 0.6143 0.4154 0.4054 0.3947 0.3947 0.3889 0.3797 0.4328 0.4133 0.4026
0.3803 25 0.3649 0.4091 0.3649 0.3699 0.3600 0.6481 0.3425 0.3378 0.3333 0.3692 0.3676 0.3571 0.3472 0.3425 0.2973 0.2895 0.2821 0.2750 0.2716 0.4138 0.3623 0.3521 0.3521 0.3636 0.3378 0.4828 0.4118 0.4000
0.4493 23 0.4306 0.4844 0.4306 0.4366 0.4247 0.4219 0.3333 0.3289 0.3247 0.3788 0.3571 0.3472 0.3378 0.3333 0.3067 0.2821 0.2750 0.2683 0.2651 0.4000 0.3521 0.3425 0.3425 0.3529 0.3289 0.4426 0.3803 0.3699
    
 
182  
90c Compound 90d 90e 90f 90g 90h 90i 91b 91c 91d 91e 91a 92a 92b 92c 92d 67 66 31 90j 36 33 35 25 23
0.3733 79m 0.3733 0.4000 0.3590 0.3544 0.3636 0.3766 0.2118 0.3421 0.3421 0.3521 0.3906 0.4627 0.4429 0.4306 0.4189 0.3913 0.4918 0.3538 0.4000 0.3810 0.4516 0.3014 0.7000 0.4500
0.4722 93 0.4722 0.5075 0.4533 0.4474 0.4595 0.4533 0.2771 0.4384 0.4384 0.4559 0.5082 0.3836 0.3506 0.3418 0.3671 0.7368 0.5667 0.3582 0.5303 0.5254 0.5763 0.4203 0.4426 0.5254
0.5000 25 0.5000 0.5385 0.4795 0.4730 0.4861 0.4795 0.2805 0.4444 0.4444 0.4627 0.5167 0.3889 0.3733 0.3636 0.3896 0.7500 0.5763 0.3433 0.5385 0.5345 0.6140 0.4265 0.5263 0.4355
0.3797 54 0.3797 0.3684 0.3659 0.3614 0.3704 0.3659 0.2247 0.3500 0.3500 0.3247 0.3571 0.4247 0.4459 0.4342 0.4231 0.3600 0.4478 0.3239 0.3684 0.3478 0.4118 0.2949 0.6250 0.4091
0.3733 79k 0.3733 0.4000 0.3590 0.3544 0.3636 0.3590 0.2118 0.3421 0.3421 0.3521 0.3906 0.4627 0.4429 0.4306 0.4189 0.3913 0.4918 0.3538 0.4000 0.3810 0.4516 0.3014 0.7000 0.4500
0.3919 79q 0.3919 0.4412 0.3766 0.3718 0.3816 0.3766 0.2262 0.3421 0.3421 0.3714 0.3692 0.4203 0.4028 0.3919 0.3816 0.3913 0.4918 0.3538 0.4203 0.3810 0.4516 0.3194 0.7000 0.4500
0.3919 79t 0.3919 0.4203 0.3766 0.3718 0.3816 0.3766 0.1977 0.3247 0.3247 0.3333 0.3692 0.4203 0.4028 0.3919 0.3816 0.3913 0.4918 0.3538 0.4203 0.3810 0.4516 0.3014 0.7000 0.4500
0.3766 79u 0.3766 0.4028 0.3625 0.3580 0.3671 0.3625 0.1910 0.3125 0.3125 0.3200 0.3529 0.4028 0.3867 0.3766 0.3671 0.3750 0.4688 0.3382 0.4028 0.3636 0.4308 0.2895 0.6604 0.4286
0.4103 79z 0.4103 0.3816 0.4125 0.4250 0.4000 0.3951 0.2941 0.3625 0.3625 0.3205 0.3333 0.3816 0.5000 0.4103 0.4000 0.3553 0.4412 0.3194 0.3816 0.3429 0.4058 0.3077 0.6140 0.4030
0.3733 79r 0.3733 0.4000 0.3590 0.3544 0.3636 0.3590 0.1977 0.3247 0.3247 0.3333 0.3692 0.4000 0.3836 0.3733 0.3636 0.3913 0.4918 0.3538 0.4000 0.3810 0.4516 0.3014 0.7000 0.4500
0.3684 79s 0.3684 0.3944 0.3544 0.3500 0.3590 0.3544 0.2093 0.3377 0.3377 0.3472 0.3846 0.4559 0.4366 0.4247 0.4133 0.3857 0.4839 0.3485 0.3944 0.3750 0.4444 0.2973 0.6863 0.4426
0.3766 79n 0.3766 0.4028 0.3625 0.3580 0.3671 0.3797 0.2184 0.3462 0.3462 0.3562 0.3731 0.5075 0.4857 0.4722 0.4595 0.3750 0.4688 0.3382 0.4028 0.3636 0.4308 0.3067 0.6604 0.4286
0.4177 79x 0.4177 0.3718 0.3690 0.3810 0.4074 0.4024 0.2727 0.4231 0.4231 0.3291 0.3425 0.4658 0.5942 0.6000 0.5833 0.3462 0.4286 0.3108 0.3718 0.3333 0.3944 0.3000 0.5932 0.3913
0.3816 79o 0.3816 0.4085 0.3671 0.3625 0.3718 0.3671 0.2209 0.3506 0.3506 0.3611 0.3788 0.5152 0.4928 0.4789 0.4658 0.3803 0.4762 0.3433 0.4085 0.3692 0.4375 0.3108 0.6731 0.4355
0.4231 79v 0.4231 0.3766 0.3735 0.3855 0.4125 0.4074 0.2759 0.4286 0.4286 0.3333 0.3472 0.4722 0.6029 0.6087 0.5915 0.3506 0.4348 0.3151 0.3766 0.3380 0.4000 0.3205 0.6034 0.3971
0.3718 79l 0.3718 0.3973 0.3580 0.3537 0.3625 0.3580 0.2159 0.3418 0.3418 0.3514 0.3676 0.5000 0.4789 0.4658 0.4533 0.3699 0.4615 0.3333 0.3973 0.3582 0.4242 0.3200 0.6481 0.4219
0.5000 79y 0.4074 0.3625 0.3605 0.4217 0.5263 0.4096 0.2391 0.4675 0.3780 0.3375 0.3333 0.4533 0.4933 0.6056 0.4872 0.3375 0.4167 0.3026 0.3625 0.3243 0.3836 0.2927 0.5738 0.3803
0.3457 80a 0.3457 0.3684 0.3333 0.3294 0.3373 0.3333 0.2111 0.3333 0.3333 0.3421 0.3571 0.6508 0.4459 0.4342 0.4231 0.3784 0.4058 0.4242 0.4444 0.3478 0.3913 0.2949 0.4444 0.6909
0.3718 79a 0.3718 0.3973 0.3580 0.3537 0.3625 0.3580 0.2159 0.3418 0.3418 0.3514 0.3676 0.7000 0.4789 0.4658 0.4533 0.3699 0.4615 0.3529 0.4783 0.3582 0.4242 0.3026 0.6481 0.4444
0.3580 82a 0.3580 0.3816 0.3452 0.3412 0.3494 0.3452 0.2088 0.3293 0.3293 0.3377 0.3521 0.6667 0.4595 0.4474 0.4359 0.3553 0.3803 0.3380 0.4583 0.3429 0.6441 0.2911 0.4375 0.4242
0.3780 80a 0.3780 0.3500 0.3810 0.3929 0.3690 0.3647 0.3294 0.4000 0.4000 0.3250 0.3378 0.4595 0.6567 0.5479 0.5333 0.3590 0.3836 0.4000 0.3671 0.3288 0.3699 0.2963 0.4179 0.6441
0.4103 79b 0.4103 0.3816 0.4125 0.4250 0.4000 0.3951 0.3415 0.4156 0.4156 0.3377 0.3521 0.4789 0.7143 0.5942 0.5775 0.3553 0.4412 0.3194 0.3816 0.3429 0.4058 0.3077 0.6140 0.4030
0.3951 82b 0.3951 0.3671 0.3976 0.4096 0.3855 0.3810 0.3294 0.4000 0.4000 0.3250 0.3378 0.4595 0.6818 0.5694 0.5541 0.3418 0.3649 0.3067 0.3671 0.3288 0.6129 0.2963 0.4179 0.3857
0.4744 80c 0.3855 0.3415 0.3409 0.4000 0.4625 0.3882 0.2637 0.5000 0.4074 0.3171 0.3289 0.4474 0.5479 0.6667 0.5395 0.3500 0.3733 0.3889 0.3580 0.3200 0.3600 0.2892 0.4058 0.6230
0.5135 79c 0.4177 0.3718 0.3690 0.4321 0.5000 0.4198 0.2727 0.5205 0.4231 0.3291 0.3425 0.4658 0.5942 0.7231 0.5833 0.3462 0.4286 0.3108 0.3718 0.3333 0.3944 0.3000 0.5932 0.3913
0.4935 82c 0.4024 0.3580 0.3563 0.4167 0.4810 0.4048 0.2637 0.5000 0.4074 0.3171 0.3289 0.4474 0.5694 0.6912 0.5600 0.3333 0.3553 0.2987 0.3580 0.3200 0.5938 0.2892 0.4058 0.3750
0.4096 80d 0.5000 0.3659 0.3636 0.3750 0.4000 0.3953 0.2857 0.4321 0.5263 0.3415 0.3553 0.4359 0.5333 0.5395 0.6761 0.3750 0.4000 0.3784 0.3827 0.3467 0.3867 0.3133 0.3944 0.6032
0.4430 89d 0.5405 0.3974 0.3929 0.4048 0.4321 0.4268 0.2955 0.4487 0.5479 0.3544 0.3699 0.4533 0.5775 0.5833 0.7313 0.3718 0.4571 0.3026 0.3974 0.3611 0.4225 0.3250 0.5738 0.3803
0.4268 82d 0.5195 0.3827 0.3793 0.3908 0.4167 0.4118 0.2857 0.4321 0.5263 0.3415 0.3553 0.4359 0.5541 0.5600 0.7000 0.3580 0.3816 0.2911 0.3827 0.3467 0.6250 0.3133 0.3944 0.3649
0.3409 80e 0.3409 0.3294 0.4938 0.3407 0.3333 0.3297 0.2553 0.3448 0.3448 0.3059 0.3165 0.4304 0.5065 0.4568 0.4458 0.3373 0.3590 0.3733 0.3452 0.3077 0.3462 0.2791 0.3889 0.5938
0.3690 79e 0.3690 0.3580 0.5325 0.3678 0.3605 0.3563 0.2637 0.3571 0.3571 0.3171 0.3289 0.4474 0.5479 0.4935 0.4810 0.3333 0.4110 0.2987 0.3580 0.3200 0.3784 0.2892 0.5645 0.3750
0.3563 82e 0.3563 0.3452 0.5125 0.3556 0.3483 0.3444 0.2553 0.3448 0.3448 0.3059 0.3165 0.4304 0.5263 0.4750 0.4634 0.3214 0.3418 0.2875 0.3452 0.3077 0.5672 0.2791 0.3889 0.3600
0.3523 80f 0.3523 0.3256 0.3708 0.3667 0.3444 0.3407 0.2660 0.3563 0.3563 0.3023 0.3125 0.4250 0.5395 0.4875 0.4756 0.3333 0.3544 0.3684 0.3412 0.3038 0.3418 0.2759 0.3836 0.5846
0.3810 79f 0.3810 0.3537 0.4000 0.3953 0.3721 0.3678 0.2747 0.3690 0.3690 0.3133 0.3247 0.4416 0.5833 0.5263 0.5128 0.3293 0.4054 0.2949 0.3537 0.3158 0.3733 0.2857 0.5556 0.3699
0.3678 82f 0.3678 0.3412 0.3864 0.3820 0.3596 0.3556 0.2660 0.3563 0.3563 0.3023 0.3125 0.4250 0.5600 0.5063 0.4938 0.3176 0.3375 0.2840 0.3412 0.3038 0.5588 0.2759 0.3836 0.3553
0.3418 80k 0.3418 0.3649 0.3293 0.3253 0.3333 0.3293 0.2045 0.3291 0.3291 0.3378 0.3731 0.4429 0.4054 0.3947 0.3846 0.3944 0.4242 0.4444 0.3836 0.3636 0.4091 0.2895 0.4667 0.7308
0.3590 82k 0.3590 0.3836 0.3457 0.3415 0.3500 0.3457 0.2045 0.3291 0.3291 0.3378 0.3731 0.4429 0.4247 0.4133 0.4026 0.3750 0.4030 0.3382 0.3836 0.3636 0.6909 0.2895 0.4667 0.4286
0.3448 80g 0.3448 0.3333 0.3483 0.3444 0.3371 0.3333 0.2447 0.3488 0.3488 0.3095 0.3205 0.4359 0.4935 0.4625 0.4512 0.3415 0.3636 0.3784 0.3494 0.3117 0.3506 0.2824 0.3944 0.6032
0.3735 79g 0.3735 0.3625 0.3765 0.3721 0.3647 0.3605 0.2527 0.3614 0.3614 0.3210 0.3333 0.4533 0.5342 0.5000 0.4872 0.3375 0.4167 0.3026 0.3625 0.3243 0.3836 0.2927 0.5738 0.3803
0.3605 82g 0.3605 0.3494 0.3636 0.3596 0.3523 0.3483 0.2447 0.3488 0.3488 0.3095 0.3205 0.4359 0.5132 0.4810 0.4691 0.3253 0.3462 0.2911 0.3494 0.3117 0.5758 0.2824 0.3944 0.3649
0.3537 80h 0.3537 0.3947 0.3412 0.3372 0.3452 0.3412 0.2333 0.3415 0.3415 0.3684 0.3662 0.4722 0.4342 0.4231 0.4304 0.3867 0.4143 0.4118 0.3947 0.3571 0.4000 0.3038 0.4308 0.6667
0.3846 79h 0.3846 0.4306 0.3704 0.3659 0.3750 0.3704 0.2414 0.3544 0.3544 0.3836 0.3824 0.4928 0.4722 0.4595 0.4667 0.3836 0.4769 0.3286 0.4110 0.3731 0.4394 0.3158 0.6364 0.4154
0.3704 82h 0.3704 0.4133 0.3571 0.3529 0.3614 0.3571 0.2333 0.3415 0.3415 0.3684 0.3662 0.4722 0.4533 0.4416 0.4487 0.3684 0.3944 0.3151 0.3947 0.3571 0.6610 0.3038 0.4308 0.3971
0.3294 80i 0.3294 0.3671 0.3182 0.3146 0.3218 0.3182 0.2021 0.3176 0.3176 0.3590 0.3378 0.4595 0.4231 0.4125 0.4024 0.3590 0.3836 0.4000 0.3671 0.3288 0.3699 0.2805 0.4179 0.6441
0.3580 79i 0.3580 0.4000 0.3452 0.3412 0.3494 0.3452 0.2088 0.3293 0.3293 0.3733 0.3521 0.4789 0.4595 0.4474 0.4359 0.3553 0.4412 0.3194 0.3816 0.3429 0.4058 0.2911 0.6140 0.4030
0.3452 82i 0.3452 0.3846 0.3333 0.3295 0.3372 0.3333 0.2021 0.3176 0.3176 0.3590 0.3378 0.4595 0.4416 0.4304 0.4198 0.3418 0.3649 0.3067 0.3671 0.3288 0.6129 0.2805 0.4179 0.3857
0.3415 80j 0.3415 0.4384 0.3294 0.3256 0.3333 0.3294 0.2222 0.3293 0.3293 0.4507 0.3521 0.4789 0.4400 0.4286 0.4177 0.3733 0.4000 0.4179 0.3816 0.3429 0.3857 0.2911 0.4375 0.6786
0.3718 79j 0.3718 0.4783 0.3580 0.3537 0.3625 0.3580 0.2299 0.3418 0.3418 0.4706 0.3676 0.5000 0.4789 0.4658 0.4533 0.3699 0.4615 0.3333 0.3973 0.3582 0.4242 0.3026 0.6481 0.4219
0.3580 82j 0.3580 0.4583 0.3452 0.3412 0.3494 0.3452 0.2222 0.3293 0.3293 0.4507 0.3521 0.4789 0.4595 0.4474 0.4359 0.3553 0.3803 0.3194 0.3816 0.3429 0.6441 0.2911 0.4375 0.4030
0.5147 32 0.5147 0.5556 0.4930 0.4861 0.5000 0.4930 0.2875 0.4571 0.4571 0.4769 0.5345 0.4000 0.3836 0.3733 0.4000 0.5484 0.5965 0.3538 0.5556 0.5536 0.6364 0.4394 0.4912 0.4500
0.2785 30 0.2785 0.2973 0.2683 0.2651 0.2716 0.2683 0.2024 0.2821 0.2821 0.2877 0.3182 0.3151 0.2857 0.2785 0.2716 0.3239 0.3485 0.5926 0.3151 0.3281 0.3333 0.2917 0.4821 0.6038
0.5000 88b 0.5000 0.4730 0.5000 0.5128 0.4872 0.4810 0.3735 0.4675 0.4675 0.4267 0.4493 0.3625 0.4545 0.3735 0.3976 0.5286 0.5000 0.3200 0.4932 0.4627 0.5075 0.4133 0.3913 0.4627
0.4928 88a 0.4928 0.5313 0.4722 0.4658 0.4789 0.4722 0.2875 0.4571 0.4571 0.4769 0.5345 0.4000 0.3649 0.3553 0.3816 0.6271 0.5965 0.3750 0.5556 0.5536 0.6071 0.4394 0.4655 0.5536
0.5065 88d 0.6111 0.4605 0.4512 0.4634 0.4937 0.4875 0.3034 0.4744 0.5753 0.4156 0.4366 0.3537 0.3735 0.3810 0.4937 0.5139 0.4857 0.3117 0.4800 0.4493 0.4928 0.4026 0.3803 0.4493
0.6111 88c 0.5065 0.4605 0.4512 0.5190 0.5946 0.5063 0.3034 0.5753 0.4744 0.4156 0.4366 0.3537 0.3735 0.4684 0.4048 0.5139 0.4857 0.3117 0.4800 0.4493 0.4928 0.4026 0.3803 0.4493
0.4512 88f 0.4512 0.4430 0.6267 0.4471 0.4405 0.4353 0.3077 0.4217 0.4217 0.4000 0.4189 0.3412 0.3765 0.3371 0.3596 0.4933 0.4658 0.3000 0.4615 0.4306 0.4722 0.3875 0.3649 0.4306
0.4605 88e 0.4605 0.5821 0.4430 0.4375 0.4487 0.4430 0.2907 0.4286 0.4286 0.5294 0.4697 0.3766 0.3457 0.3373 0.3614 0.5522 0.5231 0.3333 0.5143 0.4844 0.5313 0.4110 0.4091 0.4844
0.5063 88i 0.4875 0.4430 0.4353 0.4643 0.4938 0.6267 0.2935 0.4750 0.4568 0.4000 0.4189 0.3412 0.3605 0.3837 0.3908 0.4933 0.4658 0.3000 0.4615 0.4306 0.4722 0.3875 0.3649 0.4306
0.5946 88h 0.4937 0.4487 0.4405 0.5062 0.6216 0.4938 0.2967 0.5600 0.4625 0.4051 0.4247 0.3452 0.3647 0.4568 0.3953 0.5000 0.4722 0.3038 0.4675 0.4366 0.4789 0.3924 0.3699 0.4366
0.5190 88j 0.4634 0.4375 0.4471 0.6316 0.5062 0.4643 0.3187 0.4875 0.4337 0.3951 0.4133 0.3372 0.3882 0.3953 0.3708 0.4868 0.4595 0.2963 0.4557 0.4247 0.4658 0.3827 0.3600 0.4247
0.3718 79p 0.3718 0.3973 0.3580 0.3537 0.3625 0.3580 0.2159 0.3418 0.3418 0.3514 0.3676 0.5000 0.4789 0.4658 0.4533 0.3699 0.4615 0.3333 0.3973 0.3582 0.4242 0.3026 0.6481 0.4219
0.5676 89h 0.4684 0.4231 0.4167 0.4815 0.5946 0.4691 0.3488 0.6912 0.5753 0.5139 0.5455 0.3059 0.3412 0.4321 0.3721 0.4156 0.4444 0.2785 0.4231 0.5625 0.4507 0.3846 0.3425 0.3333
0.4810 89i 0.4625 0.4177 0.4118 0.4405 0.4691 0.6000 0.3448 0.5890 0.5676 0.5068 0.5373 0.3023 0.3372 0.3605 0.3678 0.4103 0.4384 0.2750 0.4177 0.5538 0.4444 0.3797 0.3378 0.3289
0.4937 89g 0.4390 0.4125 0.4235 0.6053 0.4815 0.4405 0.3721 0.6027 0.5395 0.5000 0.5294 0.2989 0.3647 0.3721 0.3483 0.4051 0.4324 0.2716 0.4125 0.5455 0.4384 0.3750 0.3333 0.3247
0.3049 86a 0.3049 0.3247 0.2941 0.2907 0.2976 0.2941 0.2442 0.4133 0.4133 0.4493 0.4762 0.5938 0.4000 0.3896 0.3797 0.3158 0.3380 0.3143 0.3973 0.6250 0.3429 0.2692 0.3692 0.3788
0.3537 86b 0.3537 0.3250 0.3571 0.3690 0.3452 0.3412 0.3875 0.5068 0.5068 0.4247 0.4478 0.4133 0.6269 0.5205 0.5067 0.3165 0.3378 0.2973 0.3250 0.5833 0.3425 0.2875 0.3676 0.3571
0.4487 86c 0.3614 0.3171 0.3182 0.3765 0.4375 0.3647 0.3140 0.6232 0.5135 0.4133 0.4348 0.4026 0.5205 0.6377 0.5132 0.3086 0.3289 0.2895 0.3171 0.5645 0.3333 0.2805 0.3571 0.3472
0.3855 86d 0.4744 0.3415 0.3409 0.3523 0.3765 0.3721 0.3372 0.5405 0.6522 0.4400 0.4638 0.3924 0.5067 0.5132 0.6479 0.3333 0.3553 0.2821 0.3415 0.5968 0.3600 0.3049 0.3472 0.3378
0.3182 86e 0.3182 0.3059 0.4691 0.3187 0.3111 0.3077 0.3034 0.4375 0.4375 0.3974 0.4167 0.3875 0.4805 0.4321 0.4217 0.2976 0.3165 0.2785 0.3059 0.5385 0.3205 0.2706 0.3425 0.3333
0.2667 84a 0.2667 0.2674 0.2581 0.2553 0.2609 0.2581 0.2128 0.2697 0.2697 0.2588 0.2658 0.4932 0.3494 0.3412 0.3333 0.2588 0.2750 0.2857 0.3293 0.2564 0.2785 0.6825 0.2973 0.3067
0.2889 84b 0.2889 0.2614 0.2935 0.3043 0.2826 0.2796 0.3182 0.3218 0.3218 0.2529 0.2593 0.3373 0.5200 0.4321 0.4217 0.2529 0.2683 0.2625 0.2614 0.2500 0.2716 0.6615 0.2895 0.2821
0.3721 84c 0.2967 0.2556 0.2604 0.3118 0.3636 0.3011 0.2553 0.4096 0.3295 0.2472 0.2530 0.3294 0.4321 0.5325 0.4286 0.2472 0.2619 0.2561 0.2556 0.2439 0.2651 0.6418 0.2821 0.2750
0.3187 84d 0.3953 0.2778 0.2813 0.2917 0.3118 0.3085 0.2766 0.3523 0.4337 0.2697 0.2771 0.3218 0.4217 0.4286 0.5443 0.2697 0.2857 0.2500 0.2778 0.2683 0.2892 0.6716 0.2750 0.2683
0.2604 84e 0.2604 0.2473 0.3933 0.2626 0.2551 0.2525 0.2474 0.2766 0.2766 0.2391 0.2442 0.3182 0.4000 0.3596 0.3516 0.2391 0.2529 0.2471 0.2473 0.2353 0.2558 0.6143 0.2716 0.2651
0.4493 89a 0.4493 0.4844 0.4306 0.4247 0.4366 0.4306 0.3333 0.5714 0.5714 0.6316 0.7200 0.3380 0.3243 0.3158 0.3421 0.5000 0.5439 0.3281 0.4844 0.7500 0.5536 0.4154 0.4138 0.4000
0.4737 89b 0.4737 0.4459 0.4744 0.4872 0.4615 0.4557 0.4359 0.5857 0.5857 0.5441 0.5806 0.3210 0.4286 0.3494 0.3735 0.4384 0.4706 0.2933 0.4459 0.6000 0.4776 0.4054 0.3623 0.3521
0.5833 89c 0.4805 0.4342 0.4268 0.4937 0.5676 0.4810 0.3571 0.7121 0.5915 0.5286 0.5625 0.3133 0.3494 0.4430 0.3810 0.4267 0.4571 0.2857 0.4342 0.5806 0.4638 0.3947 0.3521 0.3425
0.4805 89d 0.5833 0.4342 0.4268 0.4390 0.4684 0.4625 0.3571 0.5915 0.7121 0.5286 0.5625 0.3133 0.3494 0.3571 0.4684 0.4267 0.4571 0.2857 0.4342 0.5806 0.4638 0.3947 0.3521 0.3425
0.4211 89e 0.4211 0.5373 0.4051 0.4000 0.4103 0.4051 0.3333 0.5286 0.5286 0.6833 0.6207 0.3205 0.3086 0.3012 0.3253 0.4429 0.4769 0.2917 0.4507 0.6429 0.4844 0.3889 0.3636 0.3529
0.4268 89f 0.4268 0.4177 0.6000 0.4235 0.4167 0.4118 0.3605 0.5263 0.5263 0.5068 0.5373 0.3023 0.3529 0.3146 0.3371 0.4103 0.4384 0.2750 0.4177 0.5538 0.4444 0.3797 0.3378 0.3289
0.6508 90a 0.6508 0.7069 0.6212 0.6119 0.6308 0.6212 0.2840 0.4507 0.4507 0.4697 0.5254 0.6500 0.6190 0.6000 0.6308 0.5397 0.5862 0.3485 0.7069 0.5439 0.6250 0.4328 0.4828 0.4426
0.8387 90b 0.8387 0.7031 0.7727 0.8154 0.7059 0.8000 0.3735 0.4675 0.4675 0.4267 0.4493 0.4730 0.6000 0.5000 0.5263 0.4658 0.5000 0.3026 0.7031 0.4627 0.5303 0.4133 0.4118 0.3803
1.0000 90c 0.8413 0.6818 0.7000 0.8182 0.8438 0.8308 0.3034 0.5753 0.4744 0.4156 0.4366 0.4605 0.5000 0.6111 0.5325 0.4533 0.4857 0.2949 0.6818 0.4493 0.5147 0.4026 0.4000 0.3699
0.8413 90d 1.0000 0.6818 0.7000 0.7391 0.7101 0.8030 0.3034 0.4744 0.5753 0.4156 0.4366 0.4605 0.5000 0.5065 0.6389 0.4533 0.4857 0.2949 0.6818 0.4493 0.5147 0.4026 0.4000 0.3699
0.6818 90e 0.6818 1.0000 0.6522 0.6429 0.7121 0.6522 0.2907 0.4286 0.4286 0.5294 0.4697 0.4930 0.4730 0.4605 0.4868 0.4857 0.5231 0.3151 0.7377 0.4844 0.5556 0.4110 0.4308 0.3971
0.7000 90f 0.7000 0.6522 1.0000 0.6849 0.6351 0.6712 0.3077 0.4217 0.4217 0.4000 0.4189 0.4430 0.5000 0.4512 0.4756 0.4359 0.4658 0.2840 0.6522 0.4306 0.4930 0.3875 0.3836 0.3553
0.8182 90g 0.7391 0.6429 0.6849 1.0000 0.7183 0.7324 0.3187 0.4875 0.4337 0.3951 0.4133 0.4375 0.5128 0.5190 0.4878 0.4304 0.4595 0.2805 0.6429 0.4247 0.4861 0.3827 0.3784 0.3506
0.8438 90h 0.7101 0.7121 0.6351 0.7183 1.0000 0.7042 0.2967 0.5600 0.4625 0.4051 0.4247 0.4487 0.4872 0.5946 0.5190 0.4416 0.4722 0.2875 0.6618 0.4366 0.5000 0.3924 0.3889 0.3600
0.8308 90i 0.8030 0.6522 0.6712 0.7324 0.7042 1.0000 0.2935 0.4750 0.4568 0.4000 0.4189 0.4430 0.4810 0.5063 0.5125 0.4359 0.4658 0.2840 0.6522 0.4306 0.4930 0.3875 0.3836 0.3553
0.3034 91b 0.3034 0.2907 0.3077 0.3187 0.2967 0.2935 1.0000 0.4744 0.4744 0.3797 0.3600 0.2065 0.3256 0.2609 0.2826 0.2674 0.2840 0.2024 0.2759 0.3333 0.2875 0.3012 0.2099 0.2048
0.5753 91c 0.4744 0.4286 0.4217 0.4875 0.5600 0.4750 0.4744 1.0000 0.8387 0.6615 0.6557 0.3253 0.3951 0.4935 0.4268 0.4211 0.4507 0.2821 0.4286 0.5714 0.4571 0.3896 0.3472 0.3378
0.4744 91d 0.5753 0.4286 0.4217 0.4337 0.4625 0.4568 0.4744 0.8387 1.0000 0.6615 0.6557 0.3253 0.3951 0.4024 0.5195 0.4211 0.4507 0.2821 0.4286 0.5714 0.4571 0.3896 0.3472 0.3378
0.4156 91e 0.4156 0.5294 0.4000 0.3951 0.4051 0.4000 0.3797 0.6615 0.6615 1.0000 0.7273 0.3333 0.3210 0.3133 0.3373 0.4366 0.4697 0.2877 0.4444 0.6316 0.4769 0.3836 0.3582 0.3478
0.4366 91a 0.4366 0.4697 0.4189 0.4133 0.4247 0.4189 0.3600 0.6557 0.6557 0.7273 1.0000 0.3472 0.3333 0.3247 0.3506 0.4844 0.5254 0.3182 0.4697 0.7200 0.5345 0.4030 0.4000 0.3871
0.4605 92a 0.4605 0.4930 0.4430 0.4375 0.4487 0.4430 0.2065 0.3253 0.3253 0.3333 0.3472 1.0000 0.7031 0.6818 0.6618 0.3506 0.3750 0.3333 0.5821 0.3380 0.4000 0.2875 0.4308 0.4179
0.5000 92b 0.5000 0.4730 0.5000 0.5128 0.4872 0.4810 0.3256 0.3951 0.3951 0.3210 0.3333 0.7031 1.0000 0.8387 0.8125 0.3375 0.3600 0.3026 0.4730 0.3243 0.3836 0.2927 0.4118 0.3803
0.6111 92c 0.5065 0.4605 0.4512 0.5190 0.5946 0.5063 0.2609 0.4935 0.4024 0.3133 0.3247 0.6818 0.8387 1.0000 0.8154 0.3293 0.3506 0.2949 0.4605 0.3158 0.3733 0.2857 0.4000 0.3699
0.5325 92d 0.6389 0.4868 0.4756 0.4878 0.5190 0.5125 0.2826 0.4268 0.5195 0.3373 0.3506 0.6618 0.8125 0.8154 1.0000 0.3537 0.3766 0.2875 0.4868 0.3421 0.4000 0.3095 0.3889 0.3600
0.4533 67 0.4533 0.4857 0.4359 0.4304 0.4416 0.4359 0.2674 0.4211 0.4211 0.4366 0.4844 0.3506 0.3375 0.3293 0.3537 1.0000 0.7321 0.3239 0.4857 0.5000 0.5484 0.4028 0.4444 0.4308
0.4857 66 0.4857 0.5231 0.4658 0.4595 0.4722 0.4658 0.2840 0.4507 0.4507 0.4697 0.5254 0.3750 0.3600 0.3506 0.3766 0.7321 1.0000 0.3485 0.5231 0.5439 0.5965 0.4328 0.5636 0.4667
0.2949 31 0.2949 0.3151 0.2840 0.2805 0.2875 0.2840 0.2024 0.2821 0.2821 0.2877 0.3182 0.3333 0.3026 0.2949 0.2875 0.3239 0.3485 1.0000 0.3333 0.3281 0.3538 0.2917 0.5091 0.6038
0.6818 90j 0.6818 0.7377 0.6522 0.6429 0.6618 0.6522 0.2759 0.4286 0.4286 0.4444 0.4697 0.5821 0.4730 0.4605 0.4868 0.4857 0.5231 0.3333 1.0000 0.4844 0.5556 0.4110 0.4308 0.4179
0.4493 36 0.4493 0.4844 0.4306 0.4247 0.4366 0.4306 0.3333 0.5714 0.5714 0.6316 0.7200 0.3380 0.3243 0.3158 0.3421 0.5000 0.5439 0.3281 0.4844 1.0000 0.5536 0.4154 0.4138 0.4000
0.5147 33 0.5147 0.5556 0.4930 0.4861 0.5000 0.4930 0.2875 0.4571 0.4571 0.4769 0.5345 0.4000 0.3836 0.3733 0.4000 0.5484 0.5965 0.3538 0.5556 0.5536 1.0000 0.4394 0.4912 0.4500
0.4026 35 0.4026 0.4110 0.3875 0.3827 0.3924 0.3875 0.3012 0.3896 0.3896 0.3836 0.4030 0.2875 0.2927 0.2857 0.3095 0.4028 0.4328 0.2917 0.4110 0.4154 0.4394 1.0000 0.3235 0.3143
0.4000 25 0.4000 0.4308 0.3836 0.3784 0.3889 0.3836 0.2099 0.3472 0.3472 0.3582 0.4000 0.4308 0.4118 0.4000 0.3889 0.4444 0.5636 0.5091 0.4308 0.4138 0.4912 0.3235 1.0000 0.6400
0.3699 23 0.3699 0.3971 0.3553 0.3506 0.3600 0.3553 0.2048 0.3378 0.3378 0.3478 0.3871 0.4179 0.3803 0.3699 0.3600 0.4308 0.4667 0.6038 0.4179 0.4000 0.4500 0.3143 0.6400 1.0000
